<SEC-DOCUMENT>0001171843-16-009811.txt : 20160509
<SEC-HEADER>0001171843-16-009811.hdr.sgml : 20160509
<ACCEPTANCE-DATETIME>20160509140415
ACCESSION NUMBER:		0001171843-16-009811
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160509
DATE AS OF CHANGE:		20160509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		161631007

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_050916p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.1pt solid; width: 10%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 18pt"><b>FORM 10-Q</b></font><font style="font-size: 10pt">
&nbsp;</font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>
<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.1pt solid; width: 10%">&nbsp;</div></div><!-- Field: /Rule-Page -->
&nbsp;
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Quarterly Report Pursuant to Section&nbsp;13 or 15(d)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the quarterly period ended March&nbsp;31, 2016</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b> &nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.1pt solid; width: 10%">&nbsp;</div></div><!-- Field: /Rule-Page -->
<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 24pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>
<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.1pt solid; width: 10%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center; width: 50%">DELAWARE</td>
    <td style="font-weight: bold; text-align: center; width: 50%">62-1413174</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">(State of other jurisdiction of</td>
    <td style="font-weight: bold; text-align: center">(I.R.S. Employer</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">incorporation or organization)</td>
    <td style="font-weight: bold; text-align: center">Identification No.)</td></tr>
<tr style="vertical-align: middle">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">4505 Emperor Blvd., Suite&nbsp;200</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">Durham, North Carolina</td>
    <td style="font-weight: bold; text-align: center">27703</td></tr>
<tr style="vertical-align: middle">
    <td style="font-weight: bold; text-align: center">(Address of principal executive offices)</td>
    <td style="font-weight: bold; text-align: center">(Zip Code)</td></tr>
</table>


<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919) 859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b>
&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>
<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1.1pt solid; width: 10%">&nbsp;</div></div><!-- Field: /Rule-Page -->
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements
for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit
and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">x</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">&#168;</font></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non- accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221;
&#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 23%"><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="width: 40%"><font style="font-family: Wingdings; font-size: 10pt">x</font></td>
    <td style="width: 30%"><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td style="width: 7%"><font style="font-family: Wingdings; font-size: 10pt">&#168;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td nowrap=""><font style="font-family: Wingdings; font-size: 10pt">&#168;</font><font style="font-size: 10pt"> &nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td><font style="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td><font style="font-family: Wingdings; font-size: 10pt">&#168;</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2
of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <font style="font-family: Wingdings">&#168;</font> &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<font style="font-family: Wingdings">x</font></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding
as of April&nbsp;30, 2016 was 73,692,799.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&nbsp;INDEX</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <td style="width: 90%">&nbsp;</td>
    <td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center; width: 10%">Page&nbsp;No.</td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: center">Part I. Financial Information</td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_001">Item&nbsp;1. Financial Statements:</a></td>
    <td style="text-align: center"><a href="#a_001">3</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt"><a href="#a_002">Consolidated Balance Sheets &#8212; March&nbsp;31, 2016 and December&nbsp;31, 2015</a></td>
    <td style="text-align: center"><a href="#a_002">3</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt"><a href="#a_003">Consolidated Statements of Comprehensive Loss &#8212; Three Months Ended March&nbsp;31, 2016 and 2015</a></td>
    <td style="text-align: center"><a href="#a_003">4</a></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-left: 20pt"><a href="#a_004">Consolidated Statements of Cash Flows &#8212; Three Months Ended March&nbsp;31, 2016 and 2015</a></td>
    <td style="vertical-align: middle; text-align: center"><a href="#a_004">5</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt"><a href="#a_005">Notes to Consolidated Financial Statements</a></td>
    <td style="text-align: center"><a href="#a_005">6</a></td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_006">Item&nbsp;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="text-align: center"><a href="#a_006">20</a></td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_007">Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="text-align: center"><a href="#a_007">31</a></td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_008">Item&nbsp;4. Controls and Procedures</a></td>
    <td style="text-align: center"><a href="#a_008">32</a></td></tr>
<tr style="vertical-align: middle">
    <td colspan="2" style="text-align: center">Part II. Other Information</td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_009">Item&nbsp;1A. Risk Factors</a></td>
    <td style="text-align: center"><a href="#a_009">33</a></td></tr>
<tr style="vertical-align: middle">
    <td><a href="#a_010">Item&nbsp;6. Exhibits</a></td>
    <td style="text-align: center"><a href="#a_010">49</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt"><a href="#a_011">Signatures</a></td>
    <td style="text-align: center"><a href="#a_011">50</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt">EX-10.1</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt">EX-31.1</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt">EX-31.2</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt">EX-32.1</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt">EX-32.2</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>


<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART I. FINANCIAL INFORMATION </b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_001"></a>Item&nbsp; 1. &nbsp;&nbsp;&nbsp;Financial Statements </b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&nbsp; BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><a name="a_002"></a>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>March&nbsp;31, 2016 and December&nbsp;31, 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(In thousands, except per share data)</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016 <br>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015 <br>(Note 1)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">12,902</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">28,899</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,965</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,914</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,664</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,384</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,949</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,221</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">90</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">90</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">50,425</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63,794</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,362</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">246</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">265</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,714</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5,468</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 40pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">102,881</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,691</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,328</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,237</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,974</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,746</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,163</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,163</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">27,914</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">27,804</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 40pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63,070</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">62,257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">313</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,506</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,375</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 40pt; text-indent: -20pt">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 40pt; text-indent: -20pt">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,693 in 2016 and 73,355 in 2015</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">737</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">734</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">560,762</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">558,113</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accumulated other comprehensive income (loss)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(206</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(533,749</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(510,917</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 40pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">27,798</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">47,724</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 40pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">102,881</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_003"></a><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Three Months Ended March&nbsp;31, 2016 and 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data-Unaudited)</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">537</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,890</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,518</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,930</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">4,771</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,826</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,579</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,120</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,212</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,061</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.1pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">77</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">60</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Total operating expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23,868</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,256</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(19,048</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(14,430</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">439</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">117</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,470</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,315</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">(Loss) gain on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(2,753</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">464</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(22,832</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(15,164</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Basic and diluted net loss per common share</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.31</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(0.21</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,601</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,341</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Unrealized gain on available for sale investments</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">254</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">140</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive loss</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(22,578</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(15,024</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_004"></a><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Three Months Ended March&nbsp;31, 2016 and 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands-Unaudited)</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="width: 68%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(22,832</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(15,164</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">45</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,645</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,259</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Amortization of debt issuance costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">110</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">110</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,753</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(464</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 20pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,141</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,896</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 20pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(337</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(527</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(313</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,848</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">19</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(541</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,404</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,228</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,212</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(480</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(359</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in operating activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(18,842</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,726</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Acquisitions of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,260</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(565</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(353</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,487</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,378</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">6,320</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">2,482</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Net cash provided by (used in) investing activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,707</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(3,948</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,175</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><P STYLE="margin: 0pt 0">Net proceeds from common stock issued under stock-based compensation plans</P>


</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">7</P>


</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">326</P>


</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"><P STYLE="margin: 0pt 0">Increase in lease financing obligation</P>


</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">131</P>


</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">&mdash;</P>


</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.1pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><P STYLE="margin: 0pt 0">138</P>


</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,501</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Decrease in cash and cash equivalents</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(15,997</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(6,173</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28,899</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">54,540</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">12,902</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">48,367</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC. </b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_005"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 1 &#8212; Significant Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
cash flows from operations since inception.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient
liquidity, with its existing cash, restricted cash and investments of $78,915, to continue its planned operations through mid-2017.
The Company&#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product
candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017
it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts;
(2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash
milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional
product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research
and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred
stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public
offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues
reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection
with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a
further description of this transaction. All intercompany transactions and balances have been eliminated.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial
reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete
financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present
fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There
were no adjustments other than normal recurring adjustments.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the
financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#8217;s 2015 Annual
Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance
sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#8217;s
most recent Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Reclassifications</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During the first quarter of 2016, the Company
adopted Accounting Standards Update No. 2015-03, <I>Simplifying the Presentation of Debt Issuance Costs</I>. Accordingly, debt
issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse
notes payable to conform to the 2016 presentation.</P>



<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of March&nbsp;31, 2016 reflects $562 in royalty
revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in
Note 4) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution
and build-out of its new Birmingham research facilities.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At March 31, 2016, the Company believes that the costs of its investments are
recoverable in all material respects.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br>Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br>Unrealized <br>Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br>Unrealized <br>Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br>Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">21,666</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">53</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">15</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">(6</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">21,728</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,718</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">94</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,832</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,438</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">32</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">26</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(8</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,488</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">63,822</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(17</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br>Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br>Unrealized <br>Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br>Unrealized <br>Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br>Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">26,557</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">88</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">(99</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">26,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(41</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,884</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(72</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,838</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled
maturity for the Company&#8217;s investments at March&nbsp;31, 2016 and December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">22,914</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">22,664</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,806</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,395</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after two years</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,328</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">19,288</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Collaborations</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the
Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
from Shionogi and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine
if any reserve or allowance should be established at each reporting date. At March 31, 2016 and December&nbsp;31, 2015, the Company
had the following receivables.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,475</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,734</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,209</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,685</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,685</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">336</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">154</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">490</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,496</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,888</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,384</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">&nbsp;Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">210</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established
at each reporting date.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016 and December 31, 2015, the Company&#8217;s inventory
consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;)
method, or market. The Company expenses costs related to the production of inventories as research and development expenses in
the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is
reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to
the production of inventories.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s inventory consisted of the following at March&nbsp;31,
2016 and December&nbsp;31, 2015:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Work in process</td><td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,949</td><td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,612</td><td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Inventories</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Property and Equipment</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining
lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related
lease.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its
property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
of are reported at the lower of carrying amount or fair value less cost to sell.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes
and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability
of such expenditures is uncertain.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates
of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary
from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such
as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
As of March 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term
settlement.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accumulated Other Comprehensive Income (Loss)</I></B></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Accumulated other comprehensive income (loss)
is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&rsquo;
equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the
Consolidated Statements of Comprehensive Loss. No reclassifications out of accumulated other comprehensive income (loss) were recorded
during the three months ended March 31, 2016. During the three months ended March 31, 2015, realized gains of $8 were reclassified
out of accumulated other comprehensive income (loss).</P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each
deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered,
limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables
requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset,
or another performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#8220;SUL
Agreement&#8221;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture
and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone
payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory
and (iii) regulatory support to obtain Canadian and European Union (&#8220;EU&#8221;) marketing approvals. The Company received
an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be
deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue
in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized
during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement
will be recognized over the expected period of involvement in these regulatory support activities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
revenue recognition criteria are recorded as deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to
$12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food
Branch of Health Canada (&#8220;Health Canada&#8221;) for an adult indication in Canada. The Company evaluated each event based
payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>, and determined that each event based
payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event
based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and
substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment
from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when
there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability
is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates.
In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to
physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide
license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion
of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners,
except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate
gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with
authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following
significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
estimates, and require it to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
these programs relating to RAPIVAB sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the
differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid
by eligible customers covered under federally qualified programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based
on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through
public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization
data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
these fees by applying the contractual rates to such product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does
not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three months ended
March&nbsp;31, 2016 and 2015:</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">537</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,890</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,518</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,324</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,475</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi &amp; Co., Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">310</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total collaborative and other research and development revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,930</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,771</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,820</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,826</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Advertising</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response
advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid
to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion
to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with
the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">All share-based payments, including grants
of stock option awards and restricted stock unit awards, are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive
Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model.
The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation
cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &ldquo;performance&rdquo; is deemed to have
occurred.</P>




<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended March&nbsp;31, 2016 and
2015 includes $1,338 and $1,315, respectively, related to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly
associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on
the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the
effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the
three months ended March&nbsp;31, 2016 and 2015.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Lease Financing Obligation</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research
facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was
deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company
recorded an asset of $1,589, representing the Company&#8217;s leased portion of the building and recorded a corresponding
liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for
de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The
asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and
interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact
on cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended
March&nbsp;31, 2016 includes $132 related to the lease financing obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016, the lease financing obligation balance was $2,506
and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease
financing obligation are $4,839.</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market
adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments
for the three months ended March&nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. Mark-to-market
adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for
which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by
U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds
defined in the Currency Hedge Agreement. As of March&nbsp;31, 2016 and December 31, 2015, no hedge collateral was posted under
the agreement.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#8217;s
employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&nbsp;31,
2016 and 2015 does not include 1,330 and 3,529, respectively, of such potential common shares, as their impact would be anti-dilutive.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Significant Customers and Other Risks</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Significant Customers</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three
specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted
for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#8217;s outstanding
receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the
commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the
SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis.
In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made
by the Company&#8217;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#8217;s primary source of revenue that has an underlying
cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with
BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development
costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the
Company&#8217;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS
peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#8217;s
future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from
the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest,
and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of
principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s
drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform
their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical
ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays
in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling
of RAPIVAB or the Company&#8217;s product candidates in development.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Credit Risk</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially
subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
there is no assumed credit risk.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Accounting Standards Board
(&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-09: <i>Compensation - Stock Compensation (Topic 718):
Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU 2016-09&#8221;). The amendments in this update
simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income
taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU
2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No.
2016-02: <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221;). The amendments in this update require lessees, among other things,
to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous
authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective
for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01:
<i>Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>
(&#8220;ASU 2016-01&#8221;). The amendments in this update address certain aspects of recognition, measurement, presentation and
disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the
requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required
to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the
Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11:
<I>Inventory - Simplifying the Measurement of Inventory </I>(&ldquo;ASU 2015-11&rdquo;), which changes the measurement principle
for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable
value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal,
and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method.
The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost
methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those
years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company
does not expect this standard to have a material impact on its consolidated financial statements.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In April 2015, the FASB issued Accounting
Standards Update No. 2015-03, <I>Simplifying the Presentation of Debt Issuance Costs </I>(&ldquo;ASU 2015-03&rdquo;). This standard
amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying
amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after
December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first
quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</P>




<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15
&#8211; <i>Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s
Ability to Continue as a Going Concern </i>(&#8220;ASU 2014-15&#8221;)<i>,</i> which defines management&#8217;s responsibility
to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about
an entity&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued and
to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management
must assess if there is substantial doubt about the company&#8217;s ability to continue as a going concern within one year after
the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for
all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted.
The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09 &#8211;
<i>Revenue from Contracts with Customers </i>(&#8220;ASU 2014-09&#8221;), which provides a single, comprehensive revenue recognition
model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty
of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets
recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective
date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original
effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified
retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 2 &#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">As of March&nbsp;31, 2016, the Company had
two stock-based employee compensation plans, the Stock Incentive Plan (&ldquo;Incentive Plan&rdquo;) and the Employee Stock Purchase
Plan (&ldquo;ESPP&rdquo;), both which were amended and restated in March 2014 and approved by the Company&rsquo;s stockholders
in May 2014. Stock-based compensation expense of $2,645 ($2,556 of expense related to the Incentive Plan and $89 of expense related
to the ESPP) was recognized during the first three months of 2016, while $2,259 ($2,165 of expense related to the Incentive Plan
and $94 of expense related to the ESPP) was recognized during the first three months of 2015.</P>




<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $16,164 of total unrecognized compensation
cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&nbsp;31, 2016.
That cost is expected to be recognized as follows: $4,840 during the remainder of 2016, $5,856 in 2017, $3,796 in 2018 and $1,672
in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized
until &#8220;performance&#8221; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards
to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted
with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Since March&nbsp;1, 2011, stock
option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company
made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after
two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
These awards vest upon successful completion of specific development milestones. As of March 31, 2016, 75% of the August 2013 grants
have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting
occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and
(3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of March 31, 2016, 25% of the
August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
Plan.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards <br>Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options <br>Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted <br>Average <br>Exercise <br>Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">16</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">10,671</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7.50</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(79</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.32</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">109</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(109</td><td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9.58</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance March&nbsp;31, 2016</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">127</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,483</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">No stock option awards were granted under
the Incentive Plan during the first three months of 2016.&nbsp;</P>



<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to
be purchased under the ESPP, of which 463 shares remain available for purchase at March&nbsp;31, 2016. Eligible employees may authorize
up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month
purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee
may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued
34 shares during the first three months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related
to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p></div><p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 3 &#8212; Collaborative and Other Research and Development Contracts</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><I>U.S.&nbsp;Department of Health and Human
Services (&ldquo;BARDA/HHS&rdquo;).</I> On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract
for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This
BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional
development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of March
31, 2016, a total of $17,623 has been awarded under exercised options within this contract.</P>


<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).</i>
In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease.
NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this
contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period.
The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the
treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human
clinical trial. As of March 31, 2016, a total of $29,875 has been awarded under exercised options within this contract. BCX4430
is the lead compound in the Company&#8217;s BSAV research program.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions
that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables,
and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><i>Seqirus UK Limited (&#8220;SUL&#8221;).</i> On June 16, 2015,
the Company and Seqirus UK Limited ("SUL"), a limited company organized under the laws of the United Kingdom and a subsidiary
of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the "Territory"). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years
and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure
pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside
the U.S.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted an NDA for RAPIVAB to the
FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in
connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for
the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory
filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for
RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee,
composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the
commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront
payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory
milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in
the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the
Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them
on any future milestone payments and/or royalties received by the Company from SUL.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to
the Taiwan FDA in late 2013.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In June
2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of
the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
in Korea.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology. Under
the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia
in exchange for a $10,000 up-front payment.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued
to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally,
at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid
by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination
of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements
with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions,
any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from
Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
the terms and conditions of the contracts are substantially the same.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;).</i>
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 4 &#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Overview</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
has been fully utilized with the September 2012 interest payment.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
as a result of this transaction.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount
of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified
as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA
Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest
in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event,
the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the
PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of
any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from
Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating
the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease
to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default
of the PhaRMA Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows.
As of March 31, 2016, the PhaRMA Notes remain in default.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of March 31, 2016, the aggregate fair value of the PhaRMA Notes
was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Foreign Currency Hedge</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive
Loss. Cumulative mark-to-market adjustments for the three months ended March&nbsp;31, 2016 and 2015 resulted in a loss of $2,753
and a gain of $464, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments
based on defined thresholds. As of March 31, 2016 and December&nbsp;31, 2015, no collateral was posted under the Currency Hedge
Agreement. The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the
Currency Hedge Agreement. As of March 31, 2016, the maximum amount of hedge collateral the Company may be required to post is $9,750.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 5 &#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February
26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock,
depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the
time of sale.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company
to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from
time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration
statement.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_006"></a>Item&nbsp; 2. &nbsp;&nbsp;&nbsp;&nbsp;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>This Quarterly Report on Form 10-Q contains statements of a forward-looking
nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the
actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could
cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed
in other filings made by the Company with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#8220;Information Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We operate in a highly competitive environment that involves a number
of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our product candidates and
retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling
procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our operating expenses are also difficult to predict and depend on
several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
of our actions due to contractually committed activities and/or payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a result of these factors, we believe that period to period comparisons
are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing
factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event,
the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Overview</u></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Corporate Highlights</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>RAPIVAB (peramivir injection)</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">RAPIVAB was approved by the FDA on December 19, 2014 and on June 16,
2015 we entered into a license agreement granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize
RAPIVAB (peramivir injection) for the treatment of influenza on a worldwide basis except in Israel, Japan, Korea and Taiwan. With
the approval, commercial availability and out-licensing collaboration of RAPIVAB, we have moved our focus to: (1) obtaining a stockpiling
procurement contract with the U.S. Government to realize the strategic value of this program; (2) fulfilling our post-approval
development requirements, including conducting a pediatric trial and a trial in elderly/high risk influenza patients; and (3) submitting
a Marketing Authorization Application (&#8220;MAA&#8221;) and New Drug Submission (&#8220;NDS&#8221;) in the European Union (&#8220;EU&#8221;)
and Canada, respectively, to allow SUL the ability to commercialize the drug in those regions. In January 2016, we submitted a
New Drug Submission (NDS) for RAPIVAB in Canada, seeking approval for the treatment of acute uncomplicated influenza in adult patients.
</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>HAE Program</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Avoralstat</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">On December 18, 2014, we announced the dosing of the first patient
in OPuS-2 (<b>O</b>ral <b>P</b>rophylaxi<b>S-2</b>), a blinded, randomized, placebo-controlled clinical trial of orally-administered
avoralstat in patients with hereditary angioedema (&#8220;HAE&#8221;). OPuS-2 was a 12-week, three-arm, parallel cohort design
trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered three-times daily compared
with placebo. This trial was conducted in the U.S. and select European countries. The primary efficacy endpoint for the trial was
the mean angioedema attack rate for each avoralstat dose group compared to placebo. On February 8, 2016, we announced results from
OPuS-2. In the OPuS-2 study, HAE patients with a historical attack frequency of greater than 0.45 attacks per week were randomized
to treatment with either 500 mg or 300 mg of avoralstat, or placebo, administered three times daily for 12 weeks. Thirty-eight
subjects received avoralstat 500 mg, 36 subjects received avoralstat 300 mg, and 36 subjects received placebo. Treatment with 500
mg and 300 mg of avoralstat three times daily failed to demonstrate a statistically significantly lower mean attack rate versus
placebo. The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat 500mg and 0.71 (0.66) on avoralstat
300mg, compared to 0.61 (0.41) on placebo. Statistically significant improvements in duration of attacks and in the Angioedema
Quality of Life total score were observed comparing the 500 mg three times a day avoralstat arm to placebo. Following the analysis
of OPuS-2 results, the decision was made to discontinue further development of softgel avoralstat formulation in order to focus
development efforts on a novel solid dosage form of avoralstat to achieve meaningfully better drug exposure.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">We are currently conducting a clinical pharmacology
trial of multiple novel formulations of avoralstat in healthy volunteers. The goals of this trial are: 1) to identify twice-daily
dosing regimens with one or more formulations, and 2) to maintain plasma drug levels, in the majority of individuals throughout
the dosing interval during twice-daily dosing, that are within or above the estimated target range for efficacy in the treatment
of hereditary angioedema. The trial is ongoing, and we expect to report trial results in the summer of 2016 upon its completion.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>BCX7353</i></b>&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2015, we selected BCX7353 to advance into Phase 1 development as a once-daily, oral prophylactic
HAE treatment. In October 2015, we successfully completed a Phase 1 clinical trial of BCX7353 in Western and Japanese healthy volunteers.
In this Phase 1 clinical trial, we studied BCX7353 single doses of up to 1000mg, once-daily doses of up to 500mg for seven days,
and once-daily doses of 350mg for 14 days in healthy Western volunteers. Plasma levels increased in approximate proportion to dose,
and drug exposure was not affected by dosing with food. The half-life of BCX7353 was estimated at 50-60 hours. After daily dosing,
blood levels met or exceeded a predicted target therapeutic range throughout the 24 hour dosing interval. Inhibition of the target
enzyme, plasma kallikrein, was measured in a sensitive and specific bioassay. Daily dosing with BCX7353 strongly inhibited plasma
kallikrein at all four dose levels; the degree of inhibition was dose-related (p &lt; 0.0001) and inhibition was sustained throughout
the 24 hour dosing interval. This pharmacodynamic effect correlated strongly to the achieved drug concentration (r = 0.91, p &lt;
0.0001).</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In cohorts of healthy
Japanese volunteers, we gave single oral doses of BCX7353 of 100mg and 500mg, and daily doses of 250mg of BCX7353 for seven
days. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250mg in Japanese subjects was similar to
that seen at the 350mg daily and 500mg daily dose levels in Western subjects.</P>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In multiple dose subjects, 90% (63 of 70) of adverse events (AEs)
have been grade 1. The six grade 2 AEs observed were; upper abdominal pain (1 AE, discontinued from study); syncope (1 AE), headache
(1 AE), diarrhea (1 AE), and upper abdominal pain (1 AE) occurring on a single subject (discounted from study), and maculopapular
rash (1 AE). One grade 3 AE was observed, a cutaneous delayed-type hypersensitivity reaction. The two rash AEs are described in
more detail below.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The incidence of drug-related skin rash across all multiple-dose cohorts
was 4% (2 of 50 subjects). One Japanese subject dosed at 250 mg daily for seven days developed a grade 2 maculopapular skin rash
following cessation of dosing, and one Western subject dosed at 500 mg daily for seven days developed a grade 3 hypersensitivity
reaction, described as a maculopapular skin rash, following cessation of dosing. Both AEs were assessed by the investigator as
drug-related. The Japanese subject received antihistamines and the Western subject received corticosteroids, and in both cases
the rash resolved within a few days.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The combined data from both Western and Japanese healthy volunteers
indicates that oral BCX7353 has been generally safe and well tolerated in a total of 96 treated healthy volunteers, 46 with singles
doses and 50 with multiple doses. No serious adverse events have been seen and no dose-limiting toxicity has been identified. There
have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The safety, tolerability, drug exposure and on-target plasma kallikrein
inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase 2 trial (&#8220;APeX-1&#8221;)
to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 as a preventative treatment to
reduce the frequency of attacks in HAE patients is expected to begin in 2016. The design of the trial will be described when the
APeX-1 protocol is approved by regulatory authorities and the clinical trial is initiated.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In October 2015 the Japanese Ministry of Health Labor &amp; Welfare
(&#8220;MHLW&#8221;) announced that BioCryst&#8217;s BCX7353 was one of six products designated under MHLW&#8217;s new Sakigake
fast track review system. The Sakigake Designation System promotes R&amp;D in Japan and provides for additional interactions with
the regulatory agency in Japan from early development through filing, and prioritized development and review, with the aim of introduction
of the product as soon as possible to address a serious unmet medical need.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Other 2<sup>nd</sup> generation&nbsp;HAE compounds</i></b></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition to BCX7353, we have succeeded in inventing several uniquely
different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional drug
candidates that have suitable pharmacologic properties to advance into preclinical development. Additional disclosure on these
compounds will occur as we near IND filings for any of these compounds.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>BCX4430</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2014, we began dosing subjects in a randomized, placebo-controlled Phase 1 clinical trial to
evaluate <FONT STYLE="font-size: 10pt">intramuscular (&ldquo;i.m.&rdquo;) administration of BCX4430 in healthy volunteers. The
main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
administered via i.m. injection in healthy subjects. We have completed single and multiple ascending doses of BCX4430 administered
in healthy volunteers. BCX4430 administered by i.m. injection was generally safe and well tolerated through doses up to 10mg/kg
daily for seven days, the maximum dose planned in the trial.&nbsp;</FONT></FONT></P>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">On March 7, 2016, results from a preclinical study of our antiviral BCX4430 in interferon-receptor-deficient
mice infected with Zika virus were presented at a <FONT STYLE="font-size: 10pt">World Health Organization</FONT><FONT STYLE="font-size: 10pt">
(WHO) conference in Geneva, Switzerland. The primary goal of the study was to assess the effect of BCX4430 treatment on survival
through Day 28 in interferon-receptor-deficient mice infected with the Zika virus. BCX4430 was administered by i.m. injection
twice a day beginning four hours prior to virus challenge and continuing for eight days; two dose levels were tested. In the standard
dose BCX4430 group, 7 of 8 mice survived through Day 28. In the low dose BCX4430 group (n=8), and in control groups administered
vehicle placebo (n=8) or ribavirin at two dose levels (n=16); no animals survived to Day 28. Overall survival for the standard
dose level of BCX4430 was superior to both the placebo and the ribavirin treatment control groups (p &lt; 0.0001). For both dose
levels of BCX4430, median survival was superior to both control groups (&gt;28 days for BCX4430 standard dose and 23 days for low
dose) compared to 14 to 17 days for controls.</FONT></P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Additional studies of BCX4430 in the same mouse model were conducted at Utah State University. In one study, surviving
mice that were previously treated with the standard dose of BCX4430 after initial Zika virus challenge, were re-challenged with
the Zika virus on Day 28, without additional BCX4430 treatment. All the re-challenged mice survived through day 56 with no disease
signs observed, indicating the development of effective immune responses. A further experiment using the same AG129 mouse model
tested the delayed treatment with BCX4430 after viral challenge. Groups of mice received BCX4430 150 mg/kg twice-daily by intramuscular
injection starting on days 1, 3, 5, or 7 post infection, or vehicle (control group). All BCX4430 treated groups showed a statistically
significant survival benefit compared to vehicle controls.</P>



<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (three months ended March&nbsp;31, 2016 compared to the three
months ended March&nbsp;31, 2015)</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For the three months ended March&nbsp;31, 2016, total revenues were
$4.8 million as compared to $6.8 million for the three months ended March&nbsp;31, 2015. The decrease was primarily due to lower
collaborative revenue associated with BCX4430 development under the advanced development contract with BARDA/HHS awarded in March
2015. In addition in 2015, we recorded $537,000 in RAPIVAB<sup>&#174; </sup>revenue representing drug sold under the sell-through
revenue recognition methodology. No RAPIVAB revenue was received in 2016 as RAPIVAB commercialization is now being handled by SUL.
Revenues in the first quarter of 2016 included $1.9 million of royalty revenue from SUL, Shionogi and Green Cross associated with
sales of peramivir in the United States, Japan and Korea, $2.3 million of reimbursement of collaborative expenses from NIAID/HHS
and BARDA/HHS related to the development of BCX4430 and $0.6 million associated with collaborative revenue amortization from other
corporate partnerships. Revenues in the first quarter of 2015 included $1.5 million of royalty revenue from Shionogi and Green
Cross associated with sales of peramivir in Japan and Korea, $4.5 million of reimbursement of collaborative expenses from NIAID/HHS
and BARDA/HHS related to the development of BCX4430 and i.v. peramivir and $0.3 million associated with collaborative revenue amortization
from other corporate partnerships. In addition, we recorded approximately $0.5 million of RAPIVAB revenue under the &#8220;Sell-Through&#8221;
revenue recognition methodology.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Research and development (&ldquo;R&amp;D&rdquo;) expenses increased to $20.6 million for the first quarter of 2016
from $17.1 million in 2015. The increase in 2016 R&amp;D expenses, as compared to 2015, reflect higher development costs associated
with our HAE programs, as well as ongoing post-approval clinical trials of RAPIVAB in both pediatric and elderly/high risk influenza
patients.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the periods
indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><B>Three&nbsp;Months&nbsp;Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><B>March&nbsp;31,</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">R&amp;D expenses by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; padding-left: 10pt">Avoralstat</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8,365</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,246</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">BCX7353</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other 2nd generation HAE compounds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,881</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">BCX4430</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,299</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Peramivir</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,146</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other research, preclinical and development costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,922</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,173</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.25pt">Total R&amp;D expenses</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">20,579</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">17,120</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">General and administrative (&ldquo;G&amp;A&rdquo;) expenses decreased to $3.2 million for the first quarter of
2016 as compared to $4.1&nbsp;million in 2015. The decrease of $0.9 million is primarily due to a reduction in unrestricted grants,
as well as the elimination of RAPIVAB marketing and commercial consulting expense in 2016, as RAPIVAB is now being commercialized
by SUL.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest and other income was $0.4 million in the first quarter of
2016, compared to $0.1 million in the first quarter of 2015. The increase of $0.3 million is related to an unusual net gain benefit
on a settled dispute unrelated to our normal operations.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense related to the non-recourse notes issued in conjunction
with the non-dilutive peramivir royalty monetization transaction in March 2011 was $1.3&nbsp;million in the first quarter of each
of 2016 and 2015. In addition, $0.1 million of interest expense was recognized in the first quarter of 2016 related to the finance
obligation associated with our new research facility.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A mark-to-market loss of $2.8 million related to our foreign currency
hedge was recognized in the first quarter of 2016, compared to a mark-to-market gain of $0.5 million in the same quarter in the
prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Cash expenditures have exceeded revenues
since our inception and we expect our 2016 operating expenses to exceed our 2016 revenues. Our operations have principally been
funded through public offerings and private placements of equity securities; cash from collaborative and other research and development
agreements, including U.S. Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing.
To date, we have been awarded a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014,
a NIAID/HHS BCX4430 development contract totaling $34.0 million, which is ongoing, and a BARDA/HHS BCX4430 development contract
totaling $36.2 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options
in the active contracts is $29.9&nbsp;million and $17.6 million, respectively. Most recently, we completed a successful public
offering in June 2014 of 11.5 million shares of common stock at a price of $10.00 per share, which provided net proceeds to us
of approximately $107.8 million. This financing and the recently completed SUL out-licensing transaction provide us liquidity through
mid-2017. We may issue securities through private placement transactions or registered public offerings pursuant to a registration
statement filed with the SEC. In addition to the above, we have received funding from other sources, including other collaborative
and other research and development agreements; government grants; equipment lease financing; facility leases; research grants;
and interest income on our investments.</P>




<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of March 31, 2016, we had a net working capital deficit of $12.6
million, a decrease of approximately $14.1 million from the working capital surplus of $1.5 million at December&nbsp;31, 2015.
The decrease in working capital was principally due to our normal operating expenses associated with the development of our product
candidates. Our principal sources of liquidity at March&nbsp;31, 2016 were approximately $12.9 million in cash and cash equivalents;
approximately $64.0 million in investments considered available-for-sale; and approximately $5.2 million in U.S. Government receivables.
We anticipate our cash and investments will fund our operations through mid-2017.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We extended and executed additional lease obligations in 2015
for our Birmingham, Alabama operations, which increased the obligations by $5.6 million and extended the new obligations out
to 2027. These operating lease obligations encompass future rental obligations of our Birmingham operating facilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">lease or loan financing and future public or private equity financing;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">our existing capital resources and interest earned on that capital;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount
of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for
the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at March 31, 2016, we believe these resources
will be sufficient to fund our operations through mid-2017. Our future liquidity needs, and ability to address those needs, will
largely be determined by the success of our product candidates and key development and regulatory events in the future. In order
to continue our operations substantially beyond mid-2017, we will need to: (1)&nbsp;successfully secure or increase U.S. Government
funding of our programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our products or product candidates,
pursuant to which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from
other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce
spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. We may issue securities through
private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of our available
funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the magnitude of work under our government contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">changes in existing collaborative relationships or government contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">successful commercialization of marketed products by either us or a partner;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">competitive and technological advances;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the
RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements
will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates;
obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and
changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of
business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing
processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2016</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2016 operating cash usage to be in the range of $55 to $75 million, and expect our total 2016 operating
expenses to be in the range of $78 to $98 million. Our operating expense range excludes equity-based compensation expense due to
the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&#8217;s
stock, as well as vesting of the Company&#8217;s outstanding performance-based stock options. Our operating cash forecast excludes
any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows.
Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated
or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere
in this report.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of March 31, 2016, we do not have any unconsolidated entities or
off&#8211;balance sheet arrangements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in our 2015 Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2015, we believe that the following accounting policies are the most critical to aid you in fully understanding
and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation
of our financial statements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our inventories consist of RAPIVAB finished goods and work in process,
which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 23pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, we entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.8
million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
period of involvement in these regulatory support activities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we may receive up to $12.0 million
in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the
FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication
in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>,
and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the
milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Sales</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We recognize revenue for sales of RAPIVAB when title and substantially
all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our
specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is
persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably
assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United
States, prior to completion of the SUL transaction, we sold RAPIVAB to specialty distributors, who, in turn, sell to physician
offices, hospitals and federal, state and commercial health care organizations.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We utilize data from external sources to help estimate gross-to-net
sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have categorized and described more fully the following significant
sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
us to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
relating to RAPIVAB sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on
multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience,
changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory
or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and
the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers
of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary
adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent
actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed,
either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
rates to such sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not record a product return allowance as we do not offer the
ability to return goods once a bona fide shipment has been accepted by a specialty distributor.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct external
expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect
expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our
research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery
research efforts.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0&nbsp;million
to support our potential hedge obligations. As of March 31, 2016, the maximum amount of hedge collateral we may be required to
post is $9.8 million.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;). The Company is also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of March 31, 2016, no collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We account for uncertain tax positions in accordance with U.S. GAAP.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">the initiation, timing, progress and results of our preclinical testing, clinical trials, and, to the extent applicable, post-marketing commitments, for our HAE product candidates, RAPIVAB, BCX4430, and our other research and development efforts;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">the further preclinical development, clinical development, commercialization, or post marketing studies by either us or partners of our product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 87%"><font style="font-size: 10pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</font></td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">plans, programs, progress and potential success of our collaborations, including SUL for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to operate our business without infringing the intellectual property rights of others;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to raise additional capital to fund our operations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our financial performance;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">competitive companies, technologies and our industry.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_007"></a>Item&nbsp; 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risk</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio and
borrowings under our PhaRMA Notes.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates
relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not
significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our
fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will
be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations
due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market
value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers.
To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding
the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest
rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant
losses from our investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency
exchange risk in our normal operations.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2016 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_008"></a>Item&nbsp; 4. &nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation,
under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of March&nbsp;31, 2016, the Company&#8217;s disclosure controls
and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted
by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company
in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief
Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended March&nbsp;31, 2016 that have materially affected, or are reasonably likely to
materially affect, the Company&#8217;s internal control over financial reporting.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART II. OTHER INFORMATION </b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_009"></a>ITEM&nbsp; 1A.</b> <b><i>&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>An investment in our stock involves risks. You should carefully
read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial
condition or results of operations, along with all of the other information included in our other filings with the Securities and
Exchange Commission, before deciding to buy our common stock.</i></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><B><I>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;Since our inception, we have not achieved sustained profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;To receive the regulatory approvals necessary for the sale of
our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, avoralstat,
BCX7353 and our other rare disease product candidates), even after earlier clinical trials show promising results. The development
of our product candidates, including our clinical trials, may not be adequately designed or executed, which could affect the potential
outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. The pre-clinical
and clinical data from our product candidates could cause us or regulatory authorities to interrupt, delay, modify or halt preclinical
or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in humans could also result in the
FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. In addition, the
FDA or other regulatory agencies may determine that study data from our product candidates necessitates additional studies or study
designs which differ from our planned development strategy, and regulatory agencies may also require patient monitoring and testing
or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost
and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate
clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail
to demonstrate that our product candidates are safe or effective and have acceptable commercial viability. Regulatory authorities
may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur
substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment can result in increased
costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates,
we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval
for the product candidates.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because we focus on developing drugs as treatments for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have received orphan and fast track designations for avoralstat
in the United States. Despite this designation; we may not experience a faster development, review or approval process compared
to the conventional FDA procedures. The FDA may withdraw fast track designation if it believes the designation is no longer supported
by data from our clinical development program. Although we have also received Sakigake designation for BCX7353 in Japan, we may
not experience a faster development, review or approval process compared to the conventional process.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through
the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy
in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols.
Failure to achieve any of these endpoints in any of our programs, including avoralstat, BCX7353 and our other rare disease product
candidates, could result in delays in our trials or require the performance of additional unplanned trials. This could result in
delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;We rely heavily upon third parties for many important stages
of our product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="3">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of certain preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">formulation improvement strategies and methods, including those for avoralstat; and</font></td></tr>
</table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
be materially adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
our requirements including but not limited to problems involving:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">inconsistent production yields;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product liability claims or recalls of commercial product;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for avoralstat, BCX7353 and BCX4430.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to manufacture the materials
required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control
over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements
with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore,
changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change
of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign
requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar
foreign regulatory agencies may at any time implement new standards, or change their interpretation and enforcement of existing
standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they
may be subject to regulatory action, civil actions or penalties any of which could be costly to the Company and could result in
a delay or shortage of product.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of potential product candidates for desirable disease targets licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">other drug development technologies;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Developments by others may render our product candidates or technologies
obsolete or noncompetitive.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We and our partners are performing research on or developing products
for the treatment of several disorders including HAE and recurrent/refractory peripheral T-cell lymphoma, as well as broad spectrum
antivirals that may be developed as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical
products we plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required
regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve
a significant competitive advantage. Such is the case with Eisai Co. Ltd.&#8217;s TARGRETIN <sup>&#174;</sup> for cutaneous T-lymphoma;
the current neuraminidase inhibitors marketed by GSK and Roche for influenza; CINRYZE <sup>&#174;</sup> , KALBITOR <sup>&#174;</sup>
and FIRAZYR <sup>&#174;</sup> , marketed by Shire Pharmaceuticals, Inc. for HAE; and BERINERT <sup>&#174;</sup> , marketed by CSL
for HAE. Therapeutic products with potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&#8217;s ZMapp
(antibody-based) and Gilead Sciences, Inc.&#8217;s product currently under development (small molecule), both of which have been
used in Ebola infected patients. Further, several pharmaceutical and biotechnology firms, including major pharmaceutical companies
and specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and molecules
in development in the fields of HAE and in other therapeutic areas where we have discovery and development efforts ongoing. If
one or more of our competitors&#8217; products or programs are successful, the market for our products may be reduced or eliminated.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">capital resources;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">research and development resources, including personnel and technology;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory experience;</font></td></tr>
</table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">preclinical study and clinical testing experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">manufacturing and marketing experience;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">production facilities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face risks related to our government-funded programs; if BARDA/HHS
or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were
to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development
effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have completed work under a contract with BARDA/HHS for the development
of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development
of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus disease. In contracting
with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for
a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation,
could result in contract termination.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">U.S. Government contracts typically contain a number of extraordinary
provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">terminate or reduce the scope of our contract with or without cause;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interpret relevant regulations (federal acquisition regulation clauses);</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require performance under circumstances which may not be favorable to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require an in process review where the U.S. Government will review the project and its options under the contract;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">control the timing and amount funding, which impacts the development progress of our programs; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have termination
and audit provisions which create additional risks to us.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with applicable
laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009;
all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at
the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of its audits, the U.S. Government
may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of
revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event
BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate
was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a
result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties
and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and
suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if
allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may
not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk
of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
to private sector commercial companies.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
process requirements, and the additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships
with third parties for the development of our product candidates, including avoralstat, BCX7353 and our other rare disease product
candidates; the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for RAPIVAB
or BCX4430 by any government agency or other party; the progress and results of our current and proposed clinical trials for our
most advanced product candidates, including avoralstat, BCX7353 and our other rare disease product candidates; the progress made
in the manufacture of our lead products and the progression of our other programs.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities or collaborative arrangements with partners, including governmental
agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when needed or on terms acceptable
to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable
than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or
rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights
to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate
certain of our research and development programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In order to continue future operations and continue our drug development
programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government
funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise
additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;the avoralstat
development program (including, but not limited to, formulation trials, phase 3 trials, long-term human safety studies, and the
timing of carcinogenicity studies), the progress of BCX7353 and our other rare disease product candidates, funding for and continued
successful development of BCX4430, and the progress of our early discovery programs. In addition, constriction and volatility in
the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure
to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners
(which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current
economic and political environment. Any such instability may impact these parties&#8217; ability to fulfill contractual obligations
to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers
may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place
severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit
markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a
material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product
candidates.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing
and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our contracts for collaborative arrangements may expire;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may not comply with applicable government regulatory requirements.</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;If we or our partners fail to fulfill our responsibilities in
a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated,
or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our
partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue
further development of one or more of our product candidates, undertake commercialization activities at our own expense or find
alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect
our business, because if our product candidates do not progress through the development process or reach the market in a timely
manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty
payments.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;We do not have a great deal of experience in commercializing
our products or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we
currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of
our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful
collaborations, we will not receive any potential future event or other collaborative payments.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Commercialization of RAPIVAB by our partners is subject to the potential
commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestone
payments, royalties or other consideration are highly speculative.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;Commercialization success of RAPIVAB is uncertain and is subject
to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of RAPIVAB is subject to further risks and may be negatively impacted by a number of factors, including, but
not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">necessary funding for post-marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">effectiveness of marketing efforts for RAPIVAB by our partners;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">market satisfaction with existing alternative therapies;</font></td></tr>
</table>

<p style="margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">perceived efficacy relative to other available therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">disease prevalence;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">cost of treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pricing and availability of alternative products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">marketing and sales activities of competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">relative convenience and ease of administration.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We are subject to various federal and state laws related to RAPIVAB and
other products under development and, if we or our partners do not comply with these regulations, we could face substantial penalties.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our or our partners&#8217; activities related to RAPIVAB, or any of
our other products under development and following their regulatory approval, are subject to regulatory and law enforcement authorities
in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. In
the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and commercialization efforts, we continue
to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For example, we are responsible for reporting adverse
drug experiences, we have responsibility for certain post-approval studies, we may have responsibilities and costs related to a
recall or withdrawal of RAPIVAB from sale, we may incur liability associated with RAPIVAB manufacturing contracted by us or in
support of any of our partners, we are required to maintain records and provide data and reports to regulatory agencies related
to RAPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain
promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial
condition. In addition, we are now subject to the federal physician sunshine act and certain similar legislation in various states.
We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal
and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our
distributors, might be challenged under anti-kickback or similar laws. Violations of the physician sunshine act and similar state
legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties,
and future exclusion from participation in government healthcare programs.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial,
we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing
this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be
subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject
to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies.
Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to
the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the
approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing and
surveillance to monitor its safety or efficacy.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products that
are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
with all applicable federal and state fraud and abuse laws may be costly.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We and our partners may be subject to new legislation, regulatory proposals
and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability
to market our products, including RAPIVAB, obtain collaborators and raise capital.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Patient Protection and Affordable Care Act, or PPACA, made extensive
changes to the delivery of health care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies,
some of which became effective immediately and others of which will be taking effect over the next several years. For example,
the PPACA seeks to expand health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid.
The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid
to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual
fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical
discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that
could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also will require
reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and
teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future
will have on our business. Further, it remains unclear whether there will be any changes made to provisions of the PPACA or other
health care laws through acts of Congress in the future. The continuing efforts of the government, insurance companies, managed
care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased
net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical
and device manufacturers will also be required to report and disclose investment interests held by physicians and their immediate
family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties
for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the
PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state
laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material
adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face
a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp;As a result of
these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Managed care organizations are increasingly challenging the prices
charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
condition and results of operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>There are risks related to the potential government use or sale of peramivir
(RAPIVAB).</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">United States Government use or sale of RAPIVAB in emergency situations,
or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
generally safe, well-tolerated and effective. Such government use of peramivir may create certain liabilities for us or our partners
in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able to fully meet
the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional orders
of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or replace
peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully
enforce our intellectual property rights.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There is no assurance that the non-U.S. partnerships that we have
entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that peramivir will
be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market
approval is granted, there is no assurance that any government order or commercialization of peramivir in any countries will be
substantial or will be profitable to us. In addition, the sale of peramivir, emergency use or other use of peramivir in any country
may create certain liabilities for us and our partners.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">adverse drug experience reporting regulations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product promotion;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product changes or modifications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and,
if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge
arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest
in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes
until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated
to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014,
the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an
event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be
able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest
in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture or other documents related to&nbsp;the
PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following
repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Because an event of default has occurred under the PhaRMA Notes, the
holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;Royalty Sub&#8217;s ability to service its payment obligations
in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be required to pay significant premiums under the foreign currency
hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the foreign currency hedge arrangement.&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
amount of $2.0 million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year,
the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement)
is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the
currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results
and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign
currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a
foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;Our success will depend in part on our ability and the abilities
of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if and when patents will issue;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">whether or not others will obtain patents claiming aspects similar
to those covered by our patent applications.</p></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents issued
to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pay damages.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation or
administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent
office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
such proceeding may be substantial whether or not we are successful.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;If the use or misuse of peramivir or any other regulatory body-approved
products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
could be harmful to our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">withdrawal of clinical trial volunteers or patients;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">litigation costs;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the diversion of management&#8217;s attention from managing our business.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;While we currently have insurance for our business, property,
directors and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to
assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we
will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that
is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an
adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our
ability to obtain or maintain insurance coverage at reasonable costs or at all.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;<b><i>If our facility incurs damage or power is lost
for a significant length of time, or if we incur significant cost overruns or delays in the construction of our new research facility
in Birmingham, Alabama, our business will suffer.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we store most of our preclinical and clinical data at
our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
development process and any system failure could harm our business and operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">We also face the risk that the costs and time
required in connection with the construction of our new research facility in Birmingham, Alabama could exceed our current expectations.
If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition,
and results of operations could be adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;We are increasingly dependent on information technology systems
to operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;Several of our stockholders own greater than 5% of our outstanding
common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could cause the value of an investment in our common stock to decline significantly.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The market prices for securities of biotechnology companies in general
have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
and these fluctuations are often not related to our financial results. For the twelve months ended March 31, 2016, the 52-week
range of the market price of our stock was from $1.63 to $16.83 per share. The following factors, in addition to other risk factors
described in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments or disputes concerning patents or proprietary rights;</font></td></tr>
</table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements relating to the status of our programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">public concern as to the safety of pharmaceutical products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">actual or anticipated fluctuations in our operating results;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in financial estimates or recommendations by securities analysts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">additions or departures of key personnel or members of our board of directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">economic and other external factors or other disasters or crises; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Future sales of our common stock by current stockholders into the
public market could cause the market price of our stock to fall. As of April 30, 2016, there were 73,692,799 shares of our common
stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition.
We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms
to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of April 30, 2016, there were 10,929,679 stock options and restricted
stock units outstanding, 121,453 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 463,227
shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants
outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock
options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;We have never paid cash dividends on our stock. We currently
intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying
cash dividends on our common stock in the foreseeable future.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="a_010"></a><b>Item&nbsp; 6. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">See the Exhibit&nbsp;Index attached to this quarterly report and incorporated herein
by reference.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_011"></a><b>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 9th day of May, 2016.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 30%">&nbsp;</td>
    <td style="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">BIOCRYST PHARMACEUTICALS, INC.</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"><i>President and Chief Executive Officer</i></p>

<p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"><i>(Principal Executive Officer)</i></p>

</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="2"><p style="font-size: 10pt; margin: 0pt 1.6pt 0pt 0"><i>Senior Vice President, Chief Financial Officer and
                    Treasurer</i></p>

</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><i>(Principal Financial and Principal Accounting Officer)</i></font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 93%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font-size: 10pt"><b>Number</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.1</font></td>
    <td><font style="font-size: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed December&nbsp;22, 2006.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"> 3.2</font></td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed July&nbsp;24, 2007.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"> 3.3</font></td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.4</font></td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"> 3.5</font></td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt"> 3.6</font></td>
    <td><font style="font-size: 10pt">Amended and Restated Bylaws of Registrant effective October&nbsp;29, 2008. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(10.1)&#8224;</font></td>
    <td><font style="font-size: 10pt">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response, dated February 25, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(31.1)</font></td>
    <td><font style="font-size: 10pt">Certification of the Chief Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(31.2)</font></td>
    <td><font style="font-size: 10pt">Certification of the Chief Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(32.1)</font></td>
    <td><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(32.2)</font></td>
    <td><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(101)</font></td>
    <td><font style="font-size: 10pt">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended March 31, 2016, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 5%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; vertical-align: top; text-align: left; width: 4%">(&nbsp;&nbsp;)</td>
    <td style="font-size: 10pt; vertical-align: middle; width: 96%">Filed or furnished herewith.</td></tr>
<tr>
    <td style="font-size: 10pt; vertical-align: top; text-align: left">&#8224;</td>
    <td style="font-size: 10pt; vertical-align: middle">Confidential treatment requested.</td></tr>
</table>


<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0">&nbsp;</p>

<p style="margin-top: 0; text-align: center; margin-bottom: 0">51</p>

<p style="margin-top: 0; text-align: center; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</p>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><img src="exh101_1.jpg"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><img src="exh101_2.jpg"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.1 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 50%">
        <P STYLE="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date: May 9, 2016</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.2 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Thomas R. Staab, II, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant&rsquo;s internal control over financial reporting.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD STYLE="width: 50%">Date: May 9, 2016</td>
    <TD STYLE="border-bottom: black 1pt solid; width: 30%">/s/ Thomas R. Staab, II</td>
    <TD STYLE="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD>Thomas R. Staab, II</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD>&nbsp;</td>
    <TD COLSPAN="2">Senior Vice President, Chief Financial Officer and Treasurer</td></tr>
</table>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 32.1 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
        <P STYLE="font-size: 10pt; margin: 0pt 1.6pt 0pt 0">The Report fully complies with the requirements of section 13(a) or 15(d) of
        the Securities Exchange Act of 1934; and</P>
        <P STYLE="font-size: 10pt; margin: 0pt 1.6pt 0pt 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3">
        <P STYLE="font-size: 10pt; margin: 0pt 0.8pt 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5">
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 2.6pt 0pt 0.25in">President and Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 2.6pt 0pt 0.25in">Date: May 9, 2016</P></TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;32.2 </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending March&nbsp;31, 2016 as filed with the Securities and Exchange Commission on the date hereof
(the &ldquo;Report&rdquo;), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect;
1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0pt 2.6pt 0pt 0">Senior Vice President, Chief Financial Officer and Treasurer</P>
        <P STYLE="font-size: 10pt; margin: 0pt 2.6pt 0pt 0">Date: May&nbsp;9, 2016</P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>bcrx-20160331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20160331" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20160331.xsd" xlink:type="simple"/>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107286">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember" id="c5803998">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5803997" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5803996" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803596" unitRef="iso4217-usd">53000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803601" unitRef="iso4217-usd">94000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803606" unitRef="iso4217-usd">32000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-03-31" decimals="-3" id="c5803611" unitRef="iso4217-usd">179000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803616" unitRef="iso4217-usd">88000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803621" unitRef="iso4217-usd">184000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803626" unitRef="iso4217-usd">21000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31" decimals="-3" id="c5803631" unitRef="iso4217-usd">293000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2016-03-31" decimals="-3" id="c5803637" unitRef="iso4217-usd">32806000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2015-12-31" decimals="-3" id="c5803638" unitRef="iso4217-usd">28395000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,914&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;32,806&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;8,328&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2016-03-31" decimals="-3" id="c5803639" unitRef="iso4217-usd">8328000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2015-12-31" decimals="-3" id="c5803640" unitRef="iso4217-usd">19288000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c5803828">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2016-01-01_2016-03-31_RangeAxis-MaximumMember" id="c5803747">P1Y180D</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborationAgreementAdditionalPaymentsReceived contextRef="i_2016-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c5803976" unitRef="iso4217-usd">29875000</bcrx:CollaborationAgreementAdditionalPaymentsReceived>
  <bcrx:CollaborativeAgreementPeriodOfcontract contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" id="c5803972">P5Y</bcrx:CollaborativeAgreementPeriodOfcontract>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803505" unitRef="iso4217-usd">2930000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803506" unitRef="iso4217-usd">4771000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803676" unitRef="iso4217-usd">2324000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803677" unitRef="iso4217-usd">4475000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-03-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803678" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-03-31_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803679" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-03-31_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803680" unitRef="iso4217-usd">310000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-03-31_CounterpartyNameAxis-SeqirusUKLimitedMember" id="c5803681" unitRef="iso4217-usd" xs:nil="true"/>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803682" unitRef="iso4217-usd">2930000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803683" unitRef="iso4217-usd">4771000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107297">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&amp;#x2019;s product candidates in development.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107294">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&amp;nbsp;31, 2016 and December 31, 2015, no hedge collateral was posted under the agreement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2016-03-31" decimals="-3" id="c5803460" unitRef="iso4217-usd">246000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2015-12-31" decimals="-3" id="c5803461" unitRef="iso4217-usd">265000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803557" unitRef="iso4217-usd">-19000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803558" unitRef="iso4217-usd">-14000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107275">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $78,915, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on March 3, 2015 and November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803897" unitRef="iso4217-usd">4840000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803903" unitRef="iso4217-usd">1672000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803901" unitRef="iso4217-usd">3796000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803899" unitRef="iso4217-usd">5856000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c5803971" unitRef="iso4217-usd">34002000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107292">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the three months ended March&amp;nbsp;31, 2016 and 2015 includes $1,338 and $1,315, respectively, related to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&amp;nbsp;31, 2016 and 2015.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c5804016" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="0" id="c5803804" unitRef="iso4217-usd">2506000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803483" unitRef="iso4217-usd">2506000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803484" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2016-01-01_2016-03-31_RangeAxis-MinimumMember" id="c5803750">P1Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityOfInvestments contextRef="d_2016-01-01_2016-03-31" id="c5803740">P3Y</bcrx:MaturityOfInvestments>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2016-01-01_2016-03-31_RangeAxis-MaximumMember" id="c5803746">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-03-31_RangeAxis-MinimumMember" id="c5803748">P90D</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-03-31_RangeAxis-MaximumMember" id="c5803749">P1Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-6" id="c5804042" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c5804045" unitRef="iso4217-usd">125000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804040" unitRef="iso4217-usd">9750000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803780" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c5803985" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5803993" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5803992" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:NumberOfMilestonesAchieved contextRef="d_2016-01-01_2016-03-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c5803914" unitRef="xbrli-pure">3</bcrx:NumberOfMilestonesAchieved>
  <bcrx:NumberOfStockbasedCompensationPlans contextRef="d_2016-01-01_2016-03-31" decimals="INF" id="c5803882" unitRef="xbrli-pure">2</bcrx:NumberOfStockbasedCompensationPlans>
  <bcrx:PaymentsForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5804004" unitRef="iso4217-usd">90000</bcrx:PaymentsForModificationOfLicenseAgreement>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="INF" id="c5804026" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c5803949" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfCommonStockSharesEnding contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c5803950" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c5803948" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2016-01-01_2016-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c5804009">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="0" id="c5804019" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c5803967" unitRef="iso4217-usd">17623000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3" id="c5803969" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:RemainingAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c5804048" unitRef="iso4217-usd">10000000</bcrx:RemainingAggregateOfferingPrice>
  <bcrx:RenewablePeriodOfAgreement contextRef="d_2016-01-01_2016-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c5804010">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c5804034" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c5804014" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="0" id="c5803725" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c5804013" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2016-01-01_2016-03-31" id="s200942">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 4 &amp;#x2014; Royalty Monetization&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, the Company completed a $30,000&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&amp;nbsp;from the transaction after transaction costs of $4,309&amp;nbsp;and the establishment of a $3,000&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&amp;nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&amp;nbsp;9, 2011 (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&amp;nbsp;per annum, payable annually in arrears on September&amp;nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows. As of March 31, 2016, the PhaRMA Notes remain in default.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of March 31, 2016, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 19; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign Currency Hedge&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&amp;nbsp;will be required if, on May&amp;nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March 31, 2016 and December&amp;nbsp;31, 2015, no collateral was posted under the Currency Hedge Agreement. The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of March 31, 2016, the maximum amount of hedge collateral the Company may be required to post is $9,750.&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RoyaltyTerm contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" id="c5803986">P10Y</bcrx:RoyaltyTerm>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,475&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,734&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,209&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;336&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;154&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;490&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,496&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,888&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,384&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;&amp;nbsp;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,890&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,518&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,324&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,475&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Shionogi &amp;amp; Co., Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;310&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,930&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,771&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,820&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,826&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803955" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c5803931">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-03-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c5803927" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-03-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c5803929" unitRef="xbrli-pure">1</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803701" unitRef="xbrli-shares">109000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement contextRef="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="-3" id="c5804003" unitRef="iso4217-usd">5911000</bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="0" id="c5804015" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <bcrx:UpfrontPaymentsReceivableAmount contextRef="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" decimals="-3" id="c5803991" unitRef="iso4217-usd">10000000</bcrx:UpfrontPaymentsReceivableAmount>
  <dei:AmendmentFlag contextRef="d_2016-01-01_2016-03-31" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2016-01-01_2016-03-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2016-01-01_2016-03-31" id="c-13">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2016-01-01_2016-03-31" id="c-12">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2016-01-01_2016-03-31" id="c-11">2016-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2016-01-01_2016-03-31" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2016-01-01_2016-03-31" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2016-04-30" decimals="INF" id="c-9" unitRef="xbrli-shares">73692799</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2016-01-01_2016-03-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2016-01-01_2016-03-31" id="c-5">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2016-01-01_2016-03-31" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2016-01-01_2016-03-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2016-01-01_2016-03-31" id="c-8">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2016-01-01_2016-03-31" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803467" unitRef="iso4217-usd">7691000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803468" unitRef="iso4217-usd">9307000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="-3" id="c5803446" unitRef="iso4217-usd">7384000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" decimals="-3" id="c5803447" unitRef="iso4217-usd">6243000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803469" unitRef="iso4217-usd">17328000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803470" unitRef="iso4217-usd">16237000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2016-03-31" decimals="-3" id="c5803492" unitRef="iso4217-usd">48000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="-3" id="c5803493" unitRef="iso4217-usd">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2016-03-31" decimals="-3" id="c5803490" unitRef="iso4217-usd">560762000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-12-31" decimals="-3" id="c5803491" unitRef="iso4217-usd">558113000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803884" unitRef="iso4217-usd">2645000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803885" unitRef="iso4217-usd">2556000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803886" unitRef="iso4217-usd">89000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803890" unitRef="iso4217-usd">2259000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803891" unitRef="iso4217-usd">2165000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803892" unitRef="iso4217-usd">94000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-01-01_2016-03-31" decimals="0" id="c5804068" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-01-01_2015-03-31" decimals="0" id="c5803798" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803815" unitRef="xbrli-shares">1330000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803816" unitRef="xbrli-shares">3529000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2016-03-31" decimals="-3" id="c5803464" unitRef="iso4217-usd">102881000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="-3" id="c5803465" unitRef="iso4217-usd">122359000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803454" unitRef="iso4217-usd">50425000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803455" unitRef="iso4217-usd">63794000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-03-31" decimals="-3" id="c5803641" unitRef="iso4217-usd">64048000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31" decimals="-3" id="c5803642" unitRef="iso4217-usd">70347000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803599" unitRef="iso4217-usd">21728000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803604" unitRef="iso4217-usd">20832000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803609" unitRef="iso4217-usd">21488000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803619" unitRef="iso4217-usd">26546000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803624" unitRef="iso4217-usd">21963000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803629" unitRef="iso4217-usd">21838000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803597" unitRef="iso4217-usd">15000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803602" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803607" unitRef="iso4217-usd">26000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-03-31" decimals="-3" id="c5803612" unitRef="iso4217-usd">64000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c5803617" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" id="c5803622" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803627" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c5803632" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803598" unitRef="iso4217-usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803603" unitRef="iso4217-usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803608" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-03-31" decimals="-3" id="c5803613" unitRef="iso4217-usd">17000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803618" unitRef="iso4217-usd">99000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803623" unitRef="iso4217-usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803628" unitRef="iso4217-usd">72000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c5803633" unitRef="iso4217-usd">212000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803595" unitRef="iso4217-usd">21666000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803600" unitRef="iso4217-usd">20718000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803605" unitRef="iso4217-usd">21438000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-03-31" decimals="-3" id="c5803610" unitRef="iso4217-usd">63822000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c5803615" unitRef="iso4217-usd">26557000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c5803620" unitRef="iso4217-usd">21820000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c5803625" unitRef="iso4217-usd">21884000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31" decimals="-3" id="c5803630" unitRef="iso4217-usd">70261000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2016-03-31" decimals="-3" id="c5803635" unitRef="iso4217-usd">22914000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2015-12-31" decimals="-3" id="c5803636" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803444" unitRef="iso4217-usd">22914000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803445" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2016-03-31" decimals="-3" id="c5803456" unitRef="iso4217-usd">41134000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c5803457" unitRef="iso4217-usd">47683000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,666&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;53&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(6&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,728&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;20,718&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;94&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;20,832&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,438&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;32&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;26&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,488&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;63,822&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(17&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107276">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2015 and the notes thereto included in the Company&amp;#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="i_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="0" id="c5803805" unitRef="iso4217-usd">4839000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-03-31" decimals="-3" id="c5803440" unitRef="iso4217-usd">12902000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c5803441" unitRef="iso4217-usd">28899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c5803592" unitRef="iso4217-usd">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-03-31" decimals="-3" id="c5803594" unitRef="iso4217-usd">48367000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803589" unitRef="iso4217-usd">-15997000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803590" unitRef="iso4217-usd">-6173000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107278">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2016-01-01_2016-03-31" id="c6107279">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of March&amp;nbsp;31, 2016 reflects $562 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2016-01-01_2016-03-31" id="s200941">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 3 &amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;).&lt;/div&gt; On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of March 31, 2016, a total of $17,623 has been awarded under exercised options within this contract.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;).&lt;/div&gt; In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of March 31, 2016, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&amp;#x2019;s BSAV research program.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 16; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On June 16, 2015, the Company and Seqirus UK Limited (&amp;quot;SUL&amp;quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;quot;SUL Agreement&amp;quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;quot;Territory&amp;quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In December 2013, the Company submitted an NDA for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 17; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&amp;nbsp;1, 2006 with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&amp;#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On June&amp;nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&amp;#x2019;s common stock, or in a combination of cash and shares.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#x201c;VUW&amp;#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-03-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804069" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804070" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804084" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804085" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-03-31" decimals="INF" id="c5804058" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c5804059" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-03-31" decimals="0" id="c5804060" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c5804061" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-03-31" decimals="0" id="c5804062" unitRef="xbrli-shares">73693000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="0" id="c5804063" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-03-31" decimals="0" id="c5804064" unitRef="xbrli-shares">73693000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c5804065" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2016-03-31" decimals="-3" id="c5803488" unitRef="iso4217-usd">737000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="-3" id="c5803489" unitRef="iso4217-usd">734000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803536" unitRef="iso4217-usd">-22578000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803537" unitRef="iso4217-usd">-15024000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107288">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. No reclassifications out of accumulated other comprehensive income (loss) were recorded during the three months ended March 31, 2016. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2015-01-01_2015-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember" decimals="1" id="c5803819" unitRef="xbrli-pure">0.9</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-03-31" id="c5803510" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803511" unitRef="iso4217-usd">15000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803518" unitRef="iso4217-usd">23868000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803519" unitRef="iso4217-usd">21256000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c5804020" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredCostsCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803452" unitRef="iso4217-usd">90000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803453" unitRef="iso4217-usd">90000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2016-03-31" decimals="-3" id="c5803481" unitRef="iso4217-usd">313000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c5803482" unitRef="iso4217-usd">329000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803776" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803778" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2016-03-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="-3" id="c5803473" unitRef="iso4217-usd">2163000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember" decimals="-3" id="c5803474" unitRef="iso4217-usd">2163000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2016-03-31" decimals="-3" id="c5803479" unitRef="iso4217-usd">9194000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c5803480" unitRef="iso4217-usd">9674000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803542" unitRef="iso4217-usd">47000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803543" unitRef="iso4217-usd">45000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c5804030" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2015-01-01_2015-03-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c5803809" unitRef="iso4217-usd">464000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2016-01-01_2016-03-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="0" id="c5803808" unitRef="iso4217-usd">2753000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2016-01-01_2016-03-31" id="s200938">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 2 &amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;As of March&amp;nbsp;31, 2016, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;), both which were amended and restated in March 2014 and approved by the Company&amp;#x2019;s stockholders in May 2014. Stock-based compensation expense of $2,645 ($2,556 of expense related to the Incentive Plan and $89 of expense related to the ESPP) was recognized during the first three months of 2016, while $2,259 ($2,165 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first three months of 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;There was approximately $16,164 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&amp;nbsp;31, 2016. That cost is expected to be recognized as follows: $4,840 during the remainder of 2016, $5,856 in 2017, $3,796 in 2018 and $1,672 in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Since March&amp;nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2016, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of March 31, 2016, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 15; Value: 3 --&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;         &lt;tr style="vertical-align: top; text-align: left"&gt;      &lt;td style="width: 33%"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 34%; text-align: center"&gt;       &lt;!-- Field: Sequence; Type: Arabic; Name: PageNo --&gt;15       &lt;!-- Field: /Sequence --&gt;&lt;/td&gt;      &lt;td style="width: 33%; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Awards &lt;br /&gt;Available&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Options &lt;br /&gt;Outstanding&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Exercise &lt;br /&gt;Price&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 61%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Restricted stock unit awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(13&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;15&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Stock option awards granted&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Stock option awards exercised&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(79&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2.32&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt"&gt;Stock option awards cancelled&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;109&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(109&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;9.58&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance March&amp;nbsp;31, 2016&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;127&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,483&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;7.51&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;No stock option awards were granted under the Incentive Plan during the first three months of 2016.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 463 shares remain available for purchase at March&amp;nbsp;31, 2016. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 34 shares during the first three months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2016-01-01_2016-03-31" decimals="INF" id="c5803530" unitRef="iso4217-usd-per-xbrli-shares">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c5803531" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107295">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&amp;nbsp;31, 2016 and 2015 does not include 1,330 and 3,529, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2016-03-31" decimals="-3" id="c5803896" unitRef="iso4217-usd">16164000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803526" unitRef="iso4217-usd">-2753000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803527" unitRef="iso4217-usd">464000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="-3" id="c5803963" unitRef="iso4217-usd">13314000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="-3" id="c5803965" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="-3" id="c5803966" unitRef="iso4217-usd">36169000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107287">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803559" unitRef="iso4217-usd">-541000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803560" unitRef="iso4217-usd">3404000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803565" unitRef="iso4217-usd">-480000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803566" unitRef="iso4217-usd">-359000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803548" unitRef="iso4217-usd">-2753000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803549" unitRef="iso4217-usd">464000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803563" unitRef="iso4217-usd">1228000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803564" unitRef="iso4217-usd">1212000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803553" unitRef="iso4217-usd">337000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803554" unitRef="iso4217-usd">527000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803555" unitRef="iso4217-usd">313000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803556" unitRef="iso4217-usd">-1848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803551" unitRef="iso4217-usd">1141000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803552" unitRef="iso4217-usd">-3896000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803572" unitRef="iso4217-usd">353000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803573" unitRef="iso4217-usd">2487000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2016-01-01_2016-03-31" id="c6107285">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803522" unitRef="iso4217-usd">439000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803523" unitRef="iso4217-usd">117000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-03-31_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="0" id="c5803795" unitRef="iso4217-usd">1338000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-03-31_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="0" id="c5803796" unitRef="iso4217-usd">1315000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="0" id="c5803803" unitRef="iso4217-usd">132000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803524" unitRef="iso4217-usd">1470000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803525" unitRef="iso4217-usd">1315000</us-gaap:InterestExpense>
  <us-gaap:InterestPayableCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803471" unitRef="iso4217-usd">7974000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803472" unitRef="iso4217-usd">6746000</us-gaap:InterestPayableCurrent>
  <us-gaap:InventoryNet contextRef="i_2016-03-31" decimals="-3" id="c5803448" unitRef="iso4217-usd">1949000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2015-12-31" decimals="-3" id="c5803449" unitRef="iso4217-usd">1612000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107283">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At March 31, 2016 and December 31, 2015, the Company&amp;#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During 2014, in connection with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following at March&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015:&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Work in process&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2016-03-31" decimals="-3" id="c5803667" unitRef="iso4217-usd">1949000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c5803668" unitRef="iso4217-usd">1612000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107280">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March 31, 2016, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,666&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;53&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(6&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,728&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;20,718&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;94&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;20,832&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,438&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;32&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;26&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,488&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;63,822&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(17&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at March&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015.&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,914&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;32,806&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;8,328&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:InvestmentsAndCash contextRef="i_2016-03-31" decimals="0" id="c5803713" unitRef="iso4217-usd">78915000</us-gaap:InvestmentsAndCash>
  <us-gaap:LeasePolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107293">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended March&amp;nbsp;31, 2016 includes $132 related to the lease financing obligation.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At March 31, 2016, the lease financing obligation balance was $2,506 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-03-31" decimals="-3" id="c5803498" unitRef="iso4217-usd">102881000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c5803499" unitRef="iso4217-usd">122359000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803477" unitRef="iso4217-usd">63070000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803478" unitRef="iso4217-usd">62257000</us-gaap:LiabilitiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803587" unitRef="iso4217-usd">138000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803588" unitRef="iso4217-usd">1501000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803578" unitRef="iso4217-usd">2707000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803579" unitRef="iso4217-usd">-3948000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803567" unitRef="iso4217-usd">-18842000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803568" unitRef="iso4217-usd">-3726000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803528" unitRef="iso4217-usd">-22832000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803529" unitRef="iso4217-usd">-15164000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107299">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In March 2016, the Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update No. 2016-09: &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU 2016-09&amp;#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02: &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic 842)&lt;/div&gt; (&amp;#x201c;ASU 2016-02&amp;#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01: &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU 2016-01&amp;#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11: &lt;div style="display: inline; font-style: italic;"&gt;Inventory - Simplifying the Measurement of Inventory &lt;/div&gt;(&amp;#x201c;ASU 2015-11&amp;#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs &lt;/div&gt;(&amp;#x201c;ASU 2015-03&amp;#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern &lt;/div&gt;(&amp;#x201c;ASU 2014-15&amp;#x201d;)&lt;div style="display: inline; font-style: italic;"&gt;,&lt;/div&gt; which defines management&amp;#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&amp;#x2019;s ability to continue as a going concern within one year after the issuance date.&amp;nbsp;Disclosures are required if conditions give rise to substantial doubt.&amp;nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2014, the FASB issued Standards Update No. 2014-09 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#x201c;ASU 2014-09&amp;#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NotesPayableCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803475" unitRef="iso4217-usd">27914000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803476" unitRef="iso4217-usd">27804000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableFairValueDisclosure contextRef="i_2013-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="0" id="c5804027" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803520" unitRef="iso4217-usd">-19048000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803521" unitRef="iso4217-usd">-14430000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-03-31" decimals="-3" id="c5803462" unitRef="iso4217-usd">2714000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c5803463" unitRef="iso4217-usd">5468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803534" unitRef="iso4217-usd">254000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803535" unitRef="iso4217-usd">140000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2016-01-01_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="0" id="c5804033" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2016-01-01_2016-03-31" id="c5803574" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803575" unitRef="iso4217-usd">3378000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803570" unitRef="iso4217-usd">3260000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803571" unitRef="iso4217-usd">565000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-03-31" decimals="INF" id="c5804050" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c5804051" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-03-31" decimals="0" id="c5804052" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c5804053" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-03-31" decimals="0" id="c5804054" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2015-12-31" decimals="0" id="c5804055" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-03-31" decimals="0" id="c5804056" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c5804057" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2016-03-31" id="c5803486" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockValue contextRef="i_2015-12-31" id="c5803487" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803450" unitRef="iso4217-usd">3221000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803451" unitRef="iso4217-usd">2674000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustment contextRef="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" decimals="0" id="c5803737" unitRef="iso4217-usd">2196000</us-gaap:PriorPeriodReclassificationAdjustment>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2016-01-01_2016-03-31" id="c6107277">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-01-01_2016-03-31" id="c5803581" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803582" unitRef="iso4217-usd">1175000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803772" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803773" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="-3" id="c5803984" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="-3" id="c5803989" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803576" unitRef="iso4217-usd">6320000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803577" unitRef="iso4217-usd">2482000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803583" unitRef="iso4217-usd">7000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803584" unitRef="iso4217-usd">326000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803585" unitRef="iso4217-usd">131000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2015-01-01_2015-03-31" id="c5803586" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="0" id="c5803801" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-03-31" decimals="-3" id="c5803458" unitRef="iso4217-usd">8362000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="-3" id="c5803459" unitRef="iso4217-usd">5149000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107284">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c5803762">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" id="c5803763">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" id="c5803764">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" id="c6106670">P20Y182D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803643" unitRef="iso4217-usd">2475000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803644" unitRef="iso4217-usd">2734000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803645" unitRef="iso4217-usd">5209000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803646" unitRef="iso4217-usd">1685000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c5803647" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803648" unitRef="iso4217-usd">1685000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803649" unitRef="iso4217-usd">336000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803650" unitRef="iso4217-usd">154000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803651" unitRef="iso4217-usd">490000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c5803652" unitRef="iso4217-usd">4496000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c5803653" unitRef="iso4217-usd">2888000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-03-31" decimals="-3" id="c5803654" unitRef="iso4217-usd">7384000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c5803655" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803656" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c5803657" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803658" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c5803659" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c5803660" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803661" unitRef="iso4217-usd">210000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803662" unitRef="iso4217-usd">28000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c5803663" unitRef="iso4217-usd">238000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c5803664" unitRef="iso4217-usd">679000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c5803665" unitRef="iso4217-usd">5564000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c5803666" unitRef="iso4217-usd">6243000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107282">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2016 and December&amp;nbsp;31, 2015, the Company had the following receivables.&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,475&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,734&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,209&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;336&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;154&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;490&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,496&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,888&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,384&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;&amp;nbsp;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2016-01-01_2016-03-31" decimals="0" id="c5804067" unitRef="iso4217-usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2015-01-01_2015-03-31" decimals="0" id="c5803768" unitRef="iso4217-usd">8000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803512" unitRef="iso4217-usd">20579000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803513" unitRef="iso4217-usd">17120000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2016-01-01_2016-03-31" id="c6107290">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="i_2016-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="0" id="c5803745" unitRef="iso4217-usd">1403000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="0" id="c5803743" unitRef="iso4217-usd">562000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-03-31" decimals="-3" id="c5803442" unitRef="iso4217-usd">1965000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c5803443" unitRef="iso4217-usd">1612000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-03-31" decimals="-3" id="c5803494" unitRef="iso4217-usd">-533749000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="-3" id="c5803495" unitRef="iso4217-usd">-510917000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2016-01-01_2016-03-31" id="c6107289">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;&lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;  &amp;nbsp; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the three months ended March&amp;nbsp;31, 2016 and 2015:&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,890&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,518&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,324&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,475&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Shionogi &amp;amp; Co., Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;310&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,930&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,771&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,820&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,826&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="0" id="c5803774" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803684" unitRef="iso4217-usd">4820000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803685" unitRef="iso4217-usd">6826000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803516" unitRef="iso4217-usd">77000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803517" unitRef="iso4217-usd">60000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803503" unitRef="iso4217-usd">1890000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803504" unitRef="iso4217-usd">1518000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-03-31" id="c5803501" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803502" unitRef="iso4217-usd">537000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803507" unitRef="iso4217-usd">4820000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803508" unitRef="iso4217-usd">6826000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Work in process&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2016-01-01_2016-03-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Awards &lt;br /&gt;Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Options &lt;br /&gt;Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Exercise &lt;br /&gt;Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(13&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(79&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2.32&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;109&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(109&lt;/td&gt; &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;9.58&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance March&amp;nbsp;31, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;127&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;10,483&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;7.51&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803514" unitRef="iso4217-usd">3212000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803515" unitRef="iso4217-usd">4061000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803544" unitRef="iso4217-usd">2645000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803545" unitRef="iso4217-usd">2259000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c5803906">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" id="c5803908">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803692" unitRef="xbrli-shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803689" unitRef="xbrli-shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c5804079" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803952" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803946" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803947" unitRef="xbrli-shares">463000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803686" unitRef="xbrli-shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803704" unitRef="xbrli-shares">127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c5803706" unitRef="iso4217-usd-per-xbrli-shares">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803702" unitRef="xbrli-shares">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c5803703" unitRef="iso4217-usd-per-xbrli-shares">9.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c5803910" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c5803911" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803687" unitRef="xbrli-shares">10671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803705" unitRef="xbrli-shares">10483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c5803688" unitRef="iso4217-usd-per-xbrli-shares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c5803700" unitRef="iso4217-usd-per-xbrli-shares">2.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2016-01-01_2016-03-31" id="c6107291">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="INF" id="c5803905" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" decimals="INF" id="c5803907" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-03-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c5803912" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c5803932">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c5803933">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2016-01-01_2016-03-31" id="s200930">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 1 &amp;#x2014; Significant Accounting Policies&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $78,915, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on March 3, 2015 and November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&amp;nbsp;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2015 and the notes thereto included in the Company&amp;#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 6; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of March&amp;nbsp;31, 2016 reflects $562 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March 31, 2016, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,666&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;53&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;15&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(6&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;21,728&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;20,718&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;94&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(3&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;20,832&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,438&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;32&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;26&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,488&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;63,822&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;179&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(17&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Amortized &lt;br /&gt;Cost&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Accrued &lt;br /&gt;Interest&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Gains&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Gross &lt;br /&gt;Unrealized &lt;br /&gt;Losses&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Estimated &lt;br /&gt;Fair&amp;nbsp;Value&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 8%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;Certificates of deposit&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;    &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at March&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,914&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;32,806&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Maturing after two years&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;8,328&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;64,048&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2016 and December&amp;nbsp;31, 2015, the Company had the following receivables.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;March&amp;nbsp;31, 2016&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,475&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,734&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,209&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,685&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Seqirus UK Limited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;336&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;154&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;490&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,496&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,888&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,384&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Billed&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Unbilled&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;Total&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;&amp;nbsp;Seqirus UK Limited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At March 31, 2016 and December 31, 2015, the Company&amp;#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During 2014, in connection with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 8; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following at March&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015:&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt"&gt;Work in process&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt;      &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt;      &lt;td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;       &lt;tr&gt;     &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;    &lt;/tr&gt;    &lt;tr&gt;     &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt;     &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt;    &lt;/tr&gt;     &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. No reclassifications out of accumulated other comprehensive income (loss) were recorded during the three months ended March 31, 2016. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive income (loss).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 10; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the three months ended March&amp;nbsp;31, 2016 and 2015:&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt;   &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;         &lt;tr style="vertical-align: bottom"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2016&lt;/td&gt;      &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid"&gt;2015&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="width: 68%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 2%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt;      &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,890&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;1,518&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,324&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,475&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-left: 20pt"&gt;Shionogi &amp;amp; Co., Ltd.&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt"&gt;Seqirus UK Limited&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;310&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 1.1pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;      &lt;td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;Total collaborative and other research and development revenues&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;2,930&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;4,771&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: White"&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;      &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,820&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,826&lt;/td&gt;      &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 12; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the three months ended March&amp;nbsp;31, 2016 and 2015 includes $1,338 and $1,315, respectively, related to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&amp;nbsp;31, 2016 and 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended March&amp;nbsp;31, 2016 includes $132 related to the lease financing obligation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At March 31, 2016, the lease financing obligation balance was $2,506 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&amp;nbsp;31, 2016 and December 31, 2015, no hedge collateral was posted under the agreement.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&amp;nbsp;31, 2016 and 2015 does not include 1,330 and 3,529, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 13; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&amp;#x2019;s product candidates in development.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In March 2016, the Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update No. 2016-09: &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU 2016-09&amp;#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02: &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic 842)&lt;/div&gt; (&amp;#x201c;ASU 2016-02&amp;#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01: &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU 2016-01&amp;#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11: &lt;div style="display: inline; font-style: italic;"&gt;Inventory - Simplifying the Measurement of Inventory &lt;/div&gt;(&amp;#x201c;ASU 2015-11&amp;#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;      &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Simplifying the Presentation of Debt Issuance Costs &lt;/div&gt;(&amp;#x201c;ASU 2015-03&amp;#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.&lt;/div&gt;    &lt;!-- Field: Page; Sequence: 14; Value: 3 --&gt;    &lt;div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"&gt;   &amp;nbsp;  &lt;/div&gt;  &lt;!-- Field: /Page --&gt;    &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern &lt;/div&gt;(&amp;#x201c;ASU 2014-15&amp;#x201d;)&lt;div style="display: inline; font-style: italic;"&gt;,&lt;/div&gt; which defines management&amp;#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&amp;#x2019;s ability to continue as a going concern within one year after the issuance date.&amp;nbsp;Disclosures are required if conditions give rise to substantial doubt.&amp;nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2014, the FASB issued Standards Update No. 2014-09 &amp;#x2013; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#x201c;ASU 2014-09&amp;#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c5803957" unitRef="xbrli-shares">34000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c5803699" unitRef="xbrli-shares">79000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2016-03-31" decimals="-3" id="c5803496" unitRef="iso4217-usd">27798000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c5803497" unitRef="iso4217-usd">47724000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2016-01-01_2016-03-31" id="s200943">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 5 &amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February 26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="d_2016-01-01_2016-03-31" id="c6107296">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-03-31" decimals="-3" id="c5803532" unitRef="xbrli-shares">73601000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c5803533" unitRef="xbrli-shares">72341000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-02-01</xbrli:startDate>
      <xbrli:endDate>2006-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2010-05-01_2010-05-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-05-01</xbrli:startDate>
      <xbrli:endDate>2010-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-12-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest50PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">bcrx:December312015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">bcrx:DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">bcrx:JapanYenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_DeferredRevenueArrangementTypeAxis-DeferredCollaborativeRevenueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-03-31_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-04-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcrx-20160331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><xsd:schema xmlns:bcrx="http://www.biocryst.com/20160331" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20160331">
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20160331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-income-loss-unaudited" roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation" roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization" roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity" roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 1 - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 1 - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-receivables-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 1 - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-inventory-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 1 - Inventory (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-revenues-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 1 - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 2 - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BirminghamResearchFacilityMember" name="BirminghamResearchFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborationAgreementAdditionalPaymentsReceived" name="CollaborationAgreementAdditionalPaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_CollaborationReceivablesMember" name="CollaborationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementPeriodOfcontract" name="CollaborativeAgreementPeriodOfcontract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyDomain" name="CurrencyDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" name="DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December312015Member" name="December312015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DeferredCollaborativeRevenueMember" name="DeferredCollaborativeRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JapanYenMember" name="JapanYenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LeaseFinancingObligationNetOfCurrent" name="LeaseFinancingObligationNetOfCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityOfInvestments" name="MaturityOfInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfStockbasedCompensationPlans" name="NumberOfStockbasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PaymentsForModificationOfLicenseAgreement" name="PaymentsForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RemainingAggregateOfferingPrice" name="RemainingAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" name="RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyTerm" name="RoyaltyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" name="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest50PercentEachYearUntilFullyVestedMember" name="Vest50PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-inventory-details" name="statement-statement-note-1-inventory-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-receivables-details" name="statement-statement-note-1-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-revenues-details" name="statement-statement-note-1-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" name="statement-statement-note-2-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-tables" name="statement-statement-note-2-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bcrx-20160331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160331.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:href="bcrx-20160331.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcrx-20160331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-document-and-entity-information" xlink:href="bcrx-20160331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20160331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20160331.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20160331.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20160331.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20160331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160331.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:href="bcrx-20160331.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20160331.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20160331.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20160331.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20160331.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcrx-20160331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciesandconcentrationsofrisktables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1fairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1scheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-inventory-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1inventorydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="bcrx_statement-statement-note-1-inventory-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Principles, Early Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</link:label>
    <link:label xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from the sale of inventory to be recognized when the inventory transfer is complete.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVABMember</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repesents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_CurrencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PaymentsForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for modifications of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, for Modification of License Agreement</link:label>
    <link:label xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock issued during period value for modification of license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyTerm</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the date of the Agreement and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyTerm" xlink:to="bcrx_RoyaltyTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborationAgreementAdditionalPaymentsReceived</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Additional Payments Received</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaboration agreement additional payments received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Birmingham Research Facility [Member]</link:label>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Birmingham Research Facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BirminghamResearchFacilityMember" xlink:to="bcrx_BirminghamResearchFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Filing Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreationDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Report Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNetCurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Loss) gain on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PriorPeriodReclassificationAdjustment</link:label>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 31, 2015 [Member]</link:label>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period reclassified.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December312015Member" xlink:to="bcrx_December312015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Reclassifed from Other Current Assets [Member]</link:label>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt issuance costs reclassified from other current assets to conform to the 2016 presentation as per the newly adopted Accounting Standards Update.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,693 in 2016 and 73,355 in 2015</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementPeriodOfcontract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Period of Contract</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement period of contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementPeriodOfcontract" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueProductLineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Receivables [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents receivables from collaborations for reimbursable research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Collaborative Revenue [Member]</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborativeRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue deferred under collaborative arrangements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RemainingAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityOfInvestments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Investments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity of investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityOfInvestments" xlink:to="bcrx_MaturityOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen [Member]</link:label>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Japanese Yen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JapanYenMember" xlink:to="bcrx_JapanYenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options and restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 50% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 50% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt maturities after two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMilestonesAchieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Milestones Achieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of milestones achieved.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesAchieved" xlink:to="bcrx_NumberOfMilestonesAchieved-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Financing Obligation, Net of Current</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfStockbasedCompensationPlans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock-based Compensation Plans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of stock based compensation plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockbasedCompensationPlans" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcrx-20160331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 09:28PM UTC 2016-05-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-document-and-entity-information" xlink:href="bcrx-20160331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20160331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20160331.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20160331.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20160331.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20160331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:label="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAgreementPeriodOfcontract" xlink:label="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfcontract-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20160331.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborativeRevenueMember" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_DeferredCollaborativeRevenueMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160331.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:href="bcrx-20160331.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20160331.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20160331.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20160331.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20160331.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160331.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exh101_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X2)-17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$Q+C @5VEN9&]W
M<P R,#$V.C U.C T(#$T.C(R.C0X   #H $  P    $  0  H ( !     $
M  -2H , !     $   1,          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  (0\         2     $   !(     ?_8_^  $$I&248  0$! 2P!+
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M<H&1P=$5(S-2DJ&Q\ 8D-$)48I/24V."HL+B%B5#LN'Q_\0 % $!
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MY93N"B%@?8*85@RAAR(SN,4'%L.%P<D$_GVU-4;Z9/,?=5Z#J0XXJOPV56)
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MW8BWR3,F0/M<^7MKO#9WF1(%NB';"LTR]N-]Z#T6JXV^:B[_ )P_VT5<E1J
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M>4B'JSV^;VT%^,&UAB$]E<Y*[:0&R !D[>>@.UG&X/2<,M2=.-])]7*C1J\
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MV0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<" S+C  .$))300$       /' %:  ,;)4<< @   E&  #A"24T$)0
M$-IV;Q+U=Q8]-@7A<+LX K@X0DE-!#H      ),    0     0      "W!R
M:6YT3W5T<'5T    !0    !#;')396YU;0    !#;')3     %)'0D,
M26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !    .$))
M300[      &R    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    2
M     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R
M;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D        X0DE- ^T
M     ! !+     $  0$L     0 !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$         @  .$))300"       "   X
M0DE-!#        $! #A"24T$+0      !@ !     CA"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      -I
M!@             ,Y   "?8    : $( :0!O $, <@!Y ', =  @ $4 >  @
M #$ ,  N #$ ( !2 &4 =@!I ', 90!D "T ,0    $
M         0             )]@  #.0                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P  #.0     4F=H=&QO;F<   GV    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   SD     %)G:'1L;VYG   )]@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M%       !     (X0DE-! P     (2L    !    ?    *    %T  #H@
M(0\ &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="
M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M        ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M# P,#/_  !$( *  ? ,!(@ "$0$#$0'_W0 $  C_Q $_   !!0$! 0$! 0
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M]H64UL#\:V2W0"':!H<^?3W;?SDE)#CM>"7X=1<6ZSM/[K=GT/+_ *"FT65
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MB2PE]1(:]K7>F]VYBE3TS QW;\>EM+B TFN6>T:M9[-OM1C2PB"70=/IN_\
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MJ3[2 .\@G^*C%WBW[C_Y))3'U,C_ $/_ $@EZF1_H?\ I#^Y2C(_>8/[)_\
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M &@ ;P!T &\ <P!H &\ <  @ $4 ; !E &T 90!N '0 <P   !T 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !% &P 90!M &4 ;@!T ', (  Q
M #$ +@ P     0 X0DE-! 8       < "     $! /_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$(!$P#4@,!
M(@ "$0$#$0'_Q  >  $  @(# 0$!            !P@%!@($"0$#"O_$ !0!
M 0                    #_V@ , P$  A #$    ??P
M
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MQ--WB+)3             ./SF    ''D./(            ./SF
M    'X_MBS*     ?C^WPC:2HAEX
M                     C*38_D         '$Y. YN'(^OR'ZL!TC;&AZ43
MB@S&%AE9.N6C50Z1;Q1G*%TE6\>6T58_$M:K+ABV:KG[%G59/W+**H_H6J5
MQA=+C4[HEOU5/U+3*??F7%4PYES%3HU+]J&:.>E#S-ZYZ;O+K\CU)_3RXV\]
M%^'E/&Y[/?K4;&%ROM1\N6?_ $K1P+-*L= MK\J/B2Z/'QQUD]HL/XK>@I:;
M ^-UP2W>.\K=!/7K]:#^F1$F&LWF2H>'NO\ "B&ZV[XG8    !'T@QK)0
M     C^0(N-!TKS!A4]I^%#XX/3S.?S^W@/2WO4+[!=GO1I0L]-MY\O)8+F9
M*H\7E]NU!]3CU7AJA.L'IUH.@PJ7)R5:Y8)!T"-MA-DD.,.D96586G(BN%)$
MC F+0+20,9C9M,L&3.  #Y T\UZ-]B2T@I)(=F!5/:[ BO7<GD59S5C
M^??A7&=(0L41IM\738:9BY$@DG;'948KM]J%"8>U ,_       $92;HF]@
M     #AST,WA L>%O5,L87@>>>;+V_/*.3ST3_/S(YGIE^GGYH9Z@?GY42R7
M]_3S,M>6!Y1)VB4OD.8<G_\ &#\T2M^OD]+AZ"O('O'K4\K8X/7;I4&UT]']
M:\WO5XC_ %V>OA6K\K-_2NOXV/$ _G6N;C/1+!.^EI.-$Y)+%_K3S9RS'8J3
MCRX'[58[Q876(@_8L]^4,:T35(6CV?(._&>!!/4L"*>YJ ;"D$2=I73/TR4D
M[H5FD'5K'E;-FS4"$DX;:=",[8&";ZD!=:PXKKLLR@    #0=^A^8
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M%K%<M7+<,=D0   "$)O@R<P        <3A]H1JAZ1O,B]1)V(\Q\B>GWV@?
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M]A^'Y:_-D7& L[$.:/M0;?:>2WIG=S)4"R^!WPKKEY"S166P>ZC:P
M  #X0Y,D12Z         5'DC'<3 6(AF8"!^K(/3.EKLW:83"^<1SZO1,PP'
MZF:8C+@          %:ZX6!LZ>=/ZWS_ '*L]6U_THE)\W[<5)L5(7ZGE_Z%
M;;VBG6I7Q'G-FK_CA^OSZ               /GT0O-$/3"         >6<@^
MA(\UIRMN//\ T3T[U0JOPNL(1IKZ<_"+H6MT/-K;+\?2B-[GT^@
MX\N/(KE8VMMD@           #KXO.           ?"%)LBJ50
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M+L<J5;J79U6 (M+OQ]5R6BPNV55M<=?'0M"Y<?)UXLZ9C1Y,$5Y"1!#$A;*
M  -3VS7=B*[V(KO8@\Z9)KK)1)>IQ9O!D)5J_-AULK%4^D42S%W[$K;#'4TF
MM8.R(K[W)V$$=Z:173,3F(.ZL]BN_"Q8@C\I\$(:Q985J65$!8NR(K+^ME14
M[9K%BKV6L6.CD./(    A";X:F4        <.>EFL_O76-2\V=@G:#<\#"<0
MEXL;$$ ESYBH-=<T?)4FE0F*8JT36:GA=)QQ9O7?N@FVHRV\G=S'!S
M&G[AI^X%:++UXL,5SL;6^R                 ?!]     /A$<NQI)8
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M9M/[X;?B&-NQ?;-_CO/3L1/K-@                  !%\H1?*
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M-"&XS+;\8#RI*_R&-(+4]"ILHDP=JG/XEP^-<N@6<S$3X,FS\*J=<M)UZN9
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M\\'H>/,#??0(>7TLWH'EEU/5@><6^W@%-*W^K8H]'OI&/+"QMPOI]
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MIJ%?/WGP5Z_6P TK=0   'PC.38[D0         (WT\G5#/YDVUNW"O1>;C
MG;)$V:M&PDV?O"'XD^JW8@L]\@W32T'9K)V"S*O&N%J58=J)U0)BBQ"N&P$Z
MXV%^9-_&$^B31DH'[!//Y0?C"9,=&./)O^09F"P&NPOG"5.]!WXDJYJ$>\2]
MRA3#DV?O%W,VGM:'B"S"MO8+%*U_@6;5[R).:%,:3ZK[C"RJO_9)W0_KA8-6
MW*$_(%PA957#N%@U;_W+$JZ?H6'0+TRPR .!8)I.[   #Y]^$;25&4F@
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MBQ(IUL%I15_MV5%2-QL,*A:C>H1+!-T12?>;/BEOVZ(IU'7H4*/R[8/B<@
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M)72,_I<V8LA;5YGXFQ[SB\H4_6J%5;?8/.GT       #Y]^$82A$DM@
M     %:H\NL.0$22WQ//W:+M#3]R   #%>>/I%\(ZK]<<4]GR11Y[0;Z]_F5
M7Z=J^T4LT#T5%)MFMCCB,*H^A,?E(K';5+Q#FJV6TXZ5:KL8$IQ97;.P50[-
MCOW*:2'8[62&-&N5TBJ6^RUE#/977=B/H               !\(IE>*I5
M      "-I'.2.?R)+8+LF4?AA387#X?HX<CZU3:#FX<CZX=<[9T3O. YN YN
M YNMUS(N YOS^G-QPIG-0V_3C'R#"4VF+R?'Z<OS_3B<@''@?JX_3Z  <3D
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MQ\NB%>O.0C; 30(@U&QHB*5OW #4MMU$Y;9'LA
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M?OE_P/43GYJ347"^5:^%J>6A[X    0K-4+32           ? ?>/(<.7T
M       <8%GNM!97JQG7<NGV\#L!QT_:*J$QRA"&U$D5HLO50M/]YC#Y#L##
M?MDQU,1L0CWN;L,%T=K$4X":.Z:?N 8;,\>0   !2G+=BVQ"^A6DYE483N;C
M" <O<;X5@D24ZT%@L_PY'T    $+33#\P        #CRZ9W$0ZR6#5#U\NZK
M_CB;>]XXU9/Z/N7B--QZF_GX7:@?T"\?+W+GI9J_DOJY[;/-\>D/Z>-=_P L
MTX_#FX#FX#FX!YM>D-+"OLN;-^I7N5M O@5)^?G/91^V-2L(>O%>I!CTL^
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MKO4G_H1)+&MR&5D]((7Q19+C@\^<',<.KW0      ^??A#TQ0W,@
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M&3HHE<                          :CMVHFW
M    ?/OPA^8=1VX    .KKIMC7>!LK6_P-HYZMU3<VK?H;*U$;<U7]C9&HX
MDU#?<)80YR)A0A^).J$_P)S0A^A-:$?I-J"/V)Q0CQ)P1-S)61?C28D,?N3
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M8X<OH                ^/@Y
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M^FB^&^O?LIKIS17&^?WB&--!SV)K(RD2(S$S=4$%MXVRI_<LCK&Q9;4:(F$
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MX2S+B$8R5N/HJ-CE'*S TF'0\'QUI2:#41)="F&F3&<:SS0K>.+ 'KBBY45
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MHCT+/#T63,G B/.W2 = M96*'(V'4?,VTBSF!&"GI%T%C3Z<;"L"R70 AYK
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MG\MH%JR=ET#N4#"8)&IY;A+%GM"URBT73!?#;NJC'W4*U;IM&T>"1\<]'8+
MZQ)!O0CT>AS5Z^\G;8FQ8.;"ZY();3LA@,<-7G'0.W<CJ5:L(^ (ZTAB669B
M^&1>-5]L,;"<#N,0$N%MY:?:5VNT2' 8B',9!)!2O7D1//<9'Y-O+#0&M $4
M4)344%2@C-,X]C7B;)]KA3** 5+(#H?!R Y /8&>U+8@$E6,B70&Q-!R]1+S
M _O $J)6TJ)XSEG-:J:/!"%=0$*K RB!<]K7=UI70<H)M[ "W!3QY7ZJZPJ
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MEJL&0BVT9'I1C60"HF1?MPR$;2B  --8IT%LI".>!\2]=MJ>#&\>S!63=FX
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MVZ!T&.<*G @DHJ9BB>OGP/TYK8(5MG4\#M]\V,"XYFRP''/R2!<UL4&4Y^1
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M\]>>O/7GKSUYZ\]?_P"]\\Q_Z=__Q  4$0$                   "P_]H
M" $# 0$_ 6CO_\0 %!$!                    L/_:  @! @$!/P%H[__$
M 'L0  (" @ $! (%! D*#@L (P,$ @4!!A$2$Q0 !Q4A(C$6(S)!421"87$0
M%R4S0%*!D:$F,$-08G*2L='P("<T-38W=8*3HK+!TN$(1%-C<W25EK2UU/%&
M@Y2SML+3U51@9G:$H\76UT569X"%AI>EIL-'58>DQ,;B_]H " $!  8_ O\
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M!ZY88,+,_3<7L&F<,:RL2==7VMHD"6Y9#'5S-6=:BU6J(W4F%XIV++8J^4V
M0FS"1AXE;KU5A24U'K^]T6FN_2/2-X*Y99MD*66/2[,3=6CBV9O+B-.I6E1+
M 2,0[*9LE8XC!K3]4IC+.PM;[8*782RK+>85"5&IVM[T*Z]A@-%FQ4<166M$
M>L^T"!R!(NJ<))CG,E^!8<"TPX%>5L$ M#V)TU?1OUYG4P"LZ:U:68@E>U\V
M:8PPD8B_VT<E\:C6U$K"YEMEQ=T\2)5-O^XY=>7+FTS<@G7X9KIJV&:]!@#H
ME9K0L86;&1UP"G\5EALFST[YGE+NVQ8ZQ2[ 2JE155O-"5P52&+MJHKE8&16
M>L+)O%?FPR?MVLAY<1WNM8&K!;6-BK:>OD$98G*!O3M9V$Q')S.2!#=Y=L"'
MD EX16&&,H3+B9IDSL>PTF6&]AW2NIP5*-M$AE]5LG%CUD5C=VY:7M>LK^ZG
M8+B"R[U1U2AEX".QK]/I#=5W&P:C:[LI>W]#L[>M9JTL5&:X+;E="O'5IVF+
M29'MA.XP+68I##84[+=O7@R5Z-S$"P9TT9RL$K&K)T=B?%5T3XU[)-5@U/;V
M!<*U]V$4ZAHD#])V456<BAA?;ZV>9.)(3^!R':-6,LP1A8]16/ID6B8Z036/
M:@F7,1=3J3A'(KKUX<TC/VE9"(4;-BQP_1B:/<JEI@)$N $J5DF7+'K(#PFD
M/O6,C5F,TMJ2I+&K$Y0ZK1;*OL=Z.QCHA!;+)V-1,]\@&0"J%@L T#J,2@]!
MSIUI&CH6@T@T+-J -DPT% 8YP/VV+-E;O5:@UC@6:U>Z<2SAU*F8;%:.)YBV
MJH5>6"9]-HMBK;1WMW&L 4+DF9!KGO37LPGRX'.2C?3@<49Y*,3";,H=JZH8
MVPZE?O4M.LFKI/T?(RWT7;>QVDFP!,IR'G$<Y#-5*B6&O#/NQ]:64F!"&P F
MQ5 9J0NB'D=P(00AK681V//<ES!:?H$B1C=8@66:N7&+V 9C+A:75(;OQ57J
M(6 E Y7'$_6@ZQ4FEWE0.*%X9%+ZU7&<A,(XXD$0<I5ML?8==#:XU:CV#9*U
M:S7EFDG:5ZC)X&%(TSB"!MCL\=7FG W(N7/<2Y,XLC;)4"1[FP3RP5T0X#:J
M.KZL$^)9Q)>=5@!9V77B/L!PD1KI0^+PO2%W+5XW+3**:]3Z[69L2M6<(%K@
MQ2BSECG>@04E,=/\HZP.ES=87/!B^N*^I$7KY%)YD8,FPJ&3+60PG+J%BJM"
M;+4AQE%=89&#9@&$YX "PVS7$RM0K"K08N$!9.*YR?%487,?'4#8=L?*I8\1
MEB.4HRY??PE8:[LFH6:S&U5FKS:-L 8*3>9:!%JK0.F-W#FPY4-UJNJ^K[V<
MPRFP!6?<8K00N!9S:[58:<K.>1*B]7K(666I2(X5:/9=Q5,(JLCZF'GIK 1B
MQW Y9L1#V77YEIUG';8<+FMD2K3KF&$[!NQAAG,DED6U&U7#LX$)9A5@!I0(
M$D8[7Z:6K<K=?V(=&E:5%H*V3M1RUZANILQ8 / ($":X(@<(BL8$=0D,ES*.
M? K'9]CTNFR9FY&(XMI3)3L J[7%;,J=I80JXMR5FS7J6W2%TZZX8E6%GUXX
MQ(5D]:UR5<>2L /MO*K)&F]. TH":,6 "2<(0<%8PGG+$R0B+FE+&,Z?G7FZ
M?9JO:=E;UJ=K4W2SBZ#"NM7VQ9G"2,'5VY\M')8R^6E9ARR(OQX^'Q;,);5K
M;B]"/)KPZMY5L!I11[G$BVQ1-2A7#QE-OC-O(8X[5GW^H+RBLF-KUI>G:YX)
M79]AI!U#[ "-#=42>E8=,[5=E;.7AQ]@=4>.:4\'B$^O"NZ@M^J+KLT8[-*=
MPN#IKFZQZR)\NB%TG%"]288QZ;2\^/*8>9>E6.V:U7VG<A2]-=OJI5_O&1 .
MNIV9VX,=R<#2I@@Z?5*)D!(1S P\R6OB;?JXZ)TY5D[J>P5,*EMD&#R,NM8R
M;PF<X8JLY*(1I3'A<^91QTB<NQ/!MZ*TMJ+7["]'KP[ZO%8O]I06&QJK0'"3
M3(O4:RM9;7/A,_%$)WAB,N F?%I!S8:%0U#!&5^(]Q7BG1^IQA*O]6P4XY5\
M7L$AV4G8K]WB<,AQ+FQX<VLMQ0LBS0V5SKRY+ZO3'M,DD<N+ITSF9'BW)^4U
M5PE2"[GF;7S )LD'"=,6:4VY6][5441B,,?1-:RF,9<S+'$91B6,1XCGI<\B
M1^*/CR[2/4'@UY@:[0;$ 7J]&/*(=B#CM <77$HRD%K\GF:SS2AL,\%]=E>7
M'4IQ6'EQ%;IV:6!1@;UB@+(QL NFW,]F"R(2 P K%NFD,A]FYW2LV&M5=,@6
MW)Y@6=57D8EH=)9WAU/5:>1F05M E;9 ;LVG>C-ATS]8!^KA>T!8UDW!7)9,
M!3\6CDD"UHZW8]EH,=P<!.ZCK=PY3DL8=//,$#14BD&)B(RPC[_6!D%@W?I;
M%1.(Y8FGAQ6WKV%,MC!W1%>X$Q,/<05SAF8>?J1!GK9C@?Q>'MN/85QZX%6W
M8UV8V:(0WA%ZYFQ60JW"%[=EFP$J3"F!2)U,<21C*$9>-2W1:JQ,>TS\O<8K
MS/=&:(M^M:*J'+N8)'BR2LG>B+,?17BU$$XX*OF4<^(/0LZ^:)"E -R+JV52
M' 0H3!@Q@O2D4)5SB*/$LS&0)82QB0YXPK5'L4 VCPRE1K2N+C?<$O&4SD53
MF3##$ PC*19A'.(XQE*><8QGQ:ZV4,0>F4>NW/?D9AB!_I'8;+7KIQ#*$>4H
MIZTQ/,NM/JX8'&,,9C+QE;K"[G ^KE?J0Z^!<<1ZN1<W/@?-G$>?EY>.<8X\
M?$I".$D8%Z$Y#*.<8'XQCT99C+.(EYIPCT\_'QG''#C+'C+,#+33S#.<&A+&
M?:''GEU\3R/DCPEQX?9X9XY\(NU.LMLZW8J6C*VPBN=<(*14'6E5T.PQ9X=R
MW8#5PZ*8H$KP*N(Y8>@:38DM<V$4<IAV:GK+=)5L@<,QA:("L!+YY)Y@0XPE
M^LP+,OLRSCVQXU/6S#,5_;G+11.09+]-3TFD>O#%<C,T6,0*%&0 =$)<9+/'
M4D/&,<P@]Q$!CYE@$<RAU#=./.3 H2SQ)R0QSSY,9Y8_%GV\$C&<)2%G$2QQ
M*.<BSF&"8P3&,\89S"49XQ+AQA+$OEG'[$<9SC&9YY8XSG&,RERREPC[^^>6
M,I<,>_+'.?EC/A$+)QA-9MY0KQS^VVY%-NPDN&.,9S*<44'6Y_=!=4Y99Q <
ML^+O96E''5*&L<MVUD.U[N:=>";+<@8<:37E(2XR&S";$)3B.418(;(Q3^6?
MV(&&@]8YFV@KD"$5Y&'%UT"<G)X995AVB$39<?E$DC#2 <@0')&(9TU8/K/$
MN;][6(L(Y5*K7W%?K]ELAEK&4VA&AGT^J;A^2@<R)O$5F< EG.8MV5BR%)!!
M<SCC;,XB LJN/)3G,27PP&(<93G+/MB.,^-JH5@.P;U!RK1L3'&"*K!K:G3O
M =A,;)3$@)1T,&,L 5S$_-$<2CQ@N?\ 0-GCPX@5.;''^.(69X_D^7BL?C*,
MAOUZKL91^4HLK@-&4?T9ZDL_JX?UV[W+U<,U+N@J*0E-BLG @94C3[*3F+/U
M*>)Y_=6P&8/IT,3Q-?,"#R G<6ELEM<:^MN-ET3<'*<]%&PEZ]H[-1TI!L,6
MJ<A5UK6TJ"K:F%>Y$XJ!X%AA?NZUQG6,WM,=6SVC;=AN0W.I>J5SP]JM+>WP
MHNL/8*^SJG*5RT&Q5W-?=B;&PG N8<"=.$2K[LWE,ECY9WCZ]G4QLV7;WRX)
M70BY)_U)6< ; C4H1LA9"5Z%BL-Z%G-3)JHMZ$NXJ&8O-:W76&K0FIQS;.+;
MA<U-QZG=V7T@[N[NJW%;FO&R<H4IH=B)6NKNT8S8W-LKLL4FW=\T[?ZF!Z2+
MRE99:K1UM 95L4+-(]HK;I(9P3D:K2)9+B2^9$'DA=*NAOB48U"TL69C938=
M#9U=W2N4-S7<BUI514:.FYDB=GG#?8,BA+LF 387-03?O!VZVEZZ_J6GC%4Y
MK&EJ%Z='C.-A:]3>!>6H%=;J%@O((:\I_KB<M60C2WI^M;2.R7"O0T^R5!JP
ME:4YG8;$:C8(85C&S7@G-4NOI\D9USN"#*U'/)*8B O]G9?BW*UK:.FKD\)X
M!BGKJ>5DT:'<Y8-)MBSLK9EEH\1IP[=>L4D DD,-&SMVL7:%-:.4H*&Y!;41
MKZLLTT6V':IGMT[S77%K.N*Z^&#/J!@'2=( Z<Y@2.KH6U/[2D4^E.["X1.&
MMR"!_P"D%3FE(JE.-[U*U993,C"R[F\:F].99L]KTTAUUBRW7_1D&H;#IEEJ
MLZEG.+"JV+-:1G"]DM=)CK9"G3UT1<E6QP7@>$)#/)1E+&NGVH.P/5XF%*"]
MM*0O7 A&'+4AOUU[L?KS%?C@%AQ5FBG8K#%B< .=9X]K56>V4)FFWTMC5LJ[
M3VT6R[A5W%1<H7EZ>UVW9"V(ARI5*F-:AFG64U_/HM=V=<E4+5SK0+BO+9[)
MM[VS[68U9/*DUCTDJE&II@#:$<$*["&O8RTVV<C>5;1K,%_41IJ7HMUN*+8:
MW8I 9M0T^O7VL6C3M<^D]0\UY+>[MM:KH.TG"NJ:R%<'JL&;.4S#-C-]DU+L
M+$&L^9]=YE*QNIW=VMQK*>-8*C/)R_(QS'SDLSWL2$;D/*H#J-K5R2PEKS8D
M@W6U!V:UVV-L,E@B).RL]@AL0E5%@.XP9"K:71@K"P[GK34[HHX29*'%S<O7
MND/-M(O&GZ?I][*R;853?^CM1UF]SR/%'4MMY,.N2"@1HG=SRP"RNK6V-0">
M:0H-S2)J>R&F)6=A2K;/2'1M6D2*Q?@RQ3E="PC+ +6+.%28)!PTH_6J[3G8
MZ*>Q-:C::9L&/H^Z"CFBW8>HU;M,EZVQ8K,TYI'@P!VW;'=Q8)G!:;,08#>5
MM7=)L)ND\FY5>; !X,+#\J?0^>+\E^83$[G% MC$EA*X5RT:>8EZ,!DV'$K2
ML%&U\V-9\R5)17:+D0=?/K.)5; \D%B13K:R">&1EY,';*+I8&*!I5F&;JE)
MJM+NF][*D**3_P!(#)>8%5L\7TCLS9FC$]7;[._A8V0->H(D6.:21D")VM15
M&9T14M'>:485AKNH^CMW=7IE[7W(K#9#=PPRY=V$:Q=?"2K*E:B9BR<*Q:28
M3%6U6S!MJLI$_,;?]E.L0+48?1K?4 P92'G&)R)=(.HI=N7F61FN1B9(YF.
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M5$Q/9-<"WK4S;#Y0Z%H/6(_:"&M=:@"SK3M<T:8LBU;25H1L4^E!KN0P2FK
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M/E] \5[":T3:C97C.+.<.H$LAL)W<Q96Q*,LL+]3JA$?(A;VTPW7,56S[/\
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MC4Q4KJ=GY5;/#6;^V1SAPVGO^9Z+M5ZI6QL5@.05NZ:]58FN00I'6%G@V(N
M0VJ]TFDU5:W\M=SUYRKK+2M;6K+2YW 5XJ*SROR^HV%F+KMVMB@H51AHQC&R
M,Y,AEY6ZQZNGJ0= \OZF122)-\[>^!K*ZN"EB->T*"@*6-<Q+U\3#4@SLL=@
MC8XR::J-LX@DO;V'D;NFJW"XW 160W'8/HDR% 9,&/(BDVE+08V@Y8  :>9%
M/Q,OU[K3X:_J]I7^8NK^66OW=\>V'(VF%T[4Z'7'VR4QT1_2":K*;5K020M
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M;^U0BO\ 3BZHY[#?T_E;JM8C4T^NDLU>XM6?+FT4CFQ<+E<Q_37B,%0%V0$
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M%UE'RLV'LS8$WZ)YQVMH%3!,9D#!R(>73,1%+B,\X$6,/AAG,)3^+$-LIW-
MTRQ43\Q[5AJ3N[662*VK*D+"=U3F'H7=UUB@*R3@@ZDPK8 ,=J8&5)BC.8ZZ
MQ\N/*%ZJ79><778V&[CTF;4QSVAL!%H&!Q)9'8*R_+$_RUDI#L]0OQ^*U]G2
M?)B#E1"O#7N9L=C<DJM6NC:36"MC5D(XA73ZC=-S'F.ILL#<4! O-/Q-<];Y
M?,]0Q8%Y['88K,5YLRQD1$R5#7*;I9Q W,R<+,N>>8"Q/D\6B-;J_D6.%Q-
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MMNQ7^.F4?Z1H"W*-IL/FH@UJ2GJ5I5EO/)J!Q\R-.[A=2J39+9R!@5\A'OH
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MRBL;!19QT)AS$RP&!30E+'CBQ2UK&<7:VRXR9,)<QV!.(8*W,.>.>G9+P7#
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M*;]G&R[=5.GSKZ(@"GZP]:1V]+5[=$*WF%3VV:0RAA73M94:.WK5HX-( V
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M*AUFI;HZ7#-J1.K=JK2C*KD]LZ=GIU%P!5ZN2*V0YZ]/*RRP$"KC1672BN&
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MOS&\OE!2_B\%MEL,CX?I_*B\WX_#^'O_ &QV_&>'#&U,\/Y:6AE_CG/C_)_
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MR0L5.C*J;77&P4O>]=$2CX+" WEG LPZG@UDXUL)3M63#KG%FIS)M0]TM?\
MI)&Y4LK& H6(#2]<7=!N1UK!Y%W9VDRC"%N%.XZT!BO1KX1=BK@\8JV=[;&8
M/-(*BI66FK\P\]LBDL)1-(<%NX[QMS]G.,?>R_+/'\<N%S_S_L2L$;.=,<_E
MWBI]6"#N35H;'S%U"N==7%R%CW"R=@<H"EAE<!8P.Q* !$GAY)B(*ZMU_?\
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M6LL$V$,E7+5X-?[A-RK6O5L6T=B:7M'([&PFU9R;95B",8]=%>2*B0DZ^KQ
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M=LBI&40CR8[),Y(29SG8::(9MQME@A67'&S&;<:*5EHQ3E(27^BC_P"'LO\
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M/?AGY\>$O;[\?%C/M+'M+QC[\X^_VQG/\L<1_HX8_1X^_P#PI?Y?'^3AC/\
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M/#CCFSC.>'#WSC&(\<\<9SF7+&..;/Q8Q''#./'#G)C'O[<W'CQSQ^U+C/\
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MNT<YD67'Z9WY>'5*$O",3NEAC ^CB OAXC&0T,9^LSXC#.P;N*48\O67W38
M$E\_>41NX!S>_P!K <9SPQQ^7B&,;?YDYE">)]0F^[ 3,\8QG'3G$C,A9A+C
MQSP'B7&..$L8XXSF,]GWPL<RS+A+<KF&<<?S<$ <1>7'W8ZGMX)(6X>8@HDS
MS=+Z9V9X#_0/+>6"XC^C),^"\=NWTW4%D?UVU-YZ?'^R"Y81Y28^Z6>/#\/$
M\2V_?SRSGZLA=J<Q(,.'#(X1# (28^6>HR,[$<Q^$T<9GB7".^>9.,<A(<,[
M3S_OF>/-S$2F3GC\ARY_@Q]GQP%N>^JQ_ >Q=;/ZN=Y-LG_'\#CC>=_%R?.8
M[Q/$R?\ A.:JGC^6,8Y_3X*7Z4[N+J@Z'2#L[@Q"^*,NL*.,<8G^'ASYEG'+
M*6,1]_&0?2C?(2S",.Y'N%M!C'+^=C@7I<^?SI='XOO\?[/_ #-_EVV>?\:>
M<>.;Z>^8Q\=2!.1C9 SA\'YOM6PGD<OSX9EG$O'Q;7M7#ZS[+E:/[82AX\15
M,)?5]3JCQQY<&&*><2Y>&><VV[Y]KFY0;2VC#[$(<.%?!7X?@Y^7Y9G*><^V
M>'@:GJ%I9RASYDY;.9<<+F>>/UD\0$+V^48C".,<?*/OG^M;I#.?A@]3<N/P
MYJ%+.?X'C..;WX_#.$Q3X8^>>F7$)\/][]^/'OG&,_Q92CB7].?^?Q]K'\F<
M2_HCQSX^UC']]G$?^5PSP_3\O'#CCC^'-#.?Z)?=GV_7XXYS[<<8^>/O_E_G
M\8]_G\N'Q9S_ "1XY\?K_I_5]\OP^#FSC.??Q^=_)"6?Z<8X?T^...;./T0E
M+'RX^THXS&7S^<)2CQXXX\<9\>W'/ZL?Y>'C[,OU>W_/G&/Z?'RS_-_1^']/
MCWC+'Z\<?^3Q\?+/MGA\O\_;Q]_\N,X_QX\9^&7M^CY^V,^WO[?/\[E^_P"[
MQ\L_Y_T9_D\?G<./#CB.9>_W_9XY]OOS\OZ?'^?\WZ_&/G[_ (8SG'\^,</'
M'DG[_+'#&>/MQ_-SG$>/XSS'''VSPSX^4_;C\Q%Q\L\/OA[_ *.'SQ\6/;W\
M?9GG'][]_'&,8X9X2]^/SX<N.&>;./'RE_@Y_P \?R\/'',<X_7P^7X^V<_Y
M?T>/LR_7[?Y>/]'C[,OZ,_XLY\?*6/UQEC'OPX>_#A[\V/T\>/X9\9^&>.&<
MX]X_A^'XX_#/V<_CX]H3_FQC\[E_.SC/]U\OL_+\/''A+_!SQ_FS[_Y?'-RR
MX>^?NQ\L<?E+./\ /]'C[,L?I]OT_=C.<_T??CQCAB7O_<RC_/S8Q_E_1X_.
M_P &7X<?P]_Y/GGV\5^""*&4%8PE HY1G&6)9CPS'WX?8X^_YN8Y^_Q^=_)&
M6?Z<8SXT(F93Q#TS=N86,<?^U=?ESSSC.8XQ#IRC\_>9L8Q^/C/Z\X_P?A_Q
MX_F\>8=8]$DU3:YY7%G$1I@)S)7.YO!S$H^$X<IUAR^'/OC&<??X;M^IL:=P
MT^>P#9(;+9JO4Y'W;JSLEJ-L1H3KD'G=AM)NIAQ$+.#1Q.' 0L0'J4,V"U0I
MZ3Z9VMD<3E3C7VJQVDQ7O2S-D78-5*9@X)(L<S'RFP4<I1R ^:$#CRC*3P+5
M]IERW@XG=-;)!D-FT4[:YYWC;;K6%2)@;R\<1AR7C$7BN+7%MZ@M6[?/+>F6
M[J\2SV:^6V2[6=QU?RI%^V3"8BV9#Q '46!(0R2Q)Y]25LR9P+Z@X6ER[9@K
MD+"R-:,HUB[<IA468;)&<X<LY\@%@Y+* <8\5=7:8N+96NHDJ3MSWMHO7EFI
MKL=5C="J4V0UR%QZ'-E++E<!/.(&)+$,EZ115EQPV'%K4Q*-2Q^FVZ%L,JL/
M+V1ZUYTM_DUG42=6$?-4_DZ6.E& PPA*<96+I:L$G;2QUZS>8S.?.RYJ3*SF
MNF)F.>..Q94"0<,>WV\$ZD92CDE3A:T9IIS@2-+8[+L=G5+$&\1Z!$4V[60E
M)X,8I<]*&.;.80SG,1QQD^L(5O;4K:LTF4HNO$E-::"]7.'>S/WL>=%0 I3@
M>,^,>?$N?X\^O]2YPY*T!9G"2\M'*XG;N5EM%-6L>:9KZE<E]1T5TR2H51;9
M8J@JG9G6%92+_:3;N6&,3[^JZL_^Z?N$CR_X./;^![G;L VS-)I9&OI*Y6[O
M=UDTS5VBH[;+TS7$[!--RK+5OH+Y)AP;_KQL_N9Z:,UG'&N2!M)=ACV#.$[+
MS6V3TYBFM$;UQ1Q>SDI!XUCW.OVU<6G)6 (O)/+1&8U\A-&#BH1VX-9*KK+(
M;UML^Z3F7%OK-!LRXNWA*PU^6!*;&JLQU-B@T*P6:@-0H,+,-9Q)W9/GG/-'
M;=G%G''/'ACI6T,<,?=[<>'WY\$?LB;\=0-?:6#)*R\W=M=1.MQWS9V2(VF,
M!)$1>50$B=PV(4Q*!/E8G)7*MM[Z/%KFO$G8DN_,QND[FY:BC6)L6^+ ]6BV
MZW,2RXW6 9[AA5?FBPZH,]I4JD\P#SK!@E8OSW+>1T:K; HE#6+LGV,.'GI*
MDPTP*N$\%"$A8L3IL,*!-<WP_P!L>5' (5LNYV7S,ZEI79PLYZG1K>O^K2KX
MY<SS6ZZRO<  T8)V*N,6"$M+0OF7 !P.YL+>IW;S,:2H40ACAFVL8+;-E9)5
M6)8DS."Q20' S?0RHFZ=?JF?W$K&1AB8V/,+?%\&F$ U^KE938UTQS)$,9%Z
M"XHS)F9,QYYRSGCW6TYX>_"6];O/'^#+8<Q_H\2P8^VYQ+/'.(>8>_AQ_,'9
MH8Q_)P\9/(VY=21<FSR^9GF3"'4EGCG.!0VS L8_N,0Q#A[<O#V\3^+89]0<
MA3ZVZ;D?C"7SQ]=?3X9_"6.$L?=G'@9>WMYR$7)Q];:]K8A$N83'SX$>[(/[
M!)QQ\'"/-[8QXB'M[B X0%",0[9MB_"(92D/'U%V//MF<N;/S)CA@F98C'&$
MP=O<Q&@/(ENGMVW#)&$AX%GJ&'>1,Q+IXY>=F99X^Z7'.<^ JI1N @7ATQ0S
MM.T%Y88SG/#F-<DG+Y_.<I9^[CPQCP)DP[,A01#$?'8=BZ6, @08N*_JO0GF
M$"DQS3'*6>;C+.<\,^(=6N++IQ%&'[JV\>$09GD6/A?QS<N22X\W',N/Q\W#
M'#NC*,Y-[^\+BZ##W^?U(;$8<_X'@S;&O .R=&5<4Y6[&9)I2C*.0YEESC]F
M<L<^.!,<?:>/'EHJO62 )ZTV:N)A=VWA]1G5+>PE"<@V ^6$C5H9<QNI'GC&
M$,1(3$\;#LY:'-C:0V1W2M4K$\[V!>]<'L-FL-5'96'K<6P0]/UT;[KM;5J!
M080L$9_OD>.R[7KE @]IVKZT=XGJFQ[,M<6W<^7P]_0)6#R\5<"DHLU=2R H
M9/=:5HQ @<5>5W-9E]'% YV'S,OM%X1V2^> DQK>=W G;2CWZO<=XSJXI11^
MIQ)9SFRS*?3QC1K@OE_HC=AO>7:RKL$R'60I=CKBVC9P6D)O6CC-6YKU%<6*
M;5;B; WT\4[RH.Y&YXO$(ZMIR^H:7;5RMF ^;,.R6CV=5^E"3="5<RJ$<C;M
MZZO!6LP/W?3N"]Z"0UEI:W3U.D^5-59;5C4[Q&RC2W%O6J4.XZGYA7Y4VE)6
MM>R6S79\NAJ0LPNP29 _@T:Y8T,P\#"OY?5=3J$-;TUNPAE'-HWT[2A?V%%8
MU^UM%5VR2MDTI)#T[4[9JT6GS.>EKS+A68SZY6%B3$<3YP<9RQ!B+<<9)QZG
M#N(1)PYN&<QQC/P^WB9#ZY3F(27/,A4%R2E+.,8XYS.$ONQCQ++.FZVQSQE&
M76J$B<8RQF,L9Y@Y^>,YQXP;&BZM$T1S'@L*5&!,#)*4YCYH!CGDE*6<YC\N
M.?$8PT[7HQACEA'TM7A&/X8QD?#QG)M1H"9S'$,\:U;WAB.88CGA#'MB,LXQ
M_/\ /PH+Z'Z]@91C:)&-6K'$S\YBXG+E'CCPFVQG&,\<?'^KQP^B&M^WXTM?
MG_&OX\MO1:>JJ,MI[PH?"-<DL4JPZ9 @Q9*$$"],,E0<L.;A[8YN;Q_OI_\
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M!YXSL#16\N66QW#=F\_A<*98@Y((TU>+ >;@*EI5D4!EE*4FF0LV9(C.^:&
MZGFVNW44V*YNM<<G4PLJ]FH=2M*T\#U]2D%\X+= 5J<UTM:%M7",^LDL5V"K
MR5IPM6 @@MLWYF($5[FPNR7,MB/9.YFG)?JL7TYVA%E5U4(%EA==,->,28P'
M<>M))C;K'RTN&0RJ6GJ5T%E5,E$98K2\DWE5F>E7.(K-D /+X&\<<9\?+/\
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MF&AK:Q:<Q7,D'D1%B'W$<!JC!U.I G4G(DL<I,8ARR%T+;78_78ZW7UNPGS
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M4E76F@W2&L56K-D86$/W/UC=+-YFI6@]73NH4][J7H3Z)+"CR0C7-!Y?DS+
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M%TZG5#27%8@R0?TG69!P+UTW!MAZK >LLR-D/748(HV#GA,HL$5:"94X^/4
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M6B$C9@U^2@[FL(2-PT5A1>EDO!B4HV)C)N '7YAW$IJ-0P+\G-R>F^HUK,K
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MFK S.\9&C)?O(NL,%YHA)'.9^*]6PNZ==IU5VTK1L/I0*=-!&33KZD"&P0@
M(3(4IP1EB*V23EG >>7BF.'9=4L3LXM'=?(.UJ63GC6A<7N'*?/7D4D4U16
MWV$N; UAMP+/I\^,U=37OI7KEXM-A=BJ;H[!<U0GW7=/MNQL\870KF5Y+SDQ
MF)CN?5UX',Q/(/J;.U41E26C-8'*K:KS#ES7S@(]>DFGDSKUFK/*T,+J ,QP
M93E"$H'#+.KZYMSU##8:]VJ]%K[-VM XW;J5C&%6$4!M8*0:\+!M-6+0!1@Y
MF<(0D:2\R&UCZ0)BN!D8"-=X\4LNM)V%G6OIHY8F/O6TF:EJ3 5H_ "020Q*
M'4Z>;TVWZK/7#.SIY6T[NLG3F>EB<9U^6\L94*:0^<F5\RES+XZ_+D'UGB:&
M+2OD^&UEKST%2!Y*YY:@O-A@N^Q/I"77BAKUH#!(9F 5FNQ72Y&@-P#5 2VJ
ME?A<NV=8BTC:5S09V=5E3N$<C$UEW.<A;BY%P2A*P:<8,M/+C>JO4)X7VNDD
M+-1B_P"_PV*-:Q6X+>K%8#9YSA)B:N=6N^[",\F%5ZM@QAP +,\)5=9N&LV%
MG8C.9"M3O*QBP;&KW'=972$S)DG;=HW@\8CY@Y3;P3$<JGZ=E55]YK?TEM+G
MI65>%Y/U5^YK*Z*N>=?GZ[)$$J.2,BCC(2QZEI&4X.I-!'85!MOH06-59(T[
MZC%@!<@+.QY^S1^NE")6#9&0?(&1.F410EY"CG"),7E]K5+=3JEF#9L7:]&Q
MS1QL#+*F,0\QG]+%8LLQ',DNU 8C9.,/RB7@5GG>]/\ 33-E0'81V2G(C)U<
M0#L+=V-R2\2K@:5*Q&1,9 -I:1>7# >=-E/:*>WC8W2FO5\*>P3L)O6S;]-7
MX55Z)^F?("7]2=J4"9BNFV-J>>CG$LBD+9JYN3&PAU< $YY88-<F:14B 081
MYYKX)9U\\V$<>G]%Q4T6I097R6KH+BX1K;*Z788K1O,!5&SV[M=7X! IIPCE
MIINT6$DMCB5J6#1%C,A9QX/?$V6E%2K3KQGM2V"XD1$M4*ZTK829).(^=ZNM
MJQQ6/'B9=U<D.."8\6O';Z*7H@9,VF1.C-%0 VAIG)F0>>)(J,F )[HY)V&6
M5<N="+2^2!%;;!7K38K"W(L1G-GC5#$8T7Y94@? UFXK,0K2%S#U5@)%*WNV
MH9#XKRVYK%,5A7T5I@F*MM[M4]AK=KMDS.#K(.G&-=/3;LED<8BKU\!#89-!
M3)60[=D=\DZ;1JPMOLJ:$NY:12"H5R4XCC\+.>D*4<X7F3 C\JY\B++$?#S(
M3OV3%3WT;>J05'FRK"U^K[)M+03Q;844/(8-5N*F1$''%A7X)59SBF!R:IZM
M;::<U@L[Z>9.#.,G@WZM5T.!\G#C*,[JYK:H9H<P"/GRJ,DBKLQ"1)?:J#KX
MP4R\?6JF67$05:UJS9"&%TI@(JA.0+!+ 21!L)MXR+HP$<RNW$V)&.NO3.)6
MR^OE$QE!.F<!A>(<N182#6V!7@27B9(2+DVH"BL;,$[8V[4T4;!.Q?2-@A99
M87J\N19Y!8#U<'F2O= BK.$&;-E8JU:)H\>GX8$?8EE'ECM@G3LP/&])).V=
MI395I(#):.<':]CG@JJ8RXL8*X);&?9\$]F4D.I33<M70Q*=&NQ9L*JU:[!Q
M0EF35@5F72"O ^5^U:B_E,D!P+7RDT,F+.S-3I=.8\X,\H.P8?'B<YP'C%>I
M4VC;?&?& *]GDP0L8#G6 U^V7N(6Z5^^DVCGJIS%K+]-6VT)&]N4PF;U#I0S
M'Z\,IG'G(L1E.RN%7I5R=2OEIV5D6MERA%2 V!O(BU-C:K'+75AXDLE@GFTB
M4;*[ 8&6/ =C56&S5"5A4+IM6:S#@Q31%8G562[G,LX@,K)GD(C7E+N,X?0G
MTNFZK(J=:KONHLV%@5,"*2]_6&9;/8=+L0@"-B4R%:R<. CCC,YY)#&,<98\
M0=SM=26JS7V5@6Y5< W6*1JV]<3*JV=8A"!L&)[53D22Z.3- /DT,<G3R23@
M]OH\5L&["O\ 5#62:R1'JOCEP"LF3".Z* 8%9C8I 8J2+!(4;\L<O-:)4]Q5
MV=A4]$5L)!H#1DLR,X$(6Y!S/IRPPJ^+I3ES#,!F&8QG$F/X'YBAQ_VE>T@)
M>WYT]/H&O;\?@8A_+QQ_!+[EV1^EI]Q%3#W"M2KZQIFUS0"9%731LK(+?H\N
M!$Y,=))G,Y5:DELJ3*_)Q/$S7J/I^232S5N)HD3/*ITJD$PD4==SHG6K=$J0
M"(ID,L]S9]7),-1B'8GTW[I:OV/3%-'8UU<Z0:9:L3K$Z8#8(#0PV6T7K$ *
M*NO--S7%-D..9>2P%*JU#ZBG8T+ 6Z1I:5;SUK0*W3*D9Q1/6&$R3%?I""W&
MP@YC$;*XX8QDR64$KB#MW*P5EJ!3GF=#&;1K2@P6J7[6*]<O%UZ:O<JG.3'+
M!=YD*(DAQ4BK:;BY<VK-X\TF1"5C7ZS;(:^F"48M*5%;841E.9E4CX8'L8/P
M$PR&S*LU8J88*TH"-KVSJMZ%D4FE?=K99:UF\M5YP1@6NL7(:I5!'FLFFG7"
M[GTI-&9N>"0VW]B:.A,8UW@.(4[^:M).EK*>G8;HJRM.TK3UE&%5%DY)V8R6
M-V[%V+5E*8H7&;'8!G7+EJO /&L85K7<&?9 VK"6LS+/H,63)Y5[IFZ>P)F.
M;BML<1X99R?=+D^L6;KM_=I,*5$KRVVFP7V]<]G.R7K5*]56/TN8E"F#4YU\
MPQL*OTKF+)@T5==D2UR@GJK&HBEU:Z)LUS=TA?M%GR5D0==FPK5LF!%>-5,&
M)+9K>CG$</U [38UZBTN 7UA4I_1=&L;L5>CV^2HIZN!;L1R77)BGB.-/DP
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M/$O)#$!,/V=R]M!JF_':>H;*/UG8DK]2RJ6[&X$N,++';H6+E:D=7"BZZT8
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M9;HLBZU*>=HQ8V6NZ_L[54=_=["TLJJZ=I_,-15$$"UBU??VKQ=EUT(]CM,
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M4\5[N.$ REH:K;%P2D59I/I2:R8T&TOY&BO3BV +LQNJA<U&7):8ISINL;K
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M[4T>IW^SUKY7$$<;-C7;9BFM%T0$,5JO"D\M,!F;0*YLRS&<$>G,.3V@/1+
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MEO+V%*_M@NLMW+#$KABVNX-.0>K]HZ^P V.*%]5V074IJ*.J*Q3]/%7F"(&
M]62Y# )NT"(C";=UIH.6"2M>K:557/5:G4O2Z=^*DBK(#1JL'&H3K*X8;;Q(
M$URY#XR74[>TTOC/9(86HE->DDO7[8"@Q<UB*EA2N#36G8:VA<)RAQ*B\5T
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MO5X]Y60K5&?4I=(D<0(ZR3+*N(YS$F.GB.<Y'C$B9YN'@D">8*!Q?7\DY:,
M3L<SEGHXRS&\&C/ <?!P["$B_:E/&<\?!<PWREB&7#HBGH>23'\<,RSU/I1#
M!<]/!(X^JCPY\3X2Y.66.IYH(=7JEE*<?+Y(<,AS/ZH<13O"2CD<?AR7JSZF
M?BY(?+P+#'F77%S'JY+T-#1!DV,YCTLCZE^U$6!XYL2XX)U..,_5\.&2]'S
M(O.0\1@3.JT)1BGCCS$S"1L2GS<?L9GPQP\,]#S+7C,G#*F6M'J3B5CQQS=6
M"]HD1F7#VQ+!@QQ[YS&7MXQ&7F#43+G/L?.CAP.6,XQPQ@4=FQGY\??G^_\
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M1KZ+N%@D3J.XV+8 @MC%P8"2YJ5>TV 5V]:O+QV&[U>JUK7VK.!NROUP@0?
MQ;>7OF5KMJSDE>KWL3EV+8==LG91SQ=Z&'I3,VE",1STJIJ_+&%?>H65148V
M=G=:Y6TK=-W^I?OY1MD\#@GM,]AH]=<66 .R@LAG8"P&['()>7M(G0+;"S4>
M51=+G.=_"DCIVVX6U05?MRC,3R(UVA:UO),(*E<Z*D1!-D3I@'\VK3GKZC9M
MZMMWA0W*J%3.PI:RY.>5:Y*U61%;FR=GM+4U8Q8G7 5=?E&-C$^6A5;\M-:9
MJ47W?5=%'NCTJNT;>U>IJE]U[CTVNKJVYKCI6"QE:^IQU_6G;@>?511:8I%;
MLU;>ZIEA6&UIM'ZX[4B'DI2:)"TP JN),+/6R]FL[7/$-S1C76D<1(/,(:*[
M74]*.6BZYHS)*=4U<KF]V*LVYA[9@1NQ*)G2==IAK\]W+F[\V(!<#DG*XO:0
MV>DH]T3O=]KO,^RTOU)9$3%A>I;&GLFML--M$1>6UYV6J7:$3AS5V!Z\X(XQ
M*42B9L5]#KNZ_:AK-7&K5[D6N>C>QD:F>KE-E=K;)J<U=1G*FC:6JK"UDG$%
M-8"RA]8#2H6^O4]A7:R2N2L](Q9*JU.Q4D[S<[%EJSA#N%#6M:S::_=RJLFG
MKS+P61AQ$72$).R/9T=S8CI UJ76<_*4U;+1-QH,I!MK%9IE:OIG[FLEFL5_
M(+1;&6%QHGKUXSH#(:-2U=;56S[6--G;:M?+)0^AFOULF@,;!5V5*1K8K:I+
MR\:'!Q6./6WG(39)TMUMB5"CLMM^D9"T%,W35-H*9?-*LVJJZ]M:1;J-LB>H
M@29A[$JD%(21*0&8@?@<>OT5^C5(.5*(UR0J+ KZ<\Y(P7,8P**&$I!S,7%=
M<S*8L\P$YQ4$",=5V'95*@MO3:):ZW,H30<*DX?<+*QKIJDDH/,BAU=X=)-V
M),3 H'-8#F2G/,[E5FTUEFH*EO2U&N*YM@E@EN5^K;V51;,^GC)TWE1NH1RJ
M(^ >I-2RW'&!<!%J-1)0I=SMMEI5*AO$54/+>YN\Z$*GL[,:QNW[="PIMGVY
MW7M:6OJF+M@*L6DW#/<XOZZS2U4MGC3FM?I>X21(T:W^EV]6P+E&W!]=K YI
M7=5,JZV3PL D-66((#3%GQO4*RC0=M-I\P0;/EH=U1MP:4QL6T-P[ZINZ:O!
M9)+U=VM(U98W>"8LUQV23&<@C72\M;2TUG7V]BIW"2O3\JS"E3 VB[2'$%&+
M"&&V:Q/=&:-A/ ES.#*%:SBKB:Q"#H4[KL+Y*%9Y?3:P133S+U&=0TG<]:)1
MRJ[I"RK;IA=O9D)UMJXJY!@"3C#)4VEZB/C2=Q9H)7:534U*BB>-N=HI:1>B
MNN]M+[ 4"01N!-5)NQ95 L7U M2B@P'%<WENOK<H&JM+,)#1)[$[%E>_+LF\
M:;MSEFSO9I'1*TS-ZO*XPLH=JN/8%N!J7?1"E,.511U[7([+'R9V?56;$9$,
M$GMEG;UT4LQ<R+K=3Z.>KUOJ7MF*;9:TC';&SCQK-=26%,!/R_WK8=S4QD@Z
MJEV[U5VKDK6I5J4;0^J)AI;+<:Z0<Q,)=EGMPB,LR.U!YDTUCHVOK6-M3[O!
M':E=O=(;<;ZXL[6XUNRMJ*->LK%NK+:&6]8N'3/(1F=&M#"F=,N.Y$CKZ]SK
M9E=K2UO5H[&2J3UIZ'EYJ&LZ;L 5\D$F[D9-9MJV:QYPG71V,3$8L0&ZQC9;
MZY?5VM_:>XCLE8"PG4GNA(^9>H;'SCL(E7% ^SZ[47P8!G-"%.5U963<1M,8
M0URRE28]#KT[I6LK6-@J66M/Q8^8=I<T^,DL W6&94^OM+Y8?J&<7,>6"59:
M<$AQ/YG:DV(;]CL^FT1J/M+F*.,; ?7#UES1EZKC0@.5KJ2LFK3#4*G9(/"G
M$J$>\70N4[Q>.]..9WA2L:7NA4H%[%C6?+W6=%WAY-JR&/-@FIK=ZW:"7ZQ5
M+6Y?].6FLWUY%UM)9:IV&W=%46K9[@RZ :=&Q)-^SPU4$]2FELU;7X7!7@Q"
MP&._&K915@!\H:S>-@1_<^WT2DIMGDU<*.JU;P]:18MPT:2EQ#TUB>Y(@'E4
M=;=59U)VUH.X78=$O&S)3(,50@[5=VUO$^R"M@^9B=AYC-VU#%K6W+4=%(6M
M:JRU(T-@80);L.QK##R,/<CU>WH4YZU7IZ%]'N^G9:_!:H>#I6QTBA)4E3G,
MZ*:5W:"<!4Z\?::-W\CL&'J\Z,$@4M;+6%=$9UJHV9D"OTHEMH[G8,U6HKUH
M C9?"KK*]\9*S[MI0[O!U+%E9"D1D>2T^Y5U2.OKD-Q>N\-GV1*$05]EY@[+
M=O@Z"+A7)!L:-\8[!80HX:7?RJ6,Y]T$00;7Y?76RVP-XE;V,++?JA)BVHW:
M+;U)*UNQUE\S<5ZRUL?7+.S5*8'JC6!RZ#& ,$AY;))N-$MZS3J?5MKVBOV"
M<&Z]L.Z^4=J_>57JV8DL6\JZSL3^3'7"R\($(O98;["M9\O%MUK9VC*U]YO%
MW]8-Q%-5I78@[H.H[.?>B8B@TT[4^C93QW--"23<!I=GU0>5=BE1N$21TZI5
MW.PA9TK/9[3:/VGKC\AV6T88*Y2)6,.G9UREI@HE @J%QYZ6$W2>9-E:L*SU
M&OI*SK6E6UZ<17MG.7@A8.=T] ]E9*^J-KF8)BLYB.%7.H/QY:F=,?;M>TAK
MS#+=(PN1?2[9+&Q-OX-?N')W%I.L8K25+6N1KU9WI;.L9MFH.K&PIU$?X'M'
MX2-43A_>YJ@Q]_T\T,_T?VQ_3^/SS_3Q\?\ -[8QP_B^V,>V/T\<_I\9QG/'
M&<<.'"'#W^>>')^=GWSQXXX_=XY?BQCAP^&68?F\OYG+R^W\7EX9]\>_CEY<
M</PY8\/T>W#AGA]W'&?#?PQSR*FQ[QQ[QP+CRYX</AS]^(\/T</"L<_+M0?+
MC'Y !]^,X_C2_P \>/F3[_[*3[\</XW']./OQGY>/M2_''#/+[_C\.,<?U2X
MQ_1X^_\ S_S^6/;^V.RYSP^%FK'CA_%])6+_ ,HT_P"3A_ XF9M;:O4"L49/
M3K25:&,>&"3:8F,,9CRO <L]:;L1QCS8Y)2E&/@!0['M!%\]KB#"VT.9B3F/
MT!YR:)^4F9FSF!>66>:4.7..;$<96LJ[S VBQ7L!R@B6H\P2]DS.$L2E!3*)
MX+F-CJ1AF4.I*/#DER_G-L8\Q-U03!"$FF6-L7/%3E$(_P!<>[KFY)X,)E>>
M<EF.>1E"04(CGB<\G^GVZY#* SXG])T.C$!1]:!<%[7$.C('4/&<B9YP@*0?
M-&/'-H]6[UM5HF-VBG RNP(OPG,&QU?7#DHDQ\X_;D.'O.$X\XI1CQSB1RXW
M#?09,P0W2!LQ!!%S_P!C!'M"<@(_V,6>/)]V?Q@3&^>8N.3/N+.S#*(G]_@M
M5.7\V8^.8/F/YE=3EY>8UY4NQX9X<?JWM>9!S>WV^CSX_-ECCGCQSYG^8\?T
M0;U#A_\ "9CP.1=Q\PB2@F%/CC;6U<2Z7_;4QHB6#)TG]E-T_C_#'C_99OI^
M&8>[.UMS]HX-CARX%C&<?'C,LRXRGG$.:7U>./4EM>_?=]4/<;,(O:49<> N
MGG.?AY>&<\N8REQ^[.,R'YD^:LN.,8^OVT+4<<').<<#:J#1XYC+L,YSQXIQ
MCC]^^OSD4MU\P',9$,?4=V(<RXZ?/Q+B8D19ZI>;'4S]GX8\,1X>\,?2K>O@
MEG/-]*6\2GC/W3Y8<,X_#VQG]/C./I9O</[J&TM\W\G././Z/$3_ +8GF?T(
M\GY%+:!R!/,8MQEF1,H=U\>61SS'!\0QE,'".,<^)J+!\S/,@>5 2%W<[+6K
M!IN>68'BRY*TU1P4CQC'((X@*(.A.<9BG/$2>%R,[-M;108SQSZBDA W$F)?
M7K4]?6I2X<.&.1:'PYS'/'[H"QMV]+\G6^M5V*0SEZLQSQU296EG/1Z?(#Y<
MD"EC[\V,X,3Z1;>[U9<W([?F(,7MC' ,(P'RQ]N/#/-[YS^/A?"F_>9"N%\S
MSG$MC4MNOQCG'Y1._J;0I,8X\8\)1X2QC[O'2GN.VPX=?@=9NF2/GKU\Z_AG
MM-?&/ZCJ9>7SR\86$!L9XXCB'B8OI;O4"$&&$FA;'RL\P\XSDL8=IV:Y)_(G
M;+#'/''ZN/@&/I3N? 2YEY_N]P[KJ?9*QF*F)1./^Q&5R&6,?;Y^&/ YXN]I
MC*!CF^"_=Q"6#&$;(9BD3,)AAT>@",L<0"*7$,_%QQRCVG95HXYO81JHOVB3
MGCB1^I>-G,8SP+]]Y>4<>$,>_$$"[?MLHAD7/P,TRTS=66,\#E3I%S$B'WP'
M'4QRXE+CS>W#A]*=V6^(<OR78S0SGD^<<YD&6>4G]DQC_>YCXQ+Z7;R2'5:)
MT2[!Q'Q9S&7#GBG%B0UN7E5%DW3'&<^;$_AX9&'?-XY,DF3@PSKCTX\_YF#O
MZVTSTX\/@A(TL1^[QT<;[N,)8Y_RB(]-R;//.,^&>IJ,Q?!R\D?J^/)*7OG.
M>;!,_MD[ZO@A1DY5):8O@6!XX=(?+IF<],OS+SRS+.?LRCXC"7F%OD\1(V27
M,SK R%[J<)P%,Z^K#-@*?+*"D1RCD42DYI$SGCAZ<=QVP&/3B#P&!Z!L>.DL
M?Z_$WM;,?N"\N<EXDE#FQ',(X]_&R?U4[74Y8O"X'A!]&?: S7T[0Q(XLZ9P
M:XU<SRG"*L,+E#B4\\V9\(FX[]N)^K/GQ@Z^CSZ'MC' /#3H\(>W'$9<_OG.
M?O\ $\3W[=BR)^?.>JPD/] \+:L$6/Y82_7X7A'=]OAD'7YBP^BV2L]<4A1[
MF9-9GS]IG/76Y<0Q$OV^I#X/'+C=]QQGC]OJ:W*7ZOCUN4>'^]X_I\+S'YB;
MJ* ,\<AB'19P8^LQ+@Q)C1V#RQC'M'D./ACX<<O'F\0QG>=O/R8)\3$=2EDG
M4E'/Q\NJPQQ%R\!YQB/#$I<>;Y^,QQMFPXSR$C@F5]6S+FGPY2?['<8XBX?!
M[??[\?$0PW?9URQX\6@JZ=UI?%Q^3.IN!Q_%_>>/+G/Q8\$X>8FX0Y_LQBIY
M?\ _5\N.ES:#G/#C\7UG4]^.??'P>)XEYB;A',I1SCD4T"73QC.,YA#/T"%\
M,L?#G,N:?#/PYQGW\2E#>-H#&4<QQ""VDYP*6<?OP^MI9Y]3'W8F20O?W'GQ
MS1\R-T%'EQC QU_EOF$98_.XFT(A>/Z.;A\^&/PQR>8^YAQB.(YB)'R[X2EC
MYDSU=#)GGE^=PSB'\6$?&(X\U-ZQ/&<9R3TWRRS+.,8SQCPSY=XAC$N/'CB/
M''#V]N.,X'/?-H<SS%SUFDM'B7.)P%"$>"FF+@Y03C,X_J>?),\A9$'RQAGE
M\Q=PAGCQQGT[R]SR1^^&..C_ "S[>_OGV^?CJ$\Q-K:A]X#5NA#A+]<UM+"7
M_C>/A\RMMCQCC&>6J\O<<9\\,]7XM(E\6,8ECA]GXN/#CB.<8A^V)M628X\3
M9K=#YY<<YS[QCI<1?X,(_I]_?Q\&][ //'CQQ6:?GV_#XM;SC_W'CV\Q]FA[
M?+%/HV?Y?CU7.?&.;S1V[A]^(TOES'G_ +F7'2I_#G[^'"7MCXL8X\<9'YJ[
M=@>!FCR3I/+N><EGG'1)SQTP? :^...EB/,7CQD7V]XPAYE;.*>!1C(T*30<
MYF?\YOD)J4X8+/WYX\O2X_8A''C&,^:^Y]3CC.2^B>6?-+A^C.ARCC]&?N\1
MS'S4W#/"<,RB2C\M<QF/$\2(/ZO1@RQU88R+FQ/X>?FQCCC'"?'S6VSC*!(C
MSZ!Y=?53E/,A%QCZ'?%D(^ N67'$^7FSCCGQ_MN[A/WC[$U_RUSCVG&6?L:0
M'/'ACAQYO;CQQCFQCQ/$O-+99RECX"?1_08$'\6<_FZMTY8_1F'Z?GGQ(R_F
MCL2P,DQ**GT=T0V(AZ(X9!UB:WULXR:,V.?,N.,EZ?V81\'_ --O8L=3I]#^
MI7R_SA?D)S2YN.NYR;$H_#CWCR?;QQEXEF/G%>2YB<T8GT_1)#@+W^KQA>D6
M+DGRYBR+F.>'L./C_;5LL?WNHZCP_7\5?//]/CC^VDWG]$]0UG./E_< AGC_
M "_R>!<?,XN>3CU/ZCM>QU?P^7V.']S\_'^VK+_S(U[_ ..>/]LT1/[HFCTW
M-^KZMT4?^+_+X^K\RJW&?[O04I8X?JA?"S_QN'Z/PQ_IET/[X//Q^7,,YZ6,
M?60XQVZ'QSSPY2<. \>V1S^?B6";OJ<YY .$28\NW1Y&://@AXX^GTX_6QZ7
MU><9A#I_#[2S&,H_3K7.IG&.4_[7Y>:.?OSB.-SQ#/'\)1]OQSX@&]N%[Q[$
MS9F^M5QI1Y%F6,KBPA!M^.,BAQC(O<_69]^GCY8_K.RQZV)Y&6IQD?;S#D/-
M6PGC$BR]F.?$N;FC^]_O6>&8_P #<UL=>U*-AZ8<5CA>FL:\#2-J&Q!!^KL[
M:K]21ZE:&5@G GY2@R46)8SS9A9]75M@ :T+2MX8IH:-2:[6FH+O:[NMZM #
MS")*XR8VQ]HYFU X%AQ25ET1R-T0T;%KJ9FW$J-"J(H8>I[D6KFH[ET+FO7.
MY>9#+*KLN_L:]XK$F$VAH5F (@"B$18Z-3TNU-CK;JEMJRUN5O+]N#IZ$M:Q
M-385H^8Z#-[563"&?3QF[%JIK,5R'687K5<8<Q-#:U6K(O)8@G7Z3*FS7%IM
MJ1Q5J52WF:+  (-;:T>G<PW-ZMZ14Q$(H8.4[>L/K[N,HB&43_)7CJD,1L4V
MXG;1=\R=FML*C8YLR63LF.6..4(0"]HVZ^N#G.[?"*JKYP9,GE,UNT"LS9]X
MLLX=.%2)LEF1L2C4UAJ2/A<_)TY&H]F5L5=LKZGL;!M!]I(%M8K88"K;4M_7
MFKIY#;22#92A$B+28GH)VJJ9,F5C7JB<G.NRUY5'FL^<#^R1#W"+GF6):W=M
M9,L].8VY,KOPM>*+6:^AD$(1@$M]*R[.ZA/5J8-VQ9S6JZ.GMU]3UDCAQKR1
M(G;1M+\MA%=BNL*BY1?]83N:4]>M7N^!<LMB^ECEY33V.%P]5L:KA46Y6<[8
M.M 9<:=@N;6VNB9F@@6I"E5U^%<^LKVT2]X(.1K"U*WU2SJU7:U5AC;G:2RM
M,;C0]1X0P5M?>#IJ.IQ8.CLLH$=L(I=*8SFM(W8[ENE6)<*5K>D;!E:QNKU;
M7];I=:L,B26;=UJC>NL;&_9HLQO@4MX7$K^%CK=7WSUK;['ZG #JXRUZN;*V
MM*L(S4NK%GA=Y*^AI[0QV.;M<<UM.KG32%EL; 0DF PHILW8+2TNS5^X9:W-
M^NUT.OXW:AC4&U%"JV*N90M/HP/NN:F/4.-TWKZ=UUMKLZX?@*S[>XOOJ#66
MUR>O7C.PT$[+'F7MK+(]C=<>=(:M^A#6HAFQMY8V/HXV\*EQ?K$D-!,3^UQO
M2[*J?9,7UOO"B Z?TO?6%PQO?I?:J&68L<:T%J6C+U94L=EBQ4:A*2XJ!$OT
MFSL>/+ZP4OGZC%-:VR^R00J% M8BU:5LK"P&0EE8@[)H97,)L0BS"S/7C9TS
M)*V_4LT]CV#U5$%JM>V)Z=;7=YA3S>:D[V9AONXH#)IV5P]VC!JM6TN6W@'?
ME1E36\P7W5+M^05^M<IXV#E1T["F6#W9'K?4P][._P"U5W)7;M8,XG<YL'%:
M*QH9J"KW [A@-797N;VWJ 9YGZ6Q\VJ2>K0JP:VTM9/,0T!&S[Z53(;U,H;I
MV<<G?F*8'Z^>WA03GY9(4HK)O]S;?7F>)M\;V*KNCM62ENHEFPCDKI!7T;9>
MF#!II=DH#[WLE=;.@")JXG04*AL6K=U51UBH2JEJ]!VQ]!HIK7:]A<18&IBZ
MLV)939D!=C.#/.:<>]3I#1W!VN&P\[J;W5%JV@5FO072?&D\-D6QCW%]&HO@
MUU);R">=BZ@E95UQ#9W1#VAQ8EAAJOA%ZK0(K55>WZHR2E3IHOLT=AZEJN+G
MTF^6M*>T8S*SJ-BI^]Q76&*%NFJ;B*"-Z_?6RUD56K(]1/;+]'ZZI&LQF'=F
M!J/KVS^D,LU9$'XZL=XQ'^:I*^A<L[">P'1Z&]3.TMN+7KLEHWL5@QM5?89H
MW56HN4E$ZO4,\S[=9;@K5;8$!VY6@ \M8UCFQ9KZ.Y.I>=/9;<?=44-4N9JG
MOI^HC8O#_26MUK&6'9N-FRPX-G)$[&UP8&;%[=2.31A]-I;'7,8K5=KC>HSR
MEJ@W4*X!:9A-J\3F]K>'*!>K1IFH-2=B4[UMC7@[4%JNW:YI05]&HB41ZZII
MZU!==FV+76@:>RM'[[.WTSENC+7C*U?H^PMH!Z+><YU2@IVZ.RMF!5=[?ZUM
MU4FBJ.TNU:H# $X6=Q;+7E6O1W9-F#35M"B)AU$K:YW435U@$06J%4-R]RW/
MHPZ@&N5<;YC69&ZME>G%N/0URZQN.&F:RHI12UJ1@=\=E9=6>PJ4='+:+4U6
MMK(T!NW-.=-KL5R;1812<F85193]0M:P:IW<U]0>I)8';GWV!HI&U(U4?%KK
M&;MM-+&?34\JZ'96Z*TK)AJKO(V;I?,"@E85#91T:2M8ZTPN[VY;"@0OJE&S
M>Q95"CS8-7L39N$)KZ+"VCEQ/8X5VO.5AK3<9RV"W%BMN<4 B5]&OUX+&8=W
M&KK\X&G3I!J:U?"26WV&R$T./HM0>PM[ T-GJ.OOM2N),BH[GIKV9ZA<00\V
MTU]PXNXS57D=:?<IF65TL62FI:P/85J0H^VL4DZR^+9UZA2$A80FMUNM F(R
M\/#U]C8G'\TGGQ+J[!96EN8KZ6UU:'EB123Y7%U[ FNK]Q4 &N)"P'FP:9!E
MIUAOQMT]D?V?.5[385Z&M;K;!?7?H\2U4G7.B?A4+TK;N 0")*,;5JQ&F1WJ
M+PSW<L:(PLQLKMX;<0RWY3:*A[7ZRI&;1-BS=(U_+0I]YK:%]E&5*5<]RBU:
M0KU<7\H$DU#+[2=Q,Y-"O*B2>$*V9H[Z6@V/: [$%=:/=03C8CU[4ZB$\Y2&
MQEY<M:+)%GIV]=MB=O5(B5QE78=+&Q>#M;^OUVC7&HE%#0]ILJ36[AN=U?L-
M%T]YI:W&"CBU-<4D[+>'6)[U56/T3RQJM%#7Y60EG3^6^MN2GW*VLJ4EC<5V
MV,WD,J^M *[8IS13I8BZ(I*-8SN%;L<-DD I6*PY[-VK7N3\DL1!I"=VA3V-
M?$(A63/EZ:\KH$B1RF?P,CA[,>V8WJNQ:TM()'N7=K7BGAGR_P!//:<"U6M5
M>EJ60-A^D$3V6&:BS]7[@*=-7#@,!_*I91S:,;%=V%19;R=N[?HK%+N](O;.
MU"Z]Z+=EHE%=CA7A#4QIL*8<PK2R&D)F91;8QKA=MS?C=VJM6UT=(B#6Z[7P
M4=Q/5[VDNWJ3([JZL7D*%LPU[RS*NQL#],>I3RCU:S6 WEKL*TD_,J[2MQJ2
MJWUSZAC4W[FM,[;XUNO%8US&Q5U>%)Y="L841O)ZU9=6Z4*U"'TM586=7\IJ
M\BI4"29@]M;.7.[G:P83KI*[.""=;.5<LFXD CKX\/SQ@76J5-G0N/07'=F=
MC8S'. @*H5JM4O57(,]; <N.B%?5#?.K!DC=B%</2#F,)6@7O,96P)IMY(HZ
M<C$A#NA;M45:9\58 NQ@V'4F7'!U]?2E:M5H-.HS#=* 9D+&C8V"V3GJNS4\
M87*SH[W&WVA;.6M[#EG>%*RTB&H82 N[%SDIL+VZQ0(YKP8;3\N;0B;3=BS3
MS^ENMKH)+%8O9Z4_:PPY9L,X6HU1WR$:B,8PZ/J5JE$[4%Q9B3D"@W7^8U_?
M7=37Y=KTS*ZR!O8+<J5A89K"6U5&OH]8##LG&&6U[-T5>N4C;5E 1AV?I5RO
M2%'-,U()2I&L&[%Y56EDVHFN_J$[GT\?F F!1+;']K]$:.PK6 1L%F\&%DB.
M;#]L&%WK XYM56T<XCC8]=+9=UU]*T2!:Z-5-_U+*-*TGV^'5@6%ED<N#UM5
MZSL:$OI<*\2UF[I%*MD6@Z_K^O,6])%_ #C9O-FN;J8JI)H@W31K;N G49)2
M74N7:=G?)-L%\R9GJ[?23)J:_6J;$[]!K'7RGT4K5K8'JH52<Z<;.QD83?<L
MH54VT"<-?<U/&PL;$9W8QGF6ELV;3E#K6\%II/H;!J^ONB#/85M=#U'M;07)
MU 0%@J; 63^:8[L;6O[/!RT5U;-.:1 <J&G:_%1_7V,)LMSJ[G80V5@ 15F;
M13#YZPG,ZI[ 4!FYMZR5MY12:LKY6?TB33N7:8.Y+JK U==&P3"O$_K3!F!-
MT,&[-J65,I@S#:;:PELCF\@URPL*T%M6,YM87\=2 T%%*G9T'4(RQ"ZXB!7+
MK[2O-CG!ZY8$D1<.%*?8?-/LHI[J1*^+Y829V1S8T4M3:UC7V$+'2>@S4.SM
M=BZ+TZ;7YO'JQ50[V!$&F'U4FZUJJIK!K9\N.U@D_4Z<P_+P3*=/+#]4PM*N
MANC#/H6P).6,'9IP0<+E?I1=T/I'V9A"&N>4-CN475:,+<;+;-MM8;L%JO-H
MCC]AZ74C$LVI5W6L'U9$('V8O3(3/@H;NGW'6*78=D%:U>P5FKBNK37-#/1W
MQU5"IJT%^LC<8MJ*D]4%L=4^ZFON#:_(&5<NZGHS!;[;)TMCHMG:WE?8:W14
MZOKJ'T220%9AEKY+BD?L\7-W9LTT;Z,QN56!*\J"CBY_X+M"V82QA*=**$\D
MYHS@6MP?AB/YLH3)/FGQ^LQF/\7^$;')D>2@&*M(P.!.C,BD+BO(R'!>&>'5
M$*<?E[\>'W\?V+ZDIWXUEE95Y%E6R9-$49RSC,@&(OGN @<'&:9V 8F9<)YG
M$$TQX%-F4JW3Z-;K[&]5ZBF)5O7D/5DO+9'T89B:J(M/"XCIMXU8;%JZM1>:
M_8;!EBKG;2[PC=_/ -'5[RWN&R85,:#>^)WGFHEOTA[M9,:D[!/-+55*5'4J
MXK-J'G+=G@K0ZTN4#Z];QQK]*SKH_+2"=;7CJF588U'>]CV*_&&R#H]&>MQ9
MU5P#MBZW6Z[EE_#5?:")53G-FUND=G#7RMK_ &^Y80QZI)/!K30;32M9L%N1
MP>:^RKX6&<W^48A]<7R#BT&=0A"5R5FIU37ZJWF$J^N:FXX6LI"UZJ2@R@B6
MAI%WFKOF>-:-BKZ;"0Z^F2BK;$(U8AU^\/;5XSHMZHI=UR+3)*NTU[6/+=77
MDN,#5()YN*_;\VMD@;&%\%J+"4&V<FB!-8&R6".J,V&/,3;=JG<93ZEZ&ILJ
M>P6U> 725N#'L*&U,DX%1AG"-?( WD&,NH(\*!6J+J^L;/IX%BT=O5O&=0L;
MR=34:_96UM7?1"F$&$Z0%VL%,L;R4YW$I2<#(4)PTS7 V,ALZ9=4A4B@L75@
MLT51;]'"5C))9.-F8FJ2F P648I-7.(&G$,.#([-<%I0TZP1K7%2^F[86-E=
M^85"38XTN[;()^F@NB[=AOUVMHG7EL;8=IKU,Q7W)(#Y1\SZZJS/69QTDW"O
M Z$62Q3)W!D:^?5.G@!V0=MR*,D*H)AT08.L>)6>$U<64U8(3L.W%WTD1E(P
M-.3?)U\JC.4IX+Y)THE(0D88G.6<_P!>>GCCSP28F.6)9QF$XJN<)#S^9+^Z
M_3\N/B[@(1X2!;\C1"L2-AAHE14LR*&$LRR '2.* PXEF,)#GPX<>']M-G+U
M)2(4>O\ /'..$1XA7$Q'DSQ]^;//+/RX<?X&!%PK SL"D0<85EJQ#A'EX_E"
M:+*G''/CVRUC/\7&>&>&12+:2EB,YYZ.M[.>'*/AS_6 I2CXXXX^'GYO?VQX
MGB-B?ZM==N?-37L,17<%$ZY,R)71Q\0I8SR_:Q\IX'+&8^ 9[Z?Y1^\_N9;?
M6_WN.RXX\1R)PA,3YN7.*VUX? 0@9_\ :7W$"3'SQ\OOQPSG:P5[\B'.G5YC
M^Y=MC\F)L5:DQ+FFG&.9<#2A'WQ*,LXGF/)CCX- [+\>@P14F!Z[LC$HG%G/
M4Q+"]5/'2Q^:QC.0$^<)YQXR.-H;CTI&S.5'?1 ,8_WS)F9UT%Q<./V2$A/'
MZ?!)XMYXP*7(3!:6]5)">9DC'$A,UT"?V.6/L_./-\LX\3"&[Q,HLCP0>*VV
MXQZXYS#_ -I8^U@<I>W'VCG&>&?'5S:%E#JS#S@I;UR/4']N/Y+7$^7X\>7]
M.?&!CL7IDGQZ<<:MM?Q9Q_\ DG/B>3/N!P/(N?)-?V*&,=?$\BQQE5<,YE@<
M_EQ^7OR^/>YG_+47L<_S9J?'9^L!RUU(@[;MW>OULPG/I]/"O-F?*.>9QX8Z
M7#&)>\L<>IW1\0]__N+<RSCA[?<K'/\ Q<>)2,VP*,?G*51=2CCC+$<?9KOO
ME+&/G]_C"LKJ$6Y&FM$$Z^V'+N!QA*8N0B49<8QG'/W>TL>.O*RX!S+$<%E7
M6L8<<SR'EXY2^>31E''O_ER\^2PQ%6MG,;LL)V,RA)",,Y%%2*G=LSQU(9Y5
MA3E[_+P(WJ.>D>,IAEZ=:_'"!9@EG_4/'V+"6/?&/QQQCG$L\@[+,Y?Q,5MK
MQ_\ 0O\ F\!K@6D.]8EF( %3L 9)*,)$S&,F%0PYNG"4N7FXYQ'/#P.1;E.,
M3@[@).!N28>XPISXX#GC..YST^'-QX_=R_%XF3-P#,1QYY],#QI8ACYYY!*2
MGP]\>_+GAXA,UO (RKY;',J-D*&5X_:GSD4C'V_3G$_[CQ@,+I+,\K&;X_72
M!VZY^U,3N>G%?X3_  <G4Q.7SC',<<?$B>KUV81A$DI]S".(#G]B<L9S]F7#
MV_'Q#!+JLCF8Y$C#N89F0<>&)$AC&<YS&/''RCGY^,Q)L:(I8SPS$HVA2_F(
M*&<X_"6,<N?NSX"7.R5$!LXX@))@T8%^+I_4RFI'!8=2!(Y)CVQPQ^/LWTMI
MU_/8D3&WROPG@$K%J*-?$LOJ^63;LXKCQ[_69X<<\?9=<NUT,#-@[I44FQXF
M=?)9AP2'UOOCJCG#V^_'V?OS*?TEJ)QC.0\Y$?)N6<>'-',0Q++CCC_U>.F;
M=-7'+^*:Z5#/_ E'_G\/#KMKUYLLPS3'A>R">'=,)O2 +,X9QCB2,"2Y?PA+
M[\P\9R/=M4Q\8A,$]73CUFH5U?+G]S>^<+S#C.??VY8\>:,L>.7&]:GS?[M)
M?XNMC_'XQ&>VT,N.)YQ.+\,C^K',T^8L(2#'@,<Y?$3'R\ E/>=1'!@I@!D2
M]KXP*9<*S)AQ)W$8\X@,CE*.<8S]8/\ 'AGA#;]9EG'OG&+A+/MCY_)CQR8W
M#6,3_#-REG^CKX\9C+<]7Q+&,RSC-TCCAC'SSG/6SCA[X\2C/S TT?#.<<T]
M@3'#CC[L$+D8Y9_1B6?';Q\P])D?.,\ PV>C(3V]^/+![,O;AG[O"\3[KJ:\
MFPP.M!FZK13,$G'D*.,WAYD.?+GESB/W>.C#?=/F7&,9Z4;^NS/A(@PQSPPQ
M]Y"CA\OG/'B!V=PUI8!)P$,A[504)$ESRQ"))FC&620&3E_O?SOEXZV=^TP0
MXC&24S;'4"A&)L<12EUG!9CB6,9X<>'B+3'F!I,5I^T#XV6GS"<I>\>7E=GQ
MQPQGY9SXR(OF#I0R0]B#-L=4">)?J(WC/#]'#/Z_!<J;[I;'1"PR6"^PU3$Q
M+(@[M]B?(_C/043XLG)R<H18S.7''B,,[_I?.7',*.=EJ(]2'XCXM8ZF/?'Q
M1XX\+*8W;3\M.SP)-:&RT\V&29^45P]UU#2]\?#",O?.,??XY6]DHE)\??N+
M%<>/O]N,RP]_^OV\</IMJF/T9ND>/_I./ Q_334XD(7"\(SNZZ/5/F$R8"/G
M;AQ)F R2Q'&99SB$O$!,[YI8C%QSA@;9:97K1X\,=/!7L\WO[?#G/ZL>"\=\
MTN'1CSES+9J/@*'U6>H3'J.,PA^4 QQEPQQ*//R)#F]]WU'C]_\ 5'38_3_\
MNY^[W_5XBKC<M4RU/$,P5QL%3DQ,%B0@I1AW7-G!1BF2'#'O"&<_+P2)=]TV
M.5P]R?CLM/C(P<<XP3.,-9]LRQP^?'\./'QRBWO2R2Q@,Y1CM-%QP,\L0"7X
M7B9Y3RG# >.,8)G.(QSS9QC.),;GJ"^)>\)$V:EQ"<>;,<2QF;PN/',<_+&<
M<?;CQQGP0,MZTV)A3Z1 SV*GB2!.EACDE'-CQQ+ )8)G'+QY.,OL^_CG_;&T
M.4>GU<RQMFOXCTLFPOUN.;3ATHG^JS+CPR3ZK&>I\/B Q^9&@F)/.(P&+;:"
M1"3S[8C".+.6<RSGVQC&..<^.&=KUF&?XL[ZJC+^;#4O\?B8&]]TI,X\\I%V
MMHH@G%/^*2$K+&<9^?MG&,^/]L71/Y-LH/\ Y)>,]OMFK,<L1RET=BJB<(E'
M$H9YY#2X8,*>"0^Z4,QG',HRQGQ[;%KW_ENO_P"GXR8^R:X(4<<9D+>UXQQC
MQX<V9RGB./?.,>^<8XY\=!78M>:-@>"]%6\KCFZ4I=/!.E O-T\D^'$_LYE\
M./?V\?ZY57_E)?\ R>.,'D)X_$;BI(_X77'_ ,GQG/5%CA]^9ASCWSB.,>S/
MWYSCY_J^><>,Q(8$)8^Z681S_-ECCCC^GQB491E'./S>$L?X<,YC_6ME_O*/
M'\R1?X1M'O\ V"O_ /7-;X=V(RW=P49J%>CDI0#QFWN:^F@=@P%'SC54G81:
M;FNBXQA8)>@L<O(.0-ZURI@<CB#=@G4W-@6J&0=>V8#D3V2E7<26ST56#*<U
M=*1I] #$4LD*1>K7NZ2PKK:W1T-Q1>MA9WM1U/,%PRM0FQL(J1)"O8!&$2L8
MM8H89EDP*GU&0,YE:>8^Q4IZ1"L0+;215C?'89KXU:EB'M";-K&EX<99DSE0
M!4!N4)BX'(&P&C(_:ZTZ:@@'7K2MHVKZ_C;.N5VO.VFVV.E6"_J==KKFML5M
M)<UIB$O[78==K[>M_*:#U(^1)EH6K2AS3T6R%UMBMNBW*K PT.XH; ?6[*W4
M$O%BK;;L:BNIF4R\]>LY?+=*\;[5F/C-9'22U5)"NHG"7C#]RS+#-YIU/MV*
MWHK:C*F7<KQWB*;8K/9*XA.?KHC;G^2^%TJE5MBP+;CKCJ&.L"2R9=]TK2%;
MGC"3.6:VTCNJUS2.*P*C9AK;)*+H65RY%L(;*O=BS3H/,UZ_7%@EXW6[]L^A
M.5R\LCZ0#Q/KN+H6,D,8M0=P_;P])9ZEK6DU=HAU]BEKM1RFN^%J<.YNZ:T?
M$(ZK,[4%V$^\D/4@[@3ZV%7/ [?\C\5&J'UEKJV"];D[2I;SZEM[5;#;6!+#
MN=4H@D#6UJR'=0M7*.]_=+J1U_D28\4UC6:4$I;FGOMD73=NM@I<SH:"OUIX
MTU#W>A5X[&R<^DRX:_L^IJS>5S3%M^<8G@6N5>N4CU^_=T%5N+:W<IU<ZG4;
M1U5$=E*;L^W=L(D8*;%0N?$I+5MCF;8F<U2ML^P]JEP2I&?8EJAQ5RN,W<GT
MW:P:GM08UG5P1,JS99M4V"F)"X5A&)25;1<+QU@^OT]1<:MLK%T(=]/96DVQ
MCU\;;UG,%-#67<'-Z6H0BRC5G7&Q:P8I[3TF8.ZG>;I<:J6K6JCZRHFOBYY8
MW;NPU8;XB"+%_4:T6+570L@LIS,E&NMHDAC7[&U$99@]@IK>O^M52/Y#F[S=
M(5XI7Y=80VU!*23,.[]+<K;:L6]44PZ\K9'.)BC@BF:Q\:LX_I[@7]R1]4HJ
MFKO*>S+Z8Q8:M4U;5DRW.F71S86.SC'@,<LS$L@V?'6+ BHJ.O\ HZWENT>M
M*INN:L0 MU[>GVNHU9FJK4DU[(%N^U*V'<54<O5X'ZF(RX8"PR)?P41M-- [
M,I2U_.+GN5K-8/F33>6K,G<(5+EK7MB?O4;,225/=2:2E(("R>CV_BITV=&Y
MFYL\:]GC76-:ROB&QT)-C XHI9DH]D=K*ZMA@ERY]'5Y5G-CN%X\PNJ:J;I7
MBC7VD6LFL<-)JU\9EI-)MH3DZ_-6N5;-G=UHK)6+R(64Z:\:'8=V!*L>M]&<
MPX/8*VSTNK34XI<]Z7=#*! :I')R)2 I>[@>\FQ ';+8R4&&<RA"7&JU!QA.
MX(G#2+BQN:]&IVB$]ZUG0+!ECL1W-Q0+*V>UU;RG=TS+-A5Y,22R3@LI^)1N
MM9L@V";1*NW60L:YM.ONA;-=ZW-2-B]*HPTKQHF;#OXK#_)V4A=MW$FAJ*ZS
M7:<XU:,WWHTLGM!"14&.MT-QFP::KT;?,0 8WQ%;&1A*N4*I&HMXF<*OC-4[
M0,4W=PVMFD,1Y=R3JFF[*#5[KU!<0QRJ7H.NUIPJ<[PR+.9XMP9687B+I>6K
MY=F9M-L47UA;:* TI5^CO5]-LUH2V-)5"':7SXZA6OAU7'B\K8XPK\S:#0/(
M4]SL:NPZR';$\UDJM9B56VY3H(!"K;V%<9VWL&;I8*=,I@MB<V)+B!,WP>-W
M9SKFP#!KNPRTV;3$E$ZZQ<:V)O4.Y3LL3<D)<%BL234\H%*H(RI) )(N8#\P
MMO.H5M9/<=27Z2[LF.K])M1\L5PEYQIS/@"9KT?P KB.& MU0JR(ST<U5;3Z
MJY;X+35UW?NJVJ]>#7%;_%C'6\=ILJ^OVMI.QE5LR;%Z>LQ6XY,S <DL!\;'
ML36DE1>URPM4?00[52.DL941BJW/Y?R+)J=D89^2)I1D?(1<<P@7&?%5"\J2
M4=M=VE17TE0"V3O96B]U"L97L!6* \HAZ"%HL^<+IUHY#S] K,NGSV&WS4-1
M45<MWYCNLA(0=?&KQ;&;<@''(M@"DOK(B(UCFX\"?5Y\4]E3T%P[KKFKBVFZ
MN^]J _1JO):6='R-(M6$&[(REE3V,++TSKR7@&,P]W(L(9K9Q6N).V4MWAZ<
M&*A&Z_.CN33?E80[GE#WF(Q9K\8Y^K'X2<DNK'PC5$7LA6+UXS2"5EV\#")#
M<J;4%&CAD>),I6&-AJKE%@<3"9KR'R.>2+&C%!M/6]BE-_;$]))7F;UX-A5W
MC@),* MP$V+)JXTXP*NPL<46UK!<ZS,<\($E=6=>B_D=+4P?.,UA0XZ-BQ='
MUU#6K%B-H=2IN;:U#C%9W9RIMK9DP!KZLD(G>]#LW*./E\+S%7M5;"IEAJH*
MPFIV<5>ZP<5H-QO*DQSGT,R#G/<9EG.(5.#*VV7+4[J<E,]B#%0\C8W-01.V
M:._@&&#6FNWB2@D/4"G)5M3Z<0QP7-&F"HM+Z[V +CU;1ULJT31:^I DS<NC
M/;,URN<UX[%2(49%C8NM'% "O:P<;4?J)L&6:IY[S*X%Q3/*E1\OY0%;OV2Z
M)CL)JLRZGIF9 _+9KLX%QY(\]8@XE:)O6514.B6(12?+:6.WM:2SK/<]Q@);
MNKMD+ K"X3$(=*NLF 8)A(D?#+AZFP!SJ5UG1H^IZYBWNJNVNJK74+#T]FW7
M]*7;L;JM(N2S) 646A&E,+$^SC5:K%)B+5M4*7"[1'Z7"K*KGJ'+FNYWH$NH
M*XKY0LR4XFHHF84A/$\'S.$47K(R16)[)FN(Q7M$!;)ZGG(;VS3(C!O *]=\
M;58I*T[!FW;4E*G7L$W*MM^WP%NVN6*-STNR5H-;V"WFO<2O<ZV&D*PK6RKP
MW35QC"R-6PZ%UX95G$PF2;58-07#U\FO6;3*OC0.3ZW2LLVF 90Z/*+.88/%
MD,N8V!Q'"?.;(XPGF-Q?CN.K4T5N2@L6P(69_P!V!N+UV:Y( 4ILVS$WVET@
M1J0NX9:+%=?)2_#XV6+=OV0=8'ABSE;5[:HI*83HFCM+",OUS]D;8JVLL4Y"
M'9H6A8JM("ZZ9&3)3V*F6,JJD_V8%#DD4#Z=?8JEK@@KL3LIYKK6O?)"N[HR
MJ3,66AB!B9(,G/N-8$2B=+8G(QAD&,([".H-5-#YU8=<! W]*9H@,$Q6!LU"
MVF5!EC+Q/-[9"4@(("FY,9=9%WDG.QA*K1DS<S[Z%7<G6,*N(K(-+;3FP/LB
M8\5&ONVRJ]Q>QS*J3)$W%KX#D''K8AE<!&8JM=F-DHB/259@G \URQ@:V!L6
MN-(PK&;:0^=<)W$U?7IFBHJ^JF1HW/KMZ3H8X%Z:4FIQB XRSM5V[A1&=$64
M+).%:_DR8XY;@1GMEJZ4S5RY$'1,VBL#UBQEC".Y&<.'AV.PWJB9D*YJRFL3
MAB9<*+2<[)8DHP5+=,K1R9&EPQBT=#Q.LJ0$9$CW#.6];EZA&I[;9%D5K$=A
M%GM&PMUZ-A9.UBM:P5 3]M:@2I EM:X,+(IS$&)FQUNRI=@55=8K&7:XZ[@H
M.+<F3+]8:V8SQRS$8<X2D(X"!8#,@2#)+F[%+F_\"O\ +^^[3CXD/*2<ASQR
MS'(*^1SA+VG&<>UX9CF.<\8_G?+/MGQF3%%2ES+()2ZM6@?CVN.17XI@CG,E
MQ_"M*6/J(YS&..'B'-0T,NGC@+C3)9Z6/PCQC\..'MPCPQXXSUO79</;&<T=
M?G/+CY8]QY^7^>/!\PU'5\9:SS-<-?J<98Y?:'<9P#Z^6,9SPE/CP]_;'C.&
MM)TQB,HPA(;&K4Y\2B/][AGJ S',8?F8SCA'[N'CEQY=>7^(\>/#&ET&,>WO
MC/#M/QQC./T^_CB?R^T,^<_.1=.HB9S_ "S6SGQ[>6GE]CYX]M2H(^TL9CGW
MQ5\?EGQ_M:^7^/U:E0?_ "+Q]V,>,IT-)44269S)E6GKTJU>19\.8N5TEEQ]
M0G#XY?/VQ\_N_K.PYSP^,5%P_P!ZF>&>/\N/X1M..>(\]"O^.<2$CC]V*WWS
M ,9%S^'PQX_R<?$ZZS#DZA#*,<L#L*E&R@V"P1:7:4*!I5I)Y59M5E8PCKL@
M$81(SA'/BZL6A]O2UM6\Y:Y.6P?ZRH\/NND;Y\O-N';,ZZPZ?,&77V62'8RR
M>7'Q7W1/+?7@(YE2UKB6=@CWU)>:WFX:T2-@D36Q$5U445*B:>SMX5RA._@$
M%*]V;'.SKH/*S7\ZX,%@-VMVO<1U]/:V.I5=/:A1TU.SUZTQL]4\DYJTM*,!
M:L-<RL$6!4B"0IOXVFSI_+/5VKZN<LKX"]7=/4]E;"UNQWFS<M]W51UB08;+
M"RT:MM**IO$;9F-AMFOG[Y4K!F([EJ.L>5="PG"ZK4[";5^"R]?UP-O7U&G1
MJLRP1-)Y3;[?6WPZ6[TM<IZX_HS 4QO3<46M:O0%"VC[-(\U;U.TF=KLUMV;
M1M16P9BKIS5S^]58-OJU;C5IPD*KKT0D'LK 35LB-5*FA:JZ.D<-KMBT"_L*
M;9X*R%6[G5R,>LJUQZ51'\TK'5U:[:[N_P"@"XS8LHUXEVBVX-.H0^3FK7]'
M?65375B+5\J"SJR>@:?L5WGK[*N/.TVBEKYJ6<117.FX_E:RMFYX$8CB^D5@
M]#K=F>WNVDPK:CV)37VJP;NU4CAK35;9HXC,W3FP[ M="KM9?0=/.![5AE98
M<FL*4]IKNK5[>%ZO:.0FVNW>T3=+4T1M7?.I9K-6?2:TJZKJZ5E8[')YF2UQ
MK_I9ZB!BRU>_3HZ:NMG]9U5"MPZS:9K:P6Y?1:EM0*&M;H4ETSU*R\4 W%QB
MNE-9$5FT<!69LZ;7V\]67U!C4*Q,7,XCJ[=]7['0O=W4LT:N\D=NZQS<::O
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M6#GG(*A4*TIPR"N@&)N;/4X_?_:;8_\ Q#7O_KO_  . E=;O+J,P$/U:KT3
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M\96U=C'-Q'CEX]U]KB=>/#\6 8_LF/''UBJQ'FR/G]12Y>IB,9Y'QZ_V\0G
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M3$O'YWSQG[<_N_WWR_''RS]_AFU>RS)=7 XX$J$K3C)V##531247QU6WGW#
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M,AJSP8L.C+CE=](W64?7"XJ>./8BS(HG"2'/#$^4D)X)CJ8YL<^>/#[./O\
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M 3(.,8,E5D"<Q3('IQB6<,<PL0Q'/+XA7/5FHB>M4B"].7UZO=;LD6[1#72
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MZ52U9>]J*JYKF\TZ>YU^'7JXRO0.Y)?>KHPHC,%-:U#6N958$I),]1;6;#S
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M-]2S$H8Y 7ZLF(R]O%E<G3<".JM;^J:714>NVISH+EVH*5).K3/8N]Q)3KC
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MJ$@ 0:#9 U&K6K8*/%+:^IL$2G7<E@@^)S76<:_<LRQ$D;#)4CE0BS,53/N
MD7(3QZTU +P5[O<KQ&YQLEJ%^,MP:9:-6,:UZ.1$R203KUH>?8YJY]*2MQ5B
MKLLA"!0*=/:=O:5]@6FV'J8H[@*IN,T[&0T[',,#YL6"1)5SPQ6B2)9K3C#C
M&E70KM,Q9U?F&;=%:HAF@:]1)Y==;%5T#(: C 29E)4C+ ZFO@5YFR=P&/-
M)!98P.)\CAUXAG(@HFY<=2(IS@.<QXGQQ"4QCE*/#.81S[8<0:0HGZ*LM?,#
M:$6X.6#][8%VJNW",*CZ.2HXIKR%+<'$>Y'>666E$H0C6PG:R'6WB/H6J:@7
M8_*-;3%*ZN);Y&_:RK7NUO\ ; V6M4KZ-BBR[C'083NK561["1K Q_@("K4T
MWR^1<7NDG%Z$-XS]'%%E+(-M)U5[]K_F#;D<&4H<CUH?:-&Q8B>DT+'/8V/I
M&GMV%QHU?KBK=M:.R-H-Z%J[:9OM5+]%7"/GZ]PDT)J.=6=(QJ]3G)%\G@6K
M8W"*.NB>:WOU9BQ%,GK#&I0\M,:B.M.YZ1 LR_2 8K?T?K^EP'CNHNR>CTYG
MDF(!W(A+)0#3!$UC,X'+(!,-B5>*L A.6!6!I-S##.216/*.!2WBGJ,SKS[O
MN$)*/+71[)_6Z&SJ=?J=BNC6ML59\U@/TZ]=H0+3=,G-RA4'!-)8H*JOLM,I
MJ:UJ?HRAJ4=?=MBZ^OK@ZMPQZYZH,*NM0!K65FY)["L!"3Q!4^MR2&UA&:_B
MS?JD-9],L@Z/4A9<MVSS25JK%][:K2=1"K3D4K2EXU75*D+S]_J5GV.C%LB_
MCS.KV:BD<6VC8JJQKT<[ R+%M4*U>JU5DD\:6O9Q4,-HZ^;H8C&R%W;>0%.%
M847R[,M:V,;6+VR8<J7IE*>Q+1JZWKE%61NSF'"3%R$5-D#C?,;+_3&\4G79
M*(?\ VOFS]5C7-+&''X<CFXRGC_")Q_@:XC7495[N\NZ4/6HJIKA321\O;';
M_52G.AFX<N67%E98RM9PI1TCRV.QR]$K$]C;CM$7'&?+G3=O2M6!5!:VC>VJ
M>T#;=1[2O4 37ZP%8HRGZCA[';)39?.Y,KI3[LV!R\88J]\W75UMB8UEV[A1
MC48>?/;MIT$;4SM+K<<-5R3!ZZK4FVG7T]@--+GO#+GE'DD8 2RACWQ&1!QG
MF.,_?PSGAXA.=*L/6#[ SJJEMBW.6[-<J6#-.:4]=%2R6#5>J(MKX=^D$V8@
M'%TU<%?))"VMFUS7BI%;5BII$TK,;A18KIQ 8M@M]&TC+-M9CWV,XV&R#A=P
M2N453*S.Q5GHJZILVW]AJ*::]Q:.U"V!6I9JQ(-M&HNRX-AN2L>$D9#B"9S9
MS*8H -!-BHKV4(Z_I+-N %V$,*BQV/:G-?<G7N/5B9;V \<I%1&%3S:%6R@(
M ["Q73S&G0U_9>ABQVFI:MC4%\O6).:Q9.5DYEM6*D- 91\U<V,.4KMFP WE
M5)JM&63N:^#.%INM-OH55<G$D089LK1H:20S,SQ**JN#%P1QGIG(!6!9@5<8
MP)4U/48U!*&U6HKIW->UM')1+5=%FL$U89OU*)YPN#-W54HJK]'H-SF8Y2A"
MLK,\JPH->/C7[=?1V4[.=DOBQ@+?DNXI\MTW1Z0L@9Q-6QP"V:Z4,097[KFF
M$>UK-U%6M64ERS55S8+9@S34@5]0>$&5)U(H#P0C;9"L09SV^.W6&NWP(WX!
MO-CKN:E:U3J'-?KH/.WK]IB\Z7IP9JT%%8V C&RP"711K[4\ SD8H1] T8:^
M:JUNZ:;ODKM_L6.UJR5PM>;5KK"+_JAE# 8G8.JKJ*36BWG$R3= AE<\!PIT
M]=1S4_1_5+:SG:W4*^THYW+VTAL!="N2O5+=H J=48EUWUTI,Q-RVL@$B>+5
M@^R%-%%<[CK;)(A7546%,S#+!IYQ 00!A,A23SB,(1S*6<8QXM'ZJDS.UI]S
MU#46JVP-,02FV6PTZ,B+M0%B73C7;:O*#4P](3 RER)I<.(L+EL5 HNS'B3*
MB[>7@KDSQ^KBWE93K\,<.:?;CQS<<1YHXQ.1*$E,:2@7=>1-;P=7Y8EVB+0Z
MOD1S'#$^1U,H7^,H0 N91I>;DIMK)+JYJ+!9)ZUOJ1"T+-'HGM-=/9 <7(K!
MK+P(LXIK5FO9Z!%C*J<S)4V&5%C'?9_>PXAB,,3 ,C#!B0744#)DRZ_<NM%"
MHM@QPCFP8<)%AC/-BGC1Z]=W#UO]+9QK0L:\ Z@=)OD];OB'99O!U<Y0M;!.
M"D%; _= +EC$X0'+P%JGUMN[V_\ :OU[=7)*QJUZ>O>V:OLO2\G6>O5V3(YL
MZ:SF\!)EDJ=<#CADI"#EXL:TG5PJ.FJ7%<9$MTNM-RW$Z6)X'DU*1(Q2%T3K
MC$+M<D"0F3DY7[$^KOH87:N1H<CU,V&Y#76UE7J]C/U$)@-M!1"8HK5>M77,
MU@.'"P$4T=0NAU-I</;6NG%)%,%57,$<+0O7A)L#=OBU]8#(:QGC#%U9= DP
MKP.[QZV17,*#93T\=<+L]Q8C%1CCKE<H5D-G"W3:O5K0CM5))WO%:9"VE/M#
M01RX;I#)7:7,T9V]GF8PX ]3&R%J%78765':Z%IF_3EFJKBN1</3QJY1.F*+
M^661A\;NA8]E+Z-[;&F0*DL=7JUS.J:MLJ_=P.Z[U'5\["1,S 9+@9PM \$U
M>>0L5W"MLKJPN;+TFHJ*GT^+C[V*ZQMR#B:VL*NL7@"LJ;!PI7'UX=-:0Q=5
MD@ %59/K.VQ,2I>N[&NC7)&L**OKRX$:=F(-G,16"9ZLD4:8]L]9P78E7+M=
M/WK-=7I[DT;==9JNO)%UU"I>"PA*SS*O!:[ AL%MVJ<<D>Q443^4_BZ_+TRY
MA; EKEM6@K;;8*P5H<M:>LL/0KMBDR1>:[N78&:(J8^%F$!]" R1(;.>CDQK
M1*J+=-0<JU0UX3IK2+*QLU$.?JO,+ Q@'<]?ADG',AX^4>:<>VG47TK,Z);,
MM&@HG:6E=65]B ;MD["ML&5, AGXA!6<:>?S X:U5UP!5HW94VI-5Q-<TYQ*
M>)$RM*#Y-E8B=?$\8CQ97[8A)P]YQZ74]X^-L<#K;U5'7V-R02MK!BG;IK-G
M5;>TIL$&!*WA>PB<U=)@P':NMC$?4&!T\.V;9EL=]5VNM&$>H1+26\J8%EEZ
M["D:N"*4;@M</NHNPGROV"1TQ#-*T"AT2XBM=U!NLDS-H/OT\R$T@V>O?5G(
M)#+D(F\JPK,JIV$S2%DR;+*LPG([5JBUE6NJKRIUIIO8=C)4O65Y95]/>%1H
MTA5;HF9 HKM0ZF"M09L[/JUW:)*CQ;$<3S6;-CHLWU?7-YHFNTV*UUI9YJXJ
M:&?[XW8!A66<51L"4%:YKW9U!G@+D+AZV:Q:)HUU3IENR<J&3QZ6]FRO1K!D
M@5R##>#9#%Z 93"K%D!LGF"4B0KMD &]LJZSM'*0,*VBL&;$=PD:Q2)7,561
M#L1LRMJT]/#\FD/#TPS*05?F;PU*5BMV9%MB%#(Y&Z%O"=439A ]#5N7 ]<%
M:V\\6=/%8\L$%:+D$Q@0"IL-0*.=R@E*H:NIV5O16596A433+8FYG&@P$3/I
MZE@Y$RW73R&O9_*N>2L&6;=%ZSL *6-?5&52UO8S6_?6D,$1".D]*C;GZ\,Y
MY2 2(+G$<7/UES#AJV%:_8K$6V%MUU3(T;LY5C-(2"U@I>(E@&TK&P.9*H9<
MR/.H5*PR]VL$R2_M3M_UO-^XNGQZ7_<<X)LW''R]^?CS?//\#+;CKD(6QP85
M-:036C8F6QT\X7*[@?<D!CHAX"F3,/JA_#\$>#Z2U-5+I6F3YLU 5R8E;'+0
M^BSE\ PQ$YE@7U1^XB3JC^ G-'V\%IEZY2%2?-CDU;D,2I%Q;-,.6(IK%YQ9
M7:8<9E-;EZ&(ER& XAQ$>,1CC&(XQC&,8QPQC&/;&,8Q[8QC'RQX%:8IJKU,
M!&#!L?3D^_$5N&1M%$WT>N,C(\Y&Q.),2-#.8DS+'MX><KJJM0;LR]>R:215
M58L#=0I>L\8 H$;+U3G+U#RG/J&+/CS$EG,0N+ ;%!A1N(F0C..+2#07D68P
M+&4<,).KKN*&QCJ+M "P&4"BA/'6)2U)"] "O5G7)R)VJKOJ2JW/D.9=!:Q_
M+P!X],+OY4.,3_'X+>+T5."Z/@N#7 :Q$=H;!\#P;!;" ,-$P; 0X+S%SU,"
M'S<>2/!JKM%A.H.BR%E8V/@)#.>..&8YC,9!SQ$@3#E P#0@8,X%A"> 5^=2
MUJ:2S,W0*EHZTH1ND7BH5V,"K3QWIE817,W_ *I,&.!D+*/MXF:5'3R,5FK<
M(7-8EDA&Z3D]%:G/(.:;-1TX>EGEG)$.2':R%RX\.V<:&FC9V0R"L;&-6C%]
M\1@A7,-QR(,,,P*!=<)(F)/$Q ".7&(H8Q#6A:]5"H1F@P.J&H."D#B)$HS0
M''&.0D)0CRSCG&<1Q@>/J_A\5 B:Y3Q#0R9S3A D%4-?!W.,O+@"K$(\)/RC
M CZ$HR2=(()6@%( 4H5[4*:N$:I2#6UT@+#7BI7+9XJH"$# Q=DI+&)**YAD
M"L\<X(#E[^&Z]]<+B+ZQTG5&(8*NTHT*8&%SCEQB0)@SF,D)>TH2S'/MGQ9(
M^D(]M<%"Q:1P+EF^TN%4"[C1\9P<KP1HI])V1<MCFL$L38*.,\"24Z_0#U,Q
MRRVV^Q*12S.69G'SLN,$(4DYS*P<A)9E[R\%;9JDSLG=J;$QR"Q(DWJ$D34S
M.99]^K6EC@BLL<.E+CG'VI<<V:E2F![)K!KKPA[C:MCR9M&0PSG(@,6)R%*Z
M<,(%9F4N2SEU2<V%+)43B\6%'(0+C/U;:+(VTV13CF,Q,*LA$<!ARB09(8E&
M6/"(!U0U(5K-@VI-!ARN8@6W/)JWC-I!E=IA:W9EW%JDR8J=D<8"N@.1<$AJ
M*.Z\D1-*L3I!*#DPLH2FK>?TZI=65.$%E6U^2FDBC8P:63F=@BXAS8-*9-BC
M%_-L2.!R,2ZNC+]*,#P@"-<6PG6C7'W3!!KC4B$9RS9A"+&>KXN5U8VRH+XK
MS#X%=FV58,#V;97[$]6,%N.%"9UTYVV2T>*Z96#F+*69%GF5-1KKV,*_7G.^
MI>;8MC*]7,=LXE]1;%MIVV X2L'4L*R=DK%-B:L0X!RCPU6$K\S1=UK.HMKY
M=L.1C7Y08')(F>[YY$E!MGFL.;U+.3DEESFEQ\1V"*98V4'R6L.6RM(H1M35
M1:0UGBGP[Z/BP+5',D1WL>YF(I.8N9SE+-AZ<,\96MA*TL3-/V%DRV])1-#K
MF:LVG&<\B->DF$75P%=94(0#&.&(^ +O]V.:;7?5SU<\W6658_VK26'4'D2@
M.$W:.MJDCS2 RJRPHV$ZC!@D62.78\Q6491RR/<=K!8.INN1><7M+ -R-NT&
M<V"1CWY6)) 897KI)A-..5[+I/\ 43FL1-'UR\]!3DDGV"F5-9]2^CJO;K^X
M< JQX@UB+\<8>C%C%G:(%M!RM3M-,(2M[$U,-MZ83.M*5!6)5ZC#; LLF( $
M<Y88<-CEFXSDCE6YEB*SP9 +)1DZ3,,2^4P-+3&<!ARQB8R"G&491Q\\<<9(
MS*UVH3H\,C(^GLMBDXS76URNX[3F*O.$<5_P=LIT8!<K%9FQ5.(L&FSFSK1<
M TE=1:T&H1AA2(E.0M\L: \1SE_&.BJG#'=8POF,/R.1/K^6^$$MT);8H7V'
MDH;#<]B$FS$B>[:KT\NY70;;9QEH1UQQE7,'=)5]EZE9=W(LN][GN:9X#6'V
M.NE842TDD;!+C+(UVIID(E8YB/IVR)"H68FT3&7GVH2LFCUVV9$;/)@LC.M%
M</PSGA (>L>?057@%10/(LH *XQBBTX<UC$%@[26ME5"9B.M?N-;;K7:6W+C
MHY= \I.GK SR@ZH!]5)=>R X,(\17M<9LBD1L[:YKE6;:P8KJZUO?4,6SZJ1
M6,BZ[6+:T@/K]8: ;!I:L@DL3H^#4ZX&A*SOP[*&47F.NC;)LJL5DZ\DIYPJ
MG4P010KZR$?3152@JN:I4<E 2K0L;C9VRU-KZP&U'?-U%DPW)\CQL.9H/24C
M*FB8R':82@NM7ED%&"I,#-"Q<(1Z)K2PU"R9Z;$,1Z^E6JUO4Q'B89\HBLJP
M@_'.928!(D(3#/."81J\CM&$4ZKT4H#VA\1L:\NOW6N."?[?H9EWR5ZV8_:]
MK@3HE#HX4P'IS52;MK>UBA?5]^D9R%$LP M7B'9)2)2T=3AQ,7+G.26$6[,V
M9SZ]B3X>6J K9W56S3V]U=*VM<= =A)K8F+)J[B?+%<RF0-B>U9*;@G T28$
M01ADCF<@7'J=I& *YFOQ30.&-*23+ &)6)UL+=P:Q%A>*ZYIMY"NO-B(EXS8
M.2?]I]O#S9SD%-IWP^W",2RV26.'#''WSB6?BS+^VS.,?/E7_P#3!>+TQA,Q
M0)5T DRS/S+%8 >]F[%9;GED$Q092PP3A'N)9CPQP#_;3;L<T\_N+IWM+/''
M#FV3'''Z<YQGF_D_@?SX\?E[?LYAS1YXXC+,>..;$9YEB,LQ^>,2S">(Y^6<
MPEP^SG^O%.<@PA".93&+*(Q"$..9D(0D\X@,<(8S*<Y9Q&,<9SG.,?P)C./G
M^28_G>#C_G\<>,OSN/\ %S[_ *OS?NX9Q]_'C_;3:"8X\Q*;5(R_#@,NQ\O#
M_"SQ_@>R,AJ"+J6FLZO(]OA+HB?MJMW85"A*S+EF8ZM<Q6P'B4?8&.$9<(\/
M#N!@;#V3QD)]VM-;K3! ,\F6Y_<RL\&CTCXQB),QGP^SXKF;&ACL1*B]UHHT
M"I3MQ8KB[AK!]@-&FS X&F/1$&P9-VI6QUI[1$$L*V;X66V-5-LE76T6FZ4K
M75U2HJ^G=!J]HV@S%(<]C5V;604]:]@"537N(3"A;2BEB&%59IR3L&K16KCM
M5J+"!:0K.ON:CZ38FK&%;:OT'H(V$6(4\\2L?,(F2,EMUF40EQ75GBW8U=7#
MEX)>.4E^I 1)8ZPL-R6F1.Q%AT*663(8+76(I.C!$E<_#,E#4(/I+LJ<+7?K
M)!RZK]8BI=5^L TJ\>BN_/;/+O74PB^E":RHKT&G+1Y3U])!L]GEE\H$-ASN
MBA[/RVH^VJZ'4,62UYO1AVT=D1VF:^L7PM?3P<-!%;K-Z\$*[[[";TF5Y3J-
MA9U\$6K]>CMCT:LHXG%FX%7L$K02AF4<2B9R(1YCF4<9Q+AS8^?C?[ZLL/-2
M_,[KOEK7HW5CI4::Y4,#9-VDZ%5//E;D)ZNM6LUVKF:^A[%:))6+!0#,?M()
M^6US>7&]Z^TGN.PJ[$[44T6+GTB*^[TVOV=C266@1<?&\0>O"#%C2ZW$_6A7
M#50HV!1BO3"I(R6F,,ZMZ8F;6MG**RH[)04KUNV$KY?6;*%TL\R=49;#=M-1
MUS*E678:0X&6,V=^76P#:V(5):DH%C=+ 6+J"!Y58"Y.4 >F5[ (3ZQPBY<Y
MZA1QXSQYGB18WJS1)HQ@Z[87NFV-%M0=NM$[U(U975=1JE!9N))<=?;'8J4;
M>%VFW9PN6A+D#5TZ%-A[%8L$T%?4]>#JK_+EMB<^YH 4.L"KYY+*>>6-%7]>
M/*U*!I'RR:^E)"^/N K[7 ^7+*R-[*M!JY@:>2WCZJBD6A0KCWP]B^ET731M
M7*E=45AU*\>M#&Z@:ZV-LWKN_P!5<@-J@ZVCUNKJ-@OZ?7+C6-B-J:=;<-2S
M65ZS"+=ULAF&'7&>Q$"JL1*7B5A<7>U;+7Z)"LO$[BB8L65-C<HRTL]<.NMK
M@&+..;Q-I=R-D.UM>1CN;5V:[BIIZFS7[ UJ-'<I7SC%V74VK(Y;5'-6O4:W
MA2T4$PNQ:2<M'%E/2O5+F%))>L(O*?$P&;4=DJ8"'E1AW5JS79.U.7=N?;1W
M,Y;'%>W937H0#,V,BMN!:G)70E;$>7:Z!_'F#9UT@O:A6I:XY69K5[E6P<MS
MA?KY:ZSG9W>E:;B>:M)5QE%U1@[#=346*:+@(9-J%#M5DRK6VR>R6>X7%)>7
M5"-CS'M[O7G4$5+^J8I[A6I<:MMI7I42F7B91.IK#<Y0K+FTJ[PUOCNO_M<[
M+.7$6_67?M*O:KG79V-'T^W+?-HN;+GN+6M'9&^JRT:,5J_IWY91V)<=CH^O
MR")HVT!JI.][:QN>Q$0WT>&XHA]&1N&K.#";!^7)1M.M];7_ *0&LK:K)Y5:
MVZ':.ZLFJF\<:*">%G(,==%+;J TK>JNS0<E:WP((VEJ$,XA64UEJSLB4VL_
M2M4>TVD+1ZD&G6SI[O%7)JVKV%#(IGVWZ-J,S(T!,PV.U?E)-@XB:)FWO;5&
MZ_:1M-DU>6+NV7>N_,!!36)5A# &]C.UW(2'5F&ELAV4K(EF\)E![#)QQPA&
M[<S9AWL2,->'<L]#'EQ+REA:&LF=8$WA'*.-\*8<-I;KN]]3[>B':]'MJW._
M+7BEW7$S6Z\Z"F=MJ:QK*%:-IM5?7C7#4W5D-*POJ=:LO+(?2P3N"D&<TE0U
M,V:NQ+VD43[#355FR\QA1=)*V:[#O9-3E@(,@9,MG'7^K-Q[7C AQE@I>ZZY
MJ;58OK?G!M#YRU-@V.X4\KMFK:98-2=39PCJX;"E88;@^QZU%7'28BHT,G0\
M1J8;32ZX%/S$\KE*RCF)U79]OHGK33;"ZM*VQ^D" S4G3NK*MMEQT-JI!/7[
M43K,,NR].OJFW!0)UU>+93_5V.O@LZ?Z/WP*GH/)@W:]NWXE">9K&PLM6TD-
M*PJ-4J[DK1?MU]DL+G3K'OET9>GZC$Y<4+<U8,M5UP^:YL>K92$RDP6NRA5F
MI9$FB:=KP'8$U7M[FKIJMRR>6MS726&$"Y%5E<JAS,2[IX*RS9!'!?,9RR9R
M8!YY8QE@NSVZMA7V%*S6^2=2T')<G,,>V[+MU#7SJ3C+E9<<6K5.[9R01XNJ
M0S$>1\\31>3.E50JHL[:+&!M58+6FGK=V*@35>4CL3EK8XLNA;V)69Z_5+I1
M*B#ZW!,&D5Y E8%V=C0U:S%QU?3%BWM_64F&FX!.J4PU?4.XPM!I634QQ7[I
M?J]:%/72V/R\!L+0-N>;O,"L&]/(#4'TU6ZZ$/74F*NSD*S6(_@]M99I\UUS
MGM+,:^9!2ML5M<E2$0\I2-U$H..7N'?-)L"/+BRZR2:J^OEL43$ZE0T6R$N]
M'/IF9AG#=*BZL];[:DV+-/2(IH,H6S:\]:UK:8G.1J]>@UE%38.R;RJ@&+!5
M\OXPB*?8Q9W28]6ABP?]%U99;U]B![+&Q-:R)BV[55UL0;-R*K"2*RN<JKS_
M "^T@,TV4=<!15.NK['9GW0=C"\?LP4\(Z!LL-6N!HR50)8Y9LW"P<KQL+X[
M)"#66\',O@9JD=(#47Z)S7J"Z?/B^=*2$;)]T+QZ*P0J'$+M8"@(S2R7TV+I
M<#XF4"QDH/!K*C6Q;7L-AOM=45L+8=CUWJW<;.C?<@P(-62S3032>V!6M6 D
MXW3)P2!D!<X8@E:EBJ-F9;!)X27JO; LJBR<I[)<>+RIH[6&5WT6 $&Y5JD&
M4<X8ZPXP8+?)3A4NZNI::"C*33<T;:J+M^94V((P#6D6LUY6TJL\ NMB<Q)V
MSQ!J0H5R4'^[UJ%?KLI7>*FRPPU%P1*.]G190N$W4U.+ECT3V8254G$T1"*@
MT>9,)N6-7MSVK5*;>REUP6MU$+NZL>/T@"&0B7)JO4G'ULXD24@K5E1:DE#(
M(N31S)J:=!FLH!!M+G4-OLLZG>V+%2AW>I[9JE7%H5B?6?7!>L5E^RU6>HU=
M;GHYKL6M4@Q)C"E3BMKIF8V2'E_::TFP7 &K37=T+SOV'3A$_(UK-4C?VUHI
M')("5K02FQ##PI>+[83!FP&AIK2Y*N+V*<56B=Z81YX2X$+$&80SRY^+./;/
MBWN;;4"UN:2UJUVX9)M %VJ=UH"SCU-G8]'UFWN+6OYF)#HTZ+,;8D45*JU9
M<LA@%Y?O:]K-2TQO"]BWBKM]A/6Q43"EBQ38E;)TMMRFRIPRTA*HF09S]ODX
MI*$R9?6$=8LKD(V:%6ZL$@7)9U?TB,0*C8XK4#=,5!#A!J[+8[#3,(U_6;75
M>Z41&N[B\U<]?KE6[Y@)*6J-JI:'L"^7K=\)Z$ZR8:XZ9;)/7+9M#&2,+Q(H
M15MI?)43.[,'8=;1785I_+TFO:_565K?29L-MM]R0-*PL*S4IV*^88I!1;61
MI+H:<*XS"AW>\Q"%8DAI%\?9WU=F8)3.Q-KJ8,:IFG$^<-EM2-&Z_6V#>P4Z
M]'8+4F<.=W*;P:O*5B-34-A=B&#E]J]!<MQ7C*"\6;2J4=/$$)RG. <%/+ X
MRG.48<,2E+/OXLT"1"'3Z[7J8R\ NI2*T]9%N\'=<6+22>Q]8E!)9=6Z (&$
MI.&BWZAVZ5M8GU2S4JT;?&M5S[#]1*-WL<]R+HXTUEE&VFTT"6_9YQ9V %LX
M <Y))X@M";(*TFF.V%O&^;URU1I;FM/!.RPOKC]5E-JUQ20L$[.NVFK;FP6%
M?*M_*(-A^HE+Q3;$C$@UKFN5L!@-T^NME@<9$39Z4R"PTF7G69B,DX1.(D8S
MEC'']A+39U4R +S+,V,;&@Z8GF3Z5%"3$Y7@Y4X8!V=G!4[Q5*UMFL4X-;5M
M96JL3QTK%:?ERVQ49L8N4)%/6!9D3 N\A>=O G; 8Y]?SC.XQ+#)I:]"N'EV
M;6H K&@CC73,I839IB *_76-TI<+P:5N65;6$ *59@8U^5JPB9BQ4OQU+5><
M OX'L<<<>;%5K4I>WM\9M@Y??^3/'^!XY?;&,<N,8C#'P_='VCCAC&??'#A[
M_/CXX8YOY92EG^>6<Y_D^7]8F4I(C&.$B$(2480'"&.:<YSEPC&$8XSF4LYQ
MC&,<<^)7,[!*%1!'-G.UDV"-;&MB#NI6$GLD[7",5ORC+>2]# /K>?I_%X[A
MME=5?G"/KL&& /49,-=8?5)*,.=A@H@!CQYBF*,4,2G..,_Z BM>#"P"O6EF
M0>)D)S/75FW<69^)IDEC+5D^VSF&,X&/)LC# 8HP''_0<)QQ/&,PGPEC$L<P
MY8G"7#/YT)QC.&?G&4<2Q[X_T0\-+@9P$PF0X.$9L"87G$H&!]2,N0P2QB01
M8\)C)&,X9Q+&,_LY$8<"CE]H9(1G"7#.,XYHSQF.??AGWQ\\>/;]@IH@#$IL
M<#%P(>"%QCVX$GB/-/'#'REG/B(QQB,<(XC"$(XA"$<>V(QC'&,1QC'MC&,<
M,>#!.,11]Q3SY3 69A&<+9>4"8"V%A?GAGWC*0I<LL8E'A*,<X<D+MX=;5J8
M95(04&66*JZM)UK!1C7B;I*]<PZ^76Z*_P!;A<(B<T\D?$@L%\\(C8L !@&Q
M9A'H\L6;$48O'Q^3BQ*)6)1)B.,%Q/$8\ITW%P-J-"F!E5D0SKL +',"!. L
M9B*(D<YC,9(RA*.<XEC./"]%8:W0/4BDX$5IW*>N9JEB"P3 R+UYEIJ!F/!2
MXA(8HYAU"<N<<\N.>LN W$BQL]4(R<3)F@PF7/-'/UBC QG6G]H!H0*+,9QQ
MGP2WA6H1MBABN6SBFOBQ(O'[(".X'W,PQX8Y1R)F&.'MCPW2L:]1GIGS=R]4
MFJ:\M8XQW V^NTA-?*K!NZ$-GJF%.?<#@;CU(1EA.D/J.L'IJ\F2U]0:@JB5
MB)92S.14T)J956)*<I2E,(H2S*6<\>.?%.P_0U;)]?Y/1"D3#S5>!D5- :7"
M..@*)4DYX##@+F6#\'U<>$QEC$@R1E @R1C.$X3QRSA.$L9C*,HYSB4<XSC.
M,\,^#TF=3UK-*T<;351FAJLU;+0NG@3)T.T[4QQX"+ S$%(D.D/EECDCP7K:
ME!*KKE(]-5"N5 DDM#,LSS!=5: @!AF<I3Y1PCCFE+/SSGP:9ZU$I&6JQQ@D
MU09(PW2L!<J&3DY.<QJQI8!T2$S*2I CD',,QQXL[ZNUJC1NKF)86UJK5I@?
ML(,$@=J+3,!8*6+9X08;Q*7!MB$#L=0L(SP_K:^HZTKK]K/J6-*I25JE8Z;Z
MG@PPDLN(!&8=LMD;,H=<<EUYC)&019BJK#5*=5=*OS4KB06].C&JE90N#5DN
MPDOUJYNSAWKR1NHL^8A\NC/AEC!4=L-8LDC54%A15%)VU="OK?5F:H]C8 ,-
M2-C)IB%,DKR&;(L!?!(K@%DQ<SS&6.:,L9QF.<8SC.,^V<9Q\LXSCVSC/CMT
M=7I0 Q<)["(&$0S"I=5PQ"K[! 1<3A7&1@+'9]C%>"TIGF&$)LL2*O2&IUX5
MB;S-FHLH1A#M7GI/Y>86.B99@$W<6ED)SI%C%I>P<6/$B[)ASK+3LND]3BB!
M(RK3B>.W'#(PKN"48""S66C*>5%[(;84YE,5: B&+*0)9IJ^65B7I@8FN.<1
MEV<YFM@GB$\9AQN#L'(_QCGKY,7$OA)+&;&L3U#74$K?"F+(-;4IUN6_3C=Q
M62(9$2Y^I5'X'J2Q)$M4: R5\EIC'F(J:=&'"08V489$W8 ?S&Z9$Y=8-; ;
M';,8N60 -;]=TGJ9 BR]U^G'@C55P(*5]8FM7H*BX]-9-(,%E5Q\V92Y @'
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MORYO?PY9B5".PL )K/.1ACKLKUV6LHA+/YR&KEYS(8_*&639Q]O/\$VC[/\
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MIX>K;!9Q:NJFXY:M++8#W[5JLY<VES;4RC##+AFM=!:.UC%BZ2QYAG%CJU<
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M1MOUI6Y92B2D3-W=W9N03,TOW-C$UB9FD>K0, UQ%NM";M7)E7L$"!9S;'N
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M:K<2Q"TN9+,WC-;A1$PV&=@=(+8]JEAW9]<>U>V< ]L%A:J'-6O55+C.))V
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M6V#T5K&K(\^NQ, ,.@3$2>.TV>=94 CJ6M5\7::%2EN=J_BXMJYW:95FX/\
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MQ^UC'W>-6K36#=L6N827+9V,H3>?RM3NAFXY,<(1(TT2$CGEB..8A)9_K/\
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M_LSU?_RPG_\ '?' >XZQG/\ NPGG^CK8\?[,=8_\L)?_ !_Q_LRUC_RPE_\
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M/:[4C^C(&Y?T].'^+QP]=1_WXSCQ_A3X8_D^?CA+8:O&?_"9_P OC_9%5?\
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ME\7[T?@3Y^WPY\<); EG/Z!MXQ_\ )_RO$8"O%23E*,<1C!S.<YE+$(_)/\
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MRO[^6:? C Y<W^1U(#C^0UEZU@S>S&,H;R.W=.JNOZ8^/%+@5/Z>N"#U@0I
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MKN%LV C\4J&U?8E.'+_EF.]U/,&^6*.4)8K4+R^K0Q_?"9*-5%!E48.*/&?
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M0!0O0.MS4404Z/(4W.]3:Q;:&-B0&A<8.<HR5U:X(P6+^4]8_9(4L:T:F_\
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M3+-A$L ,Z=_*M\ U6=CZE5][CD64ID^UM/1\,2#&G =T3^O#K=B^,\CZA7!
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M<%<R! 3IZ5MDAK#'DVE$FP2:0^V"$CP@5I$ F28 QTPOB8Q0LSJ8L6.WB 4
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M#:(!4';Q;Y1=GWDI47!<5U&  "95OZ&,]P<[+ .D-12(9V.87-&5(N"!ZJ
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M4AI-XG$L8=>1+HHY(H5J8R/8P@HP&4L#T6J1@HB=!112D5.<6EOM$!(DPMS
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MB$.Q839?;D+X2&PKLO6BKHD,)58%\^4R:JD"UK0 28E"NY:*<\R0?N7D:A*
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MC"\:KN!JBR!M!3IB]H'3>BZ+>F+'./E"*]#ZJ58$%-5""L$HT:"U<FM.0+T
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M'>X7UFC$A4Q_&-M-F<#%8ZTE6<T*3H>JP%V#TB[41N\&*:&X&%UX$M$0'O\
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M$^(91?841OKAK:U-\^7HXEX%G>2G\\,)I&&;GBO=S5D58N4[1PQ]QTE"N/\
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M +*F9!)_W7D+<=5G%4X4:E*GLY-N X2L;JKNS0CMU6[&SX-!_2?( <)T9/\
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M5NQW4PLOZ.*"A3,9)4M$#\:Z19UXR2/W5# &=;T68W\$B0!0BB[K#!PF_?U
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M@R"!A+7EH- "#-$-[PZ[ZHS"[0 9QO 'P!1AM$%7=(HC\H[6T@&!.ZPJ=5.
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M0O73/S66[?.,-MH"4<'-_+3PVH*8A [1M Z76R@RKDS.](&WE+[NI!*+-)Z
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M+^4^%%/$!]?&.LB:@G):0XE =:(18RI(\JCBY^A\5\+<_7_X41!G$,P1''6
M^,@5%^KKMF9"[- 0+=@N5S4LK&X"/K(6#!(Q7H&S>[;G%NMXMBJDM:Z?D_)7
M\CC?!EF^8SFP-GB_O:C>8JJ[U779EO\ >=6=E TK=J\E?+-*Q530V@:%V&Q#
M10-@6. E%>Q*+Y=5DMT6YF;*""]#JP7 0HEN3JM;I&U/ (T@+P5IR2YS16N\
M,URPI)^UHELS:2X((!S;%?1W@Q):=&Y&UT$VIV[_ -,4]"4!HWUM(8L=CX]S
ML?'N#<M3CK"8<1QJ6AR.I9/+1].N*%W<XW>8EM]_'^&/PA-KD_X6*-P %)NG
M4Y:-#,<4HE'17A0R\N8LMT<(P '6V :B R++$5'2<"D:D8)#U%+9<*CI25;@
M3D9?1^?>*10] $5B2$/)&^0($ZX]R;'D)9'3&R]44BCAL[_TQQ\;B7UFB21E
MNIQ2<8FV#+H@=6IVAL!Z6J8$%%SL-/9LK_ :%ML_W32:2?;3SJAH*,%#0D[;
MQPI4.;KL8UG]!5F'/]\30Q'L'Y7''-Q*/'%IEU# P7)Q2!V8-9;SIKLN?)63
M2KCL0!11,X)O+Z/S[SL?Q7\SL?'N#<6H-\.Q\>YV/CW.Q\>YV/CW.Q\>YV/C
MW!O]AO:%[\$=N7!%_'TC-)P.VUAE%.)K93T^D9:4GK8M<*R/TLF)[]);8[H^
M#0>W'0GNE5IQ$V,JU=.V XJDX8/7LZN>TNJ][8Q8)W '(<[!BP_JA2<)BP#P
M5O7E^B+84>0&9*:8\#4RIJK59<#2UT");4-Z[O\ R,>D$LA[G4"STG-F\!OA
MXV4)4V:F^V6T#B YPE7N-:KQV?$?=\.P10FV,"IX;+]8SBEZKPE\254)"6'-
M-A8F4%G8'>]2@0FRGKVS!J5\^-Z15R?+1L-PNSO_ $Q34?3]=3Y3S]7OI0.6
MK3FS,(CN.N#WGJ7\2;QK&PNT,8;KN#^Z6(30?#D@F<:-BO,!FX 4"4@:%"8>
M;<\Y3#?FR#[>+<;V)6DGI455@!6J1EWQ(MC%"CB,:^)*4YDCQ\3@E9BRRG"M
M$5M^8:MP)'Z@-LZH!N^@LL4J])%]5V5W^[6AJE:",,(76*"P/F&OKT%QLYF,
MPGCKPD5+]I]S@+K#BW1>W9.0FXR1/A_M9!7"(N[UA/TG@//(1;+.[)?" I2Z
M-!:7!^/X]?EMPZNF9Y51GVM"HJE"0''<(SIB!0GA^FU$,/!FPP:'+[;I@B&T
MB#;TK_ ^KTQ&QH=Y>5U8*,?1DQ,0?7C$-G00E\3): ,R-S^V75CV=:4>?XUR
M'_I/C%T=DK?J+)I9EA4)-Y!FQC3@^U<+3ZM<A:8G,?F91G?6-"938L(',9=.
MM>_/7)*IYV,KPG_'+!-!G'=_UYS9[(SHO"<W P F(-JJUT .O(K'810F<H27
MU-KY(TQKJE&C+12*TF:"N6$('%'%,.1KIPSBI7*(P2&T&),5T]D<;(V3OTI"
M]8R!0U*V8%WGRBKJ(1@N%!6Y@%,\Q%W"A4KBM&B *[F*"0MMD^]LY^SH475:
M'VNH9NR[58?-S29(*$6J&H&2.Q"H9LY'/V75>Y:F#]B*!4,5-+#HG[)]NA!D
M*%:)F2NGLVHDT+29B#?NM!ZA]'84/^6B-,L'WBH'"M.<(X$.PHHC,XZ$.JT5
M@.!K&Q.LSA8 Q3ZKOL,M*#E2"E*36(9FZ72@"JY;PS1SSEEZ1'HM>?:<-'^6
M^":^G2N1+H$J>1!02ZKKV=BS2E8J$TH0UA11UI&2W!! :%A:FM=4.T%N"P,R
M+=>\FB$*R+.(8F#Y//3"#S*D5FA<5S"C4U0Q_GN3@1W":&7*Y*)?KA76(:#C
M*4<FLT)3$1R9EZ!T/E-N/< FTD SEY6AMUFN:SEY;43J%,A +..*"2CAP<06
M9G3TX&_U CJD-V-.K1/J"V:UFPN*IVXTV=Q*ZGVKSG%$3C-FX1FY.;8#M1S)
MBZZZRJ6,\J!(6#<:0@G:F]B#YNF%&G-OJ>XQ,%1FNX,"T.JL]REKK':YHM95
M5)KI=.NMU6]0Q0SK7P&D!*6ZC9IT.5"V8$J.LO"4)5?6P8869-+JZ--6<#0S
M3*J-YI"U;2C>Q?C\((AJ%G0^R[ Z$@SBZ"U4#FV7B7"@<TFM=<D>32S"E!H7
M96M@17>JT&(M5^0_FF=1J.:+L5K['53<F0:+M&%8NQ:PK'-;YAFB7/Z+<B N
MQ;K?;&7H32P+!I1GHA\0;^M57):^345TJ8+2BO\ 3T??%@X@S(,0;:(V05,>
M]RXYT/L5N.S'7J692ZQN$*Y/ >^W,X;"R#&=)(D9-_GZLF'4O,! Z$>#VCBU
MGEP7FKF43_\ 1$,(I=AG))_CO#M(WM<Y +/&0!.1"3FDMZ7I6GXUJO\ Z;):
MUB#%*NN>5@T\RS6:]9\M.NZMS=JV+;&;P?VZ8/:*P1.3&^5NVTNA;OQ3U@&"
MCEC'3_5O6<CJ#=NW'VC;(+J.S>FP55AG.HRB@Z#\.OW@%S%N'!,]"DI334FC
M:(Y.-K7EI'G W831 *H#RV\ENI535(9X!@*P9X #1,@)V#76!LFJBF9UO%5%
MM*=6<LSFRQA21%-]KG2<#WA6+^^@@2-<ITW<^9'6)_!+[%>5N: \=-2X#@R/
MP@>RP-!L*/QQE1)5L:DF:!N '4?U^+0!K-$0T((T?)C3DN*\48A9$E=&,58B
M-E'9]A<N#-Y;U^%(2)]9!Z\K0)_Y7\#FKS$/0F*5$:)XA34F*3K(/!7[''!4
M(A45QOZH,6DQQYE!(V?N(TB"DL)1V&]<UHK]PD>!4''W&#\QUS!3'NBJC8,;
MR*$RMU]F;N@&#54%N7@G_!#7I@)6]E(C>;B#^DFW75??!Z&3Y^[2:=,]O]M.
M.L2 FZE%L8<X1=*2Z/BXH6I\"HUODG,BI<2PA_$T]1EB 6 %8&& PH*:7'Z0
M*HW&PJ'QF*AZ8IE$P^0"NJ,3JU1UK3B4 @# @;]$-2Z$PJ6QJ4SJ=H<:>QC=
MD%E:[[J%;..IK1B=*_L@:"S"V"OC@'FV1LL),*XPE&?X!Q.2@0$8@*D&+X4-
M+MSJ>X7 RX%J;*#D 8#;I!JK_C)MG"FA4W!HLS\O>X#LW4 ,1NS^RQPBQ20M
M0\R'*703M9Q6\^ V4 $M]0 LEV.TT'H6.>V%QBK56T'0_D-C,!TD^$&OF0&%
MG_@T/6H-\&]I7POJ%[_1Z#8>!_MGE$OZL0/O6?<KX7U*!=NH/$2/A*M@0E.G
M&,#%ZB.R*^%]2OA?4)C*&5P1!W:J*MHM@(BE$4T6[1P*OA?7"P8ORQ 6?RPS
MBYJ5Z1_.L.>OM=?AN8HEH^)#4V=K6(Z=8(ZQ4:QC1+F\ RI%!; ;"8"M%YJ.
MC8CT"S K)%[9S5N3[T7 =H^UI$6>@#+=4Z]*F=F"[?:[%YG.-U$J5B4_1AH0
MK*(Z@*]-5/L:09\B:"X D@,5'EZHU(&@%):E9S!>J-2.*+1%ZG;J%'"B"A0
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M'EPOF+.'FKU#B!HA*WA3')L6FH@NB5.CDBXD5!-(=)EHQB0R+$ Z-W7@I"K
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M^%]0Z_\ X6M0;_\ SD__V@ , P$  @ #    $
M
M                            '(%/#!%/-(,.$/.'  $.!(+$+,.$+%""
M("'&,%'/,%- /  *      *,',,,'"##,*&%"-"(!&.&/.,"!(/" .#. #
M $ $    %              (                  (             %
M  %(
M      !#"""!" ##"! !##"$""!")/ ,#)&-*-,'+'$(')
M .'*+)"!%/"&.'%%+-   %( (,     %  '$!*       *         -/,&'
M,&%(#*)&), %&)*/'+%$ /$,!%.(&''.,      "        $--(($$,,
M.-(##!  $   !#####"!"#!"#"""     (         ##-$.&-/#/&"!"-,,
M ,+,(&%*- &, &.*!!. "-"    *        !/("       " % , ( & *-.
M          $, $$,     "         /,(&/-..!*(        ('%(,',*#)
M%"//          !"         (/).!*!"           &,!'*/#+(
M        $(         '#/+, *(          *"            ,
M  !(                           !*   !###############"   %*
M       /'+*!"($-$($." .*,$.*-) '$, #,!( ,$ $ $(    (
M!! &""!#" *""#"    %""         (            !         !$$+'+
M&&*%'+,  ,   ( ( (+.,,( $,$$( ( ,$*             $(%*&*!)!+ $
M,       #(                      !(        $' -#+',
M (+/.-/!"*!"-.)/+/)#"*"                             )  (%')
M...$.  $   "        %*                           *-)*)$"((+$
M+*-!+-"'+ "              (,  "#/',!((+&,!$&'*!")&($
M         (         '#&%&!!#""# //)##%")-(.'*-$+.'!)(! ") "(
M  %          - +) ,+,-,+! !/-'&*/,' %/(#.- ,&').*,-(*   $*
M        )"/&!*$*$+((!,#")%#*##&&!-(% -*/,$        %
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M($      $*         " &%!$+!/&*--!% (!(((!#!!!#  "#),""#"""
M  !          $,,",("!"* ))/%-/-!'%$-*#"(.!(',%$$($( (    *
M       #/& #%+)#.&.$+#-, )"'$,(+"! ! ! #!##""     $*
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M$)            $*  /      %-(-  -!'"    #  %(
M        $(         )-+-#*%,#.)++/ !'"+/-&,/+(#"#.$+,,-&
M   *         +&++%*/&)&." "%," /*#-*&(                  %(
M       "!   !  " #""#  #%      (                  !
M &$.,-%*)!&)#* (%&  )&)"//+()(--( %         $(             !
M (   / .*)+('*/"%.)&+-                !          ##"  "#"#!#
M#"  "#%" % ""      !!           %(         (&(.($*#!#/&"!/'#
M#.& &$,,"%#'/+#./*        %(         (( $ ( ($(,,$ $  !
M                    $*         .!,/ (           !"
M              %(         '%%$%,*!*#'! """!,("!" "- &""/"#"!
M         "         -')$/%+ ( )(#!'& !&,*)./'-.+*#.#*" ."-$*
M  $*         %* ,+!"#&)/ ((*-(%( /#.+#!")  "            %"
M       *!!+*%#(#(+"'/.%(',"'$ -"+)'!+//.! %+(.(    (
M    $(         !)$--$ $,$$(,("    ,"  '      (        %!""#!
M !&*,!###,#!. "    !#" "    $+& '%    $"         .. -)(,( $$
M $$(($ *( (, $,  ( +!% *)!%$*    *        !,*,($*
M "          $+))-" $      %*                           *
M       (($          $"                          %*   "
M              $*      # ""!#######!###"   !#
M   "     (      ($$ ,$ ((  ,$$,,$ ,$!$,, *$              (
M   "                          %                          (
M  #" +# !!" !#!" " !"!!!'#!"#""#!!!! #"""! ####"!##"#   $,$(
M(,(,(($  $(    ,,,(,,,,,,,,,,,,(,,,,,,,,,,,,,,(
M   #                                       /_\0 %!$!
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MS^W"&W"7)B8)*E1%_!%R<>-? &MKQ:T)!<5/*(@]HPRJO=;;0<$8&7 Q.4F
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MCBD]I4T%!Z4[O(S*.RN=3.AL:OBALMH=7GV8#H= /FJ%#7Z%%',^3*3K^!
M*+6:GI?*>LTBI1;$&BR0-#Q;1=W$^M$0<YGK6T=%V(@,M2.9 OQP#@7GJ^M\
ME;419@#=*#TP#?/OSGZ@M:.<"$C$&TA[JO@9J17@IFO/3OA'X7PJW)>_+,Q$
M)7#?G/)%<[<J%^UR"[&2QEZ_>;F2!0>$[[PMC(R.H8CP.:-NLHH/O(T_YP/C
MNXK(4;@%J"W](K&P]_BVA'R 8J,I1+KE5N '(.+2KLX0=@%V$ )5$)>/X[F7
M*KQ(K/Y9M[B\=<"/B".",-VFW!TQ-A@N(BQ78&7?O[_'S-'9$#XJ]5^*D>[A
MECND#!KTN"I'@PA(3NX :T8+()ZJV,%5RR8D@M:=#//D34^;#)%6I"_;W$0'
MU1MT1EQXA,8E"^F#4""/X5?T&J:#48$@2X ;/+D6#C#<<^G+>+U, ZR[+:=E
M+H <;'&)\=Z#:[D;-J("F%L%=YY/6)'R:@MZ-S%MUL?VU>(!7(G1?@N<CGT]
M+\9@_H:T7A<!)N@[)!CVLB#$85;JR1B,]'ZSFR1+ZP!M&DJ(Q!ZTB>>IKY$
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M11'N8T6(F JK 30VJFI4'*%#L!"%H!9LF1<2*!H!N\OU=:S$$IP6MA" 1X.
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MH"2NM642N+16N'K]U/*694:M.M A,.+C.(4]L3#HQ0C@2Z'<3B8 CA]]PY$
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M8^9,3'TGU=\2^LF!Z&V\ELOG+0G&"8Z#Y5[K7 G)@1+4(&T1'5ZOZ(R->^Y
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MW\2\KP,'"H\RS@I&=_<,.>C17P,F+5AE10;0':DR]W><%$@T6!-F%X((U4F
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M$RNTH"T.0+VV$<.)98%ET+R^\GC2N$#4TI<.-:K1YJU>I+ #1 )"7JG>0*+
M&H*%4$)4O:;R3  (*UNYZ#P'K@5534U.M^Q]_;%45U-SK7H/6,C>O-ZGSDAX
M_P"Q-VK^@8F+Q87)?X\Y-X'! <S,@!19!KZ3",MX76=:?III"_ *O/J1&P_"
M,&O^+BIL1US5FY1'G3CRQX4>!A][SB9UM^5L!R;=Z?XD!4IW2ED'2@4_A*(
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M"CW&1B9J.@C#'@!MCM1:CYS9&S D>=C$[M"[O'5N!/*[M6_]&L)(3-&S%_\
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M+KU^H;!Q;L)@2 .]7[3^;'5%I'6<#:M1)"IV07S:?9=%PLC C C C C C C
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M0:'/A:)ZW<3C"4-,]S0XYC;PA[&SD7<@X?=DVS^E*IO@U[RL@=KR+0XAWO\
MO?DQ&C"G>@A>,YM9 G;/=KCP93)>-S)#RR@\W>9,'.0H%5HOT32?;YC\#=Z5
M)Z5\]!"T95;',L")<X]',AI7QG^I*>(^I'?B4,&7?CC8*O3+-AX?](),]\4,
M) )M-*GP1&M"V7;Y'92!(D1.=K+4'A[3SB)966T=%SE,9LXJ_KIW(@*T ZHH
M!5&VVPH:NL%GJ\.PLI6;YN9!$\7*T5O$;4JJ8! F>U_=9^[D0"X"+V*D=@J
MJ0C:ELHLO2]H]![HX2@&D"!T!H(!T%5@3'2"MP5*A=K5JFN@@D"",T-1E"[*
M )7 %@R7'#*$$0)"3V+\[6/NG1X83PXD,ZG VDT+O)=L+== H3"&WM'8UQ.A
MR@GNT5@P"L U@"F;S +2I 3+0N  ,WZ&NS4ZD =EM=J:R4D2118Q^4BE6OLA
ML9W-?KB15U--"QL0D^ '^0)%&*&+_)&4ZW,B! >]KL046DA(.OIBY&4VP=T
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M;T0\9 W9="0]8S!4&$VZ";0*#%<LK!A6OJU<G)M$C+5K>J<H'J*@MRY5P *
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M5[B?G:AUR*<;-@2\&<K^BJBOH1@ ##"$4_:FL/'4C3L5HBO!#9R(K\RD]/\
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MTFY[,G%7BG+3*^NI=]U%WW#]4PO"TY[8\GOQDO;%=:,$Q[%)<8TTH[)+H7H
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M<2[!5DD4ZZR9P:C.O7.@HO[\=$B&-AH0G/MH1&;>W(#[PN\'0>H138&4Z'R
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MEC8RNGIL(J@(TMXRS$L6T_B2]']'_6*- *EM&"DBM]4/P@ *D;J>D\C[P:X
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M^6<>';5@3P4@OCJYB+Z7_#3)9:-JO.)L:8T!45JG\D4L(+B56=<_<AQF1AS
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M_+'W<>0<V&^]><:;0!T6Q]/VX$9@#60J\@DE8S?1X%T9J?DB]_&I*7/]TX2
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MA-?@84-85B(15H'A$4:]FFT !G-K5E6A8-@DDH,E60%6E=AL'H"J,5U-6_\
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M&     ,^0P?(8"CN)@0C-MF<PJ*)$7[9FD5?/N+;D]),M#[2X(:;ZA<>9W7
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M"6*6*>5T&A:2,OE5J#RJ@B7<%@((E2B@(0%%I!2@XR+.. UF5MF?9O\ F/\
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M4T&IXOL?>1@1@1@1@!4@U@E;:'REO6L1[!6[?T&  5(W4])Y'W@!!6MW/0>
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M$&"^#Q;99Y8H'+8[M0)=<1^7]Q9BKX;P3\8ZY08(I"7&% 9'JH!N$=\#PPC
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M@@'!329QGK':9<\!-$@7\OY5"6Z B3,GW$! *NB>X,3]AT)C[!ZB.DUNT8$
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M>O#9B!5Z(@20$JP5%YP""M;N>@\!ZR3 EP#U\"/C",#&%"' C C C C C C
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M42[$4"81$5 $7-*WD_1G('D1H 0IW$&LP^*M&0W!0^R((>"$N/(>MDN1$?9
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M QY?#^4R&/+(2F"4/8C I$@3_P!S]C9ZWX%K+9JJ&T(9?G &#S6@:9'%X_\
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M>1@C,1H:K_R1FP;09I4^.J;L^/\ #:8XV?QI1./5/1FQ)05?X-"P0<USX5'
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MT!]%U*N$JF :6F_H:@Q2-VFY2 B*[)EHDRG"1W2H9$><@>=*[49%OT,\W\2
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M"]:NRLUGP&#X#!\!@38"1:";I[7V_P 8BP$@U%W7TGH_G/@,'P&#X#!\!@^
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IMG1K_P#PL *+6:GI?*>L *"1FYZ'POO_ /5=#X?^DSH_+_T'_P"._]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exh101_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X1AK17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$Q+C @5VEN9&]W
M<P R,#$V.C U.C T(#$T.C(S.C(P   #H $  P    $  0  H ( !     $
M  -2H , !     $   1,          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  %RT         2     $   !(     ?_8_^  $$I&248  0$! 2P!+
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M<G.RP10CD:&BL<(5)$)24V*!L]'28Y*3HR4T0X/AXO#_Q  4 0$
M            _\0 %!$!                     /_:  P# 0 "$0,1 #\
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MH-N=:0?_V0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        _^$0B6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XR+6,P,#$@-C,N,3,Y
M-#,Y+" R,#$P+S$P+S$R+3 X.C0U.C,P(" @(" @(" B/B \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(@>&UP.D-R96%T941A=&4]
M(C(P,38M,#4M,#-4,34Z,#4Z,S<M,#4Z,# B('AM<#I#<F5A=&]R5&]O;#TB
M0V%N;VX@:5(M0416($,W,C8P("!01$8B('AM<#I-;V1I9GE$871E/2(R,#$V
M+3 U+3 T5#$T.C(S.C(P+3 T.C P(B!X;7 Z365T861A=&%$871E/2(R,#$V
M+3 U+3 T5#$T.C(S.C(P+3 T.C P(B!P9&8Z4')O9'5C97(](D%D;V)E(%!3
M3" Q+C)E(&9O<B!#86YO;B(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-
M33I$;V-U;65N=$E$/2)X;7 N9&ED.C=#0S$X-C,T,C4Q,D4V,3%!,# Y0S(Q
M,30U.$-",D0X(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C=$0S$X-C,T
M,C4Q,D4V,3%!,# Y0S(Q,30U.$-",D0X(B!X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240](G5U:60Z.3@P-#(Y-3<M,# P,"UF-#@Q+3,Y8S8M,C@Q.3 P,# P
M,# P(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W Z24-#4')O
M9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B/B \>&UP34TZ2&ES=&]R>3X@/')D
M9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T179T
M.G!A<F%M971E<G,](F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W B+SX@/')D9CIL:2!S=$5V=#IA8W1I
M;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C=#0S$X-C,T
M,C4Q,D4V,3%!,# Y0S(Q,30U.$-",D0X(B!S=$5V=#IW:&5N/2(R,#$V+3 U
M+3 T5#$T.C(S.C(P+3 T.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B
M92!0:&]T;W-H;W @16QE;65N=',@,3$N,"!7:6YD;W=S(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T
M179T.G!A<F%M971E<G,](F9R;VT@87!P;&EC871I;VXO<&1F('1O(&EM86=E
M+VIP96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV960B('-T179T
M.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O:G!E9R(O/B \<F1F.FQI('-T179T
M.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-T1#
M,3@V,S0R-3$R138Q,4$P,#E#,C$Q-#4X0T(R1#@B('-T179T.G=H96X](C(P
M,38M,#4M,#14,30Z,C,Z,C M,#0Z,# B('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!%;&5M96YT<R Q,2XP(%=I;F1O=W,B('-T179T
M.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B \+WAM<$U-.DAI<W1O<GD^(#QX
M;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C=#
M0S$X-C,T,C4Q,D4V,3%!,# Y0S(Q,30U.$-",D0X(B!S=%)E9CID;V-U;65N
M=$E$/2)X;7 N9&ED.C=#0S$X-C,T,C4Q,D4V,3%!,# Y0S(Q,30U.$-",D0X
M(B!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](G5U:60Z.3@P-#(Y-3<M,# P
M,"UF-#@Q+3,Y8S8M,C@Q.3 P,# P,# P(B\^(#PO<F1F.D1E<V-R:7!T:6]N
M/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(#P_>'!A8VME="!E;F0](G<B/S[_[1_P4&AO=&]S:&]P(#,N,  X0DE-
M! 0       \< 5H  QLE1QP"   "48  .$))300E       0VG9O$O5W%CTV
M!>%PNS@"N#A"24T$.@      DP   !     !       +<')I;G1/=71P=70
M   %     $-L<E-E;G5M     $-L<E,     4D="0P    !);G1E96YU;0
M  !);G1E     $-L<FT     37!";&)O;VP!    #W!R:6YT4VEX=&5E;D)I
M=&)O;VP     "W!R:6YT97).86UE5$585     $    X0DE-!#L      ;(
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !(     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M          !38VP@56YT1B-0<F- 60       #A"24T#[0      $ $L
M 0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300        "   X0DE-! (       (  #A"24T$,
M 0$ .$))300M       &  $    ".$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      VD    &
M  SD   )]@   !H 0@!I &\ 0P!R 'D <P!T "  10!X "  ,0 P "X ,0 @
M %( 90!V &D <P!E &0 +0 R     0                         !
M          GV   ,Y                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ,Y     !29VAT;&]N9P  "?8    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  #.0
M    4F=H=&QO;F<   GV     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3004       $
M CA"24T$#      720    $   !\    H    70  .B    7+0 8  '_V/_B
M#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  (
M"0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #VU@ !
M     -,M2% @(
M                $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P
M    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H
M  )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I
M97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M#')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D
M97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@
M245#-C$Y-C8M,BXQ
M                      !865H@        \U$  0    $6S%A96B
M                6%E:(        &^B   X]0   Y!865H@        8ID
M +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT
M=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C
M+F-H
M     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:
M(       3 E6 %    !7'^=M96%S          $
M   "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D
M'@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+
M )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L!
M 0$' 0T!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2
M 9H!H0&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"
M5 )= F<"<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X
M T,#3P-: V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$
M501C!'$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66
M!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'
M&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^
M"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*
MK@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS
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M_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M_HF:.T]W_1:DI*[,V E]-H:# +6[YD[1#:38_P#M;4PSZR6CTK@7$C6I^A!
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M(D?H_P X[6\U?G.0LU^58*F/Q X&V PO:2[]':=P#V^G[/Y:JWUY++JK683
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M\=FRJ0V9B9$G4HJ;7R2U24Q?_.,'Q_(IJ)!D'31224__V0 X0DE-!"$
M 'L    ! 0   !@ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !%
M &P 90!M &4 ;@!T ',    = $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  10!L &4 ;0!E &X = !S "  ,0 Q "X ,     $ .$))300&
M   '  @    ! 0#_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P@ 1" 1, U(# 2(  A$! Q$!_\0 '0 !  (" P$!
M              <(!08" P0!"?_$ !0! 0                    #_V@ ,
M P$  A #$    ?W\
M
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M'\OMZ+";Q^;VY%X9D_'2[I9'.?E- 9^W_K_*_0#]?\+^:V;/U'5KJD7KV?\
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M/'Z6X/\ '^P1^C6N?F'YC]:/OY._IP;6  #KU?;  T_<    !#,S5ZL*
M          -$WL<>0    8G+      !YO3Y/6     -?V
M     0],,72B         &D^4D!J/I-E:UX3<VF<#=FI=9N*/O&2:BOWDBH?
M^$PH7\A.:-?$2NBW!DW()W@WY'N0-R1]Y"3&I8\WU'&!)E09LY)B.L&;AN-5
M=P)Z1?\ 23T']!.Z!\D3,BG DZ(&ZR?4'>XF-"?63@A#*$MH;\A-Z!?63>A+
MQD\J_P#TG]7CD6%5[%A%?/03VKMD2>$%^4GY7L6$0SZ2741XTFY7S8B86O[
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MGN$9P.+F./(   (.G&%)K          -0B*<<4>G9\9DRLUE:V62.T
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M L^ "O\ ($?R*;I3JXM*R[8   /+4.WU.BYH         '5V^<AV:82FX
M         JC:BK5I#O>'VGT            !BLJ    *PV>K"6> !!$A:/N)
MNM/KA4M+L    \])+L5'+A@          BV4HEEH            K'9BOM@C
M[]Y             #2MUPF;    %0[>4W+D  A'/:_M9O])+MTQ+J    \U-
M+>5 +K@         ?/O AR9H0FPY@           KO8:O]@#D
M  #5]HP><    %/;A5.+8@ AK:=/WPVBG%R:9ET@   >.FMRZ2EY0
M  .'/X0Y,<-S$<P           5?LU6>S1V              C&3M4VL
M5(MO5$M< "OLO1%.QW4RN=24N\   #RT^N'10OF          "$9I@6>SL
M         !5:TE;[(G8             #2]TT?>    !6NRE0RW@ *]S_ 4X
MGIJ+;VEY=4   'EII<ZEY=<          $&S=%LIG,           %<K!5CL
M^>@             &M[)A,V    *J6KJ:6R !",BZ#OILE+KIT^+A.8   \]
M++I4P+L           @&>8=F,[            58M'7*QQS
M!A,W@\X    *S69K 6? !#4A:MZC?J<W&IR7*   !YZ?6_J07!
M!#\NQ!+YS           !6.RM>[#':             #!9W6ME    %5[45=
M+1  CO'R-$9,M&[R4M+K@   \=3+<5&+@           @V;(@E\[@
M    5]GZNUBSD             #"YKQ^P    5>M#3DN, #K@R88L)BJ5;6F
M9=,   '"I%L*MEK@         /GT5WL'"$W'<           "O5@:\V(.0
M           -=V+AS    %6+3U<+1@ QT(3-$Y-%-+G4M+L@   Z:L6IJ.6\
M          ^??A%4IPA-YS           !7RP5<;%G8
M !4RV=1BW( -(T3>M&)NJ#;NFA=$   '75ZT%;"S          'S[\($G:()
M?.X           %<[$UTL4=@             /![\7E    !4FVU9"S8 (SQ
M'/PDTT:O)1TO0   #KJC:VJY:T     #AS   #Y]^%>K 0O-)V@
M  JU9VLEGCM             !QY>/V    "K5I:GEL  0WZ,'L!*5$KUT3+Z
M    \E;+)5>+6@         'PBF4H/G [0           5>LW6*T!S
M       !X/?PY@   "K5I:M%I0 0%LW1L!N]([OTR+H@   Z*KVGJJ6R
M      /A'>_8S+'8           "L%EZT68.\             '1WZOM
M K'9RJY:@ $%Y3$9HEBEUSZ<%S@   =%3;955+8@         <>7$C"38LE$
M[@           57M%5:U)W              QF3P6=!XSV   5BL[6XLB "
M=TTF0S=*F6UJ\6H   !YZGVQJF6S          /A'$B8C,G(           %
M5+3U;M&=H            'SZ-#WS6]D    %:++UL+)@ KW(D=RX9ZH5OZ?E
MR    =%7;359+4@          CZ08[D0            IW;NJ%L#T
M       QV1Z^P    5=M%50M6 "O4RPG.)DJG6SJ>6W   !PK=8ZL):0
M     #Y]^&C;QINY'(           %0K9U'MR>D             &'S'7V
M  "J5K:@%OP 5NL' \T&8JO:2N998   '76JRM6BU(         '5V]1KNS1
M=*0           !6.R]8;-'I             !ALQB_:>@   "IMLJC%N0 5
MTG&#)?-GK?8ZNY9$   '34VV-:2SH         !\(9F:-9*/H
M*D6OJ9;(](                  %0+?TY+C  KG8BN]B#C72Q=>2Q@   .-
M:K*UF+-@    ' Y@   ?/OPB^48NE$            IK;^JUK#T
M     P^8X\@   !4&WU0RW@ *_3? L['NKM8BL9:4   '"KEHZSEFP    .C
MO     ^$72C&$G'(           %+;DU!MV>P           !Q^GT     "H
M-OJA%O0 5TL-7.QQU5[L16LLP   #KJ_:&L!:(         #Y]^$72C"4VGT
M           %9++5NLD=@/)Z^',          ZNCV ##9GS>D    4^N#1\O
M  "M-DJVV4.-<[%UF+/    ZZ@7 ID70          ^??A!LY1C)Q]
M     !6*S%9[,':       !PY^0]/+S^@         4FNS3XN" "LUEJLVF.
M%5[1UO+-@   XT=O%2 O"         !\^B+)3B26P           "L=E:QV>
M.T             'B]NK[0    *07?I276 !4VUU3;9'56^R57RTX   .JH]
MNZ0%X0         #X0+/44RJ<@           5<L_5JT9W
M,;D@   !2RZ=3"V8 *IVGJ/;@^U?L]5LM4   #A26[5&B]          !\(O
ME&'9A/H           *LV@J;;$[P                ?'$<P*?W J\6A !3
M&YE7K/G"I=L:@ER    <*?6_J86X    ZNV/"0P    /GWX0G-D03
M      4SN'5FU)W                   54M76TLD "MUC:A6_/)5:UU;"S
M8   .%0[>5%+>@         X^3V?"#ISAZ80           "EUR*A7!.T
M               '&HMNJCEN@ 5 MU5^S@J?;&GA<L   '"KUHZIEK0
M     1'+D32R            4]M[4^UYW              ,?D    #JJ);F
MFY<\ %0[<UJLL>:J%M:C%O@   =%>9Z@\L&         !U]GF(DF2'IA
M        *IVEJ?; [P             >/V    !TTTN=4(N  "N=BJU65.NK
M%J:QEH    ==>I\KJ67          ZNWX0Y,E?+!@           %4;55AM
M<@             8_(=?8    =%.[C4J+M  KM8*MME!5FU%9"SP   -9B68
MH?)^          /A"LUQ/+            !6.S5;+*'T
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M5PLG6,M& "IUIJL6I.VG-QZOEHP   5^FV!YV,L          X_2(I>AR8P
M          "JMJJLVF                   .BIEKZ:EU0 54M/5.U9U0-/
M5>"R    *LVCJG:D[@         ?//Z1$4NPY,8           !7"Q]=;%
M            &+RG'D    >6K-J:L%K@ 5+MC5*U1XH1DN,RP0   *DVPIA=
M(Y ^@        ^=/=U$,S9$$O@           %;+)U&MR
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M/GT5?M!66S15NT%4+7G8   "H%N:7W0.X        #J[1PY??A!LYP[,0
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M&&CAI]D8Q(<T2S6GFV>B[8IM:O/    ?".9'@^<
M#K[.OL     /-Z0             1++4+E%=J;"1C[\_AS?(PD/VEEIKH;;(
MD$      $'SA&$G@     !T5"+B*K^LLZJ=L!9%7_P )8Y6O&EIE</26&5)[
MBV"K_O+(H3V DQI/L-J8S('-P'-P'-P'-P',     &,R?'D
M    <?OT      /GWX1K)<(S<       ./(<',<',<',<',<7(<?G,>; [.(
M^T>>1 FPRT(5[9E$"=\Z"%LI*HB_E)PX\@TC)[(-8]F; '#R^T
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M@YCAR^CYQYC@YC@YC@YC@YCCR #C\YC@YC@Y@ #C\YCAU>@=+N'6[!X^[N
M  &E>[9P\GK&)Z<X/-Z0 <.8POW,C3\;(0CO[(8TK,9T8+NRXPWW,#"\\N,'
MSS(Q#+C%\\B/)\]@PO5GQJ?#;QXO:
M                         '__Q  X$   !@$" P8& 0,$ P$!   " P0%
M!@<! !$A,$ 2$Q87(#$($!05-U R(B<V)C,T-1@C8( E_]H " $!  $% O\
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MKS4K/(C;3K8D7FS5^O-BL,Y\V*OUYKU?KS6K#L^9U<B)S;57XSYFUYG0;)@
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MOT[Z6(RV_1:1>3JSC8L"CX\[!A&/[G\@S@&ERC$_3GCP*8=1;A8!M)?L,\L
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MSXO![=/:&_V$.WZB49VN#T2;':CM8BP.MAYV#%#L&7-R!_Q@  X7=,[=UF0
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ML<8,VW@YO]RN09C?%28QAHZ806_Q)U%L\6T/''6$EK/N/*<Q=JVO1;>_E6R
MP!F,]H,# K(Y&=5)_P!/TQQPPRGJ+<#WF"L;!ZP)A&#N4N&;YS>BV\[56TXV
M:C?XPC\A\C.JLSNP],-*L,?\=1;)18L%_P .LP'&.6N_-7HM\79JEM$$;>9O
MD,)Q_<+D#U4.1>&.F$D"-ZQU%MF8+ 5_'K *@B6<I7^</1<6"\U0F-P>0/\
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M8%BHAY,JKI<XT;E-X^ZA^QC-N@]OTV>.HT' ;>]%LA[R)8T+52F9,CW(/SG
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M.CQ>^P-TQ(=>:ZPF2^H3B==Y1,6['P]9NI,@X4#QR0,]9C5J>OVLR>&(4N"
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M]CX8WOOX.&D@"#^$K^$KRVL0?OR*O-\/OBZJ_?Y=H[8\6-&'$"Z/%''#'&P
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M:DUC"V5CM5SK*U;"D2UFFM\DO9UH)0PXP(4VQLLLN2RDK@PX;!&'$AQ(D0+
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MP(8_,YT=E7/)9PNXG&]AZ]XYY7R7DA%CDDOV]Z<9HQ(PDWD73B;A]P;[IL@
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MN%#OZS+;.'8S+B'<3X,4 TPJ[BRF/>I12.YJQI8\I#MI[V,"7%CW57 M01;
M21Y\85A%%+&":!KRL%*$TJ,.-A2L:5KD80C='KYK]:K\%X5_RM5Z?;VZ)U^K
MZM?7I]';U?K_ -/;U?8O^GMT7[55>OV]>S'.:-SV=6OT;JQR^;F;AD5JKT3X
MWJ[*GE\_1=?+U=O7]NG:U-KHTU52,;IM^-'DWCB>'3IKWD?75=?FTZ^?V_\
MJT[.1>J+T5/:GU^6OEV7U>S^"OSZ>:=NJK^I/V=O-W^4O[GG^S^GMU\NGDJ^
M?K^KV=NKE7Z]/W?5_7YM>SE:U$5R=7)HF[;T:B_0GDO;7U_2NGV=M/"J*NCT
M<G1S%\TTU\_IZ+V8)@@M&'3E#V,V#4:>\\IC41HT8OQ=/BZ>'M'6VJ*JU6*D
MA([[&#$FOC)+%R)C(W>8Q>4V8#6-)VO;S0+L)O;X>R@?3U#@>7)6KAJ)6JQ
MKJQ6JS\2B,^+\1$9U:FWLC8D"#%1.B)%B18^B+[TJ;6 <B(@-&^?B3P:(WR9
MMCQ_>AL"+WH"<D+/B #I'\(A_D,\D]6G9CRA"1XO&(CVA>\1--FHU=&56KRU
M7Q(J+^1Y+V>"0 !Q%_&"D!&<+^G]]$_PD\D_JG:/OK:M_<O[D1U=&7NW_P 5
MUU[M_$[:NVNU31ZN1BN5/S.@F>'U]?9Y=NFW3R3JC=$_-TY+^GU_5V9L$).6
MQ1BT:)O)&NFHQ:1_"-=K=6]$\*>Q.RM<QCFO:X;T56:*PG1Z:=W\7A_)7PN^
M*[IU[,*E96<X9&E&5L&,P@RM$P+2L)RR.:1H1C CDT=RQM:CD8U&]B'&$#3&
MV(<C=K7G035:+G/2/O)RD56C17>%JJB=D?,KZ\[^<DA5/$C2E60V/W5LG>4#
M7));&_!4+XE[MJ+XJ]&1HH0Q8X4V!CQ@B!'&SV""-$:-OGX4]>O;1=-%^,G3
M1S?)6NW->BHOK31/I[2(-E3U4^#+1&RH$N##DPY+6?BTD!-$<TG+7JS<B[%^
M+V(63B^-R2''R9'>**I.IPHYKV (]\-KWB"]C5$UZJWIJYJN1KFL-"HJ*&89
M$(T\6GA *A$;L0@WB:QXWM9X-VJKMZ)TZ=MA8T9[.>Z0@U!'>SO#E<JRE:^/
M_=+M[MY4ZJKG+ZU[/WA O-'R3*K1.4P.J( NL;1X='/39Y(CE3UKVC3?<OC"
MS8)EE09:4%8*3#D[&B0\:0D=Y8YD ,0.:':3EA8W=M1J(ZT7#L0])D,^22P=
MC=46<Z0]=2'?,[N.0\Q%ZN*KMZK\95[/LYF)XQ,LSJCI%C+H:B3,*YG1A#2B
M0TDE>C5<B*I?#JJ)Y]E>["<+5SEU<KL5IW.<OYRNY'55^?KV'+I<3Q>GEAYB
M"F5E#5PI+&F5KY#6%BQ $'WER+S=K]';6N5%7R:=O#W#.\"DOEBDDQZM-(Y[
MB*?FDD% XY'\]RN3>]R,T1&(U$;IW>L@0:Z*CB/2- BQH8$*5R.*5 QHX6\P
MZHCC.U\3D1>OP%-+&%SJ\5!D@),G</:.9+L<6+"#L5_-53!ASWHYHU8U Z/<
MUSF(OR)B7<:#)B <9R,L4$Z*BS8$RHD-*P_O!&2:^RFP2",CQE#*(-6KN[5U
M0RJJFP%)'-61>:OOI(6,LQ@!(KN?S9#AXH%M4KF/?OK$<PNYCGJICQ8$VM-(
M?O*:FOLAI#._U3R:Y5B%J;6&]@'6>8Y%,?'8YL=Y)P]XU975C8:%M4,I(]>:
M#/$"UF0@V-)+57%K<@BQI(A6U251&V@M!G$QI+ 858*=8LD2JGNP"5]C(MW2
MX4AZR@RS7<J;8VXBLDO+S&2SS)I"1?Q(PO<$0AQAM&P9@+(=()+++%.O<BN<
M@L'R2PQU[N799':64Y1MB,0 HS9'=XZ$.H1#?*D.+#K#\D<NKL9M[#CUEO+I
M[&)96D2YASK%BT\V%.::9'N[KFD5VCRRSRO[I8PPS),K1E"]ECWU\J9-?WL%
MG2BH;8=H8LI76$6?5QHZ3P6#SQY,J)$M3L?:1(\T<@)QR+QEFR5&-(N;NQN9
M$J,:JF4AX/>I4PI'Q65<R?&2.CE8+O,H^B22$,M-$M9"OGCK9,.)%;D,V/,N
MZ$[0.L*VS$R>V1D=-*[G')/#8]]"=1/4[G-D2T.\L'T9$G0!9$<Z#G-:2.&[
MMA7V1&E!61H@BVSQS3$D,VPGG5H%C"D/822R0Z57 B.K9O>R9KDT*50BC#M:
MZJ;4VJWXIV,58P6=S6Q(%/*K:Q8TVP@,CJ QPK63Q $T<.U#D<&P+<6!^?<.
MJ)M.RW/.D6!'6LJ5564P1Y$XLM9_.[W)4\D8CLCU4V/"&JQ+BHAQ36\L$I!9
ME:BOIPX7X>R4.9.ML=98U<N.YMA7'J'OI#P^ZEVK'(*G$0K[P_>HMR6!<*8.
M1P\FR"2.XAV$>X9)@Y/6PK2=*',:>ML(@G.)'5FWLAJ^943HE!6Y!!DR).2%
MNQ@KLRL06V0^G9-A9SN_)=V-8.5)E7;Y)B$ ?EF:U\EKXN10B [I%= +7WEI
ME=K<QH0ZZ+<U-;'KK*[N9XH==$BY#=PXU?$,*O'Z2E-9'WOU2BQJKM*P:/J1
MDQZK]+CES)=+$"QHY%>V1+/.L(( <M$E,<<;1;-2[=O:7"!,B&F5_([_ ! R
M!$DPN]#YT7O8&/4L;O(D4H.<UG-&F\>YO7M)9764"P?")R9C(4R/*=$-J]O*
MDM 1Z@)N&1-A=KM6/33PK^Y#B2Y\*+*L'/9 C290 2)SQ;.8R&$CVDDN'S1[
MVA:]6\QF[3<W6.,T^$(DN:M;$&24!CY5BV.>6Z!':XB*::V+%DR5BC1QTCQS
MF5G+$1S9$0,N*65$5$E1AG$^1&5PQ%:APM>I JX1@D1"-;J,HGIX7M5>PI61
MWU+C\60;D D7=I!J@&/L<3DB-.. 9"\MCG\MCE?L:YVFB+V@UJW-2EC: [U6
M0%L(G?;&-RC'[Q!B\[GRP<B/(-S8["#Y0#$W;!/5)$(<J,29%8$DJ(PPW28P
MY._N[Y &N4H6'Y1.2XC6H7EOV:[7:6,IMQ5.BU$HT&VDI81%!5S8R#61#L3(
M;EPI0$,%31Y+AE$A1J]B;VZ@+:VM96#E$0,8EA.BPF2"JFY! =)*-I2*WQ(P
M:N<J==-/OR&Z[WQPL7KX=!O*J:)IY^-=>O[Z5BDC/=;NH[SNDO4G+! '.Q];
M*,]$>@%?(DGK"#5PN8B1B(-[6J1J_(J]@V6JO!<P)R&J(5//E1%@<V8DKD7F
M^'H-0HT9!QILUDE\=840DC8YF*"7%;DJQ<PF3%C#=COI&#5OL;E\2TLX[;.#
M71S3V2PFD0J)'!K6S'!97U\6,2)&M8'HF=+GV.=89DU->#BZ5X:2O-CT>XCE
MLP_[&2ZJKK+V.2%*=&]-1+5D>"2:2UM(T2PJ?<A*EYI1X%D4>3:.H8DBHM;^
M9%!*G@@R9Q@^GVYK>,]-&"-#-E$$1,I)66KQQR\1)(89IMUZ6?E&%2Z\%<KW
MSTQZOK:N)'B3I9N[RXI(#ZVX?*;&BV,"::2(H^_S(D"F%3X996YX^/NK*BKD
M5>*VN,=\WQY$2KRL<IQ)U8)TR/&-(N:8K(8G"?(DR3.CQ0GB6(J!.4#'KB2:
MX) ANCI=3[2JY*QYKWOF^DEAML4*J"8(41Z"$=>:4+,]K*^.27/L<+RF!"B!
M3>:5+ET<Z/&CB;TW$,8C!L;JFKG(FO;$IT;DB.>_M;:W)!QJ)1U=6JXC)H@I
M'I.^2YD9LML:&AC3K>WE%EO79)! 6' AX9)AUJQW<-N&V*=S@%KA,F9%D+Y&
M/V5W25VVSC-HSQZ[#X^/ND$BO"@LLLHB;PQS-[93)AU,J7ONLWCAA/@5D.3M
MR3AQ$BP[2%<2)Z^D:7OHQ5MA7 [J^3;&8=[U3&6"L+6DJJJR-&R2CQ*B6^G,
MK/1])B<*QN&AQNRKS90.SGGH,?D38$N96O?-N)UZ^6<H6A ]E2MSC,C)X5-/
MSJN!"JJRJ0'*R&TB75-:0:2=</BP:JJK!6&* WS"60FE8P4=M?8RG"%*CX)8
MR:AV*<*ZF!4_VMOJ*V907V62Y!)$V1(D'C2,.C74&9 -7:ME'C& !3*^+)$/
M&[6@F]SJ0\1:^RLB-=$K)]5F%TR7##72A'$:2>VKWI(FK"1SZ>3!DQY<L!R0
M'V&5;L/F N;*TX@J"I<F/!LK*MN,ORFXH(ZD=;-K&@##R#:T$^PCL Y9B,;R
MWC?(P"X]Q=C-C4-'/JB8^%U!*N,>FRA43:^Q$-]LZK+W$%1.K"R*RWD3 LM6
M<AIHA)[P5]M2TK*.#B==BBU>/LK:>38.&R\KKC*:;'R5]_Z,JWDIJV-C1'$A
M.$1W>F5LCN3F2S96),8M"BM,N >+-;W<<4U9'PC'HIK)2E()C7>DZF34@C%>
MTA7=WD[TBDU9D.03J.W'64V&5Q1-MJNDC96-U W(I,[$ADI(<,=M6TX^0M-*
M49(YY-G+-"GV;993!$XPT"9PV.*)I.:T1%:BD&TNUG,1CM6H38S?INVMUT[<
M.S0JR5,BTV4SK>TEA+7L##AEPS+,='O;*G1Y)2/GY!")LBQY&D<,DKM'"8PD
MVPBQ)T:LL.)))ENPYXS&>CZ_'6DKLGJVEFF1HIDH"8K;0QP>^V0)D2<Q8+*8
MDB75PY^%3(V24<2T#991,J:\0W3YDD:V,^#;<Y23F9@=A;A[:ITKNR;(]X.O
ME<J/V[P6NGU3^\2@]TLNYI*VQI)H[)&D&9.!R)C1)+B^_P#-6,82G$ RO"RT
M@TW2QL(_HT)N:,7<F6)!PI-FCBZL<ZJBG-9-#M>Z0Z*@&,>\C6+28JW$K-N*
M@C54WTW"CQBPC6E)+%*HJ^7(;+29 @49(09SGE%OGS.Y11/[B*Q#89&(TJV[
MA89#;STEG!BQ,?;43JQWH8M<\( 93(NH$IE?6R06I#01PZ^0(>D5:DIK>LR2
MEOI\:NQ&@K6UYZ>E):'RDD29%RF'40*2-#C6./1)#JD\"Q,TYIAR7!TGRXPH
M[FT-88>70["UQ^+ E6%94U\JW@265X$F!L(^0Q9H0+/<PP2%F0GB54<CY44Y
M(I7UC+$8 V#:Z&V<**YQ(PIC8XDE#CO=XG@8;>T3G>)PT:J]?OI(&,D(2."*
MKWDB211WM/S59R)1!MCR7-0?OS $(Z.NQ#(Q7M1?WG<X3$(1&O5@U=R][]CM
MC.9H[E;G[44FUVU-5VKV17MV.5$56(N[:[:FYN_1-^CM?'HF[ST^#I6\_0[<
M=RC9&<BO><*V6([Y/.3P(@7<EBL5=7+)3:BH-RI\B)&#B][;(,3"=Z@DQV/$
M(KO,(5MLAKC.>S\MW+V)KY]B%3A9F2H/7WM+?ATXQ$3\H+1YN1COT7E&_I\7
MLK3\)>)>Y$W?@R8#/:K7.<C='PL\.W?HFKV>;/HT<I3MX3\3D8)6)L<'!AG)
MOW:J*.7.&E>@]$W=/RO)=.SE;POX@@<SS9,7!(SE7V#4N<,&_P#2YFG;5.%>
M>:^+P+8\,==K=NKM4XB/35=W@;N3547=MZ*M;(L^'.<L';6==2Q>[EP285EK
M;D%'KX9@@S=SVN/()MYW]S"T3G%&US7JQ5X5\0/?$8K$9(X=D=N>QI.41K>(
M&L4C$<FY92"'JB^/RU(QO"/B=[TQ7.4@\""U=-O03C9XQAEZ_%&]SNG1J]=&
M*G"7B.N]!K^.X<].:7DL1VG$%VUW,5O,:NBA KI!=HF.<FK.$?$1>K6M1TGA
MP-5<Y7_'_P!<%RM9X4U?LT;^4J;F;FHW@_FWQD0F^\X:#1K5]8E]W+D,_P!C
M/ BZ]7M[*A.$V;B:K-1N6WX9/5S_ %M<-.(#-B>I';EU7HY&+V8C.$G$7Q.<
MS<8W#N*FK/C*J%S_ ,+/S'*NA/[VK^S%^Y+Q%T+S%:G-X=-5&L3^^[N(?O2N
MU\*$V*[148C^SM.$N>=%%HBV?#%%<CU3>O3B$Y$Y?Z7LW<OJK=4X1YRQJM56
M.-;\-1JNC=="C]W2D$KEZ(FU5U5%71NO9'GX0YT@]B;N1;<-I1F$<[1K4C-S
MD)'HNNY[M6\M/-B(CU37[DW$'1=JII.X8*NBJG1S%XCHK7>IR+U9U5VFG9JL
MX3Y\[57HNZQX9"<S:OFNO$-6Z+^2N[KIKIHK=>3]R7/&.V;]Y;+AP@.GJY[,
M[*W<JZ(UJ:N5>JM:U'.0K'<(N(;'#&TNJR^'>QS7JY$1A'YV,;RZM7<%BO(Q
M-KB(U'LW<\O"3B#RFM<\J G<-I4GHU7;8\.-GY9,I_\ O8V<W1%5&.TV]MJ<
M.,_.FP;D(%F&[';V-?Y%S 9&N;KM>PC&N8]%14]?9O\ K6YY+8[<J$@2N'LA
MOA_.1<[$]J]>G1=W7155%T$_[EV=:$9(5VZ7P]1XB!$XPPE&W/2;'2MO("KG
M:-D*UA>7N3LUGW*>(+U<8PF\N5PY5GO+6+S'$?GXV#"7<[E/>]FY6*W37HN]
M_"3B0Y-$5.0_AW,?]88G$$I&K_!TU3UIV61]R+BTX;49T;5XBXR[V(_1L;W9
M]Z56ZZ/T$J->U6:[O-J#X/<84W-(_P!_HL:CHC1:;]5+EK-I%U]Z&_:XW][1
MR(JHBKP>XR+JK6],>QQR^+7JJ-RU5:G3Q*[1&=$=IKV16<(^)VUR*OC'@@G>
M$3C/:YC\XW-7EM7E:Z<Z3MBM]\<B=FJ_A!Q3\3T8G)C81(7<NJZN:'.'JQG1
M=2/1!M71'.17)V>->%O%_<QZC73#HZM1S4370K;MP3LZ]#@>\#_[V1VB]F,9
MPBXQJKU1/%C-*!K=7N9J\DC)A#:B:(Y?%T8Y'>6[:)$X0\76H8C1(Y]+C#48
M]QE!J;^V[40FN3>\SDV-'[ZJ\M4=VE]UX0\4V39+(<63)D0,5AQ'#BNF-CEY
M\O-AP11U1Y?& 07.V^^O,O(8QHW<),_W;PL>YD[AR\+7%15\)4SS1XV:>^$T
M1HUZ$5BJU'%UX3\4$(+;J)(>&OW;B\E>29F:+&)M<F]WOVJ#]\^+V+!;PUSV
M,@C,"29.9AT2O8BL*]9#9?NQ,LL'@:GX& [V/<UKF^)=IG_<JXAL46[03R8
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M_=<EC'MBHC?<+A[BHX448Y;N8Z.]FDR<A9PV\K\&&5L74BC4SVC)Q3R!Y>\
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M%&8"-&.12*G1^CG=K(M=QL-7F)BN'3W29G"G%AW!*R?8YBVM@6<"483XQXI
M3#N?W.*TKI;AMBAY#D?90X7]DK%D3ZMKW3*N+POP4]D)X(D660;XOI 96E<*
M;#>B%:-K.] 1[FH5BK#LZWC] [A-BQ;(4QW"?'F2^[R !EA[Y'-<<J,7E/\
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MO/JKE<FCF^,;G\?(Y&->)7C^Y-C#.8P;T5S-Z6CE9S$U3<B:M\V;5[-5W'2
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MKD%U50065A4U,ZQBP9,E8D>0^(!YU:60@R*QJ,8Y^B-12;>4CQ;^8RGK_<]
M/FEQ&LIK*$5^9*:/"IRQ6V,HV2DH6%4;$L*R/&&RB63(LK*,!P 5HK&X@64B
M*.<(9,?Q:Q>"3)<<,21-D9)%/#0:2S1(\Z,2K5DWN $ARP>C[$%A8BF,6-#E
M&MR^B+O)LRQ<>+2ZN"-L 6*,L @NZVS $5B]9<FADFF,LI,\$D-[#[@&O2N>
MLO/;6\D@AP,>NW$8$D.5!-C]&F-5%LL&Z25' =MQ7J68^[CD%S:^<LB$BEC
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M/=S.L62:-^)>K.U4^PH*6<ZB<A*-TRJ@274SVH%&OJE,!ZU[FI' B.B<I4Y
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MHK7IIV3Y;]6GV*J_3Z_@Z#PIK]RK,_%H_=TRO!?#^9IU]2*_K[%37[SB2O\
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MM=\G"7NZZLPLHTE=-&M)=@<L?3775W*:3RT3EIUZZ?*>'_G_ +4>)11+K_\
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M0-W?E*C>&6"*C5_@MWJK?TG?O0GT]L,1-418]H]-?/WR^M7]?\K[W#VK_P#
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M"Q(:.8$BHXC-@^8GO>\.N[L)R\;,B?&:'0T=,-X=I(,;<_WT4GW/\L(5:H]
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M1.<)S4W$1T@94>Y>B.9RT:FSK^^S^7O\#WB7>(@_$-41VF]J:I[%]?J_?3+
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M(L&;&F<E=I>[%:9HW>Q7-^]T4PF_,XB-7[%[=3,]GU_;V\1F>WZOM[?C@?\
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M]9,JFBKPIM50&^QBYC=)H'V.%A?"#!$X8,$'[!IZD;T/:T9,(\F.Y.(K>:0
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M@*946M^X7!W*;N"LO+=U&"=RVPC%@^0QQK " !U9.-=2VE5Q[C4,&SY\!$-
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M;"-]\!H*V5NM"R$!+3#4X7#*IN.(XTZ)M82!TP ;REV\4ESG'[2+<*QRQVJ
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MCB&NCB40#D-VEFO"Q6"LU#VF]PF_YTJRA[S6-22L&JM&&5LX;&!,]C$6I!O
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MM4(8;9=P'C]J+HH#WU]*6+J,U2B;(#B)57W126:( 4-21@JJ6KIXB ]5LIL
MA59FEC('<9@F)*\XE;R AH@0H;''.2&*,\--*D-9L28LA@ -51F@51(\2.8W
M#QP^X )L2I8;EV&L<OO8_P!6V)(;L%MH3,97W"T2 C<FU*(HP 2W=.,RBW4#
M@*XZ:3K"[%  0"5"3KBVQZ&!!@N!3YH/Q20BJ;+43/2YQ@YW01V@RX-GQA4$
M1W6()HT]EQ08F#E5P3K(I=*W?"AKBNBDNNF ?D8E&2.Z2E+_ )4FAEL 9PB
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MG#  CM!QVZZY8P$P%_A$F&<R[C BG"DWP,&.++@DNFC!MM-<P0A(NR];@7C
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M5Z'@.CU_QSJ]?\,>GK^<;83D559R;ASR#VJ'9FK,J?V0GOQ"LWI* %*DI16
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M3P!1,,D(*"%#G3+*HE+!DQ 32X0+"*%=##UHGB%896)1Y][EC2I[2;($:KN
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MNV(-MT/E? @GNCE0PVQ0=T0>PAFX) V]QS\O2L:5YLT5/&F<E*N#9]K!GBU
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M]U@T"]NE8(((;4=?[1G^=,&DIJ>O%!Z_0KTSI$,JLZN>1+1N?! H6B>1FM;
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MVK=M\G:_!BF #2Z]2MT X79M6WP#HT0@]BM5J^&9_IEM@TQ5X</B5>'2%O\
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M%=&K+1..^<*^'>QA.L+0"$J2O$P 0@$[#@H%8^O_  :3W2NG:OH;_N8#H&"
MTJN^K?NMT6R)K@%ZTLH)UG5Z_P"&&[G:IYJ>D5V%P>3>T;Z'^O@V7(BK!V-Y
M;#E<"Q$1Y*;**/T2?R"%%(+JV==5V&[%X!K^#2^Z*[I*UUT1\M_68=E*!5XQ
M#H'L;2^[0"@5VE8ZU^;3U VOK_AF]D]#- _E$L3SA]L/_,&]6?!A:6%VT!UR
M4-BS (%W9#@\'81%.Y\/YF&=USVTB:IY/$73$[I9+MUH/57D?P_;U_QQ"/\
MY$_87S]UA@N(7"[7K5Y#[&K&979H-G:/EAFA!!002 " U..1-B_!TK9J,'X5
MC#O*NZ02N_:U$-2V<IIX-%='&!'ICP^F$8>;RW0"]&P3P2;TR_H?SE_0_G+^
MA_.7]#^<;TR_H?S@KEU<J%\H/R_Q!6+H;YB$^I8C3BAN@_I,^Q/N\/K]B*K7
MC$MLGV2QJ5ZG1C=3DPTB=+O=V [XVK$":V>0^ ))6MVF=-FW G.!M>4)P >X
MZ-K?9X>#F73U^9(/(:AX'9&6RJKB#0IO9$$*C:.1E 8HS5@E#^#A"M,E!,*]
MF3HZJ>HE>U;PWB/'H*QRD+"'W5,[U(]2%H7 F,47 IDN>EFZD3,.MBM 5TH?
MOLY:FR4R +@4HTC<W?:;&KCZ+:E6Y=)SCC:"SH+0* X293$)FAYAS%H5,FSL
M=&V'ZNL@5TP1:>D01"IAL/8O$ 8A"-RW-F7;(X\J#2?8 QWBR_.<K[J<"DRL
MC$$?WM1"!DE &P CV&(B.L;%BK9-A"L(*N&U#!&=1PA7:<6CP=DCJF)+M2@
M1F&&A&Q5$+^Y%>Z*.SACU8RDZH:0;ND3H:WDFQ=%J\L2U2@!8/,%<#*?ZGA"
MT*8"]-'!>,ZG LBB&]BE " O2W9V]@*]+B8&.2Q1+!I,@(C0*+6""EHVTC;
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M_P!K[WV#%]\F*^A@0/GW/5"_3_\ (W__V@ , P$  @ #    $
M
M                                         #%(*,#!+!,&-  **%&*
M,,,/-(.-//,(!.,$%(!(+$&,.'*"       *-/$',.!&!(#$+/'!/,)/*!)!
M%+,#&/#/%*+   (      (              $     (      (     $
M               (         !!!!#  # # ! " !# +!#!!!!""!# #####
M!  #     *         (('$!% $# *'-$$+&/#'($,$($$, (,(($,#-).$(
M  !*         &/& &#)"$--#%-+,* " #"!## "!"""  #"%#$&"   %(
M       ()% ! ,.*/-.!-*($ &  ( ,, $(,($ (, , $$$(  %"
M (-(#-&-"$(&+,/,  """##"#### #!!!"###" , "   "         $)',
M      ,*,,&,("     !',& "#'),,,-++,(   *            ,
M "+*   "    !#*&%    "    #+     "         $ ,'(.% &/!*-+/&$
M#/% /$.(!.&#!)(.($(   ("   "  /         (
M$  #.    +           "            /(&+-+,+(#'))+#$+()"!  /%
M   .          %(            $              "    !  &-
M        %             ,"             "       &,    .
M   *            &$             (    %  /.    #          %)
M          "                   !  '!    (          !"
M    )              *    $  *&    +           (            %
M             *    %  )-    $                        -
M       *    $  #,,   +           $            ,
M (    !  (!    $           $            ,              *
M!  ,(    .           -            $              "    $  %%
M   "          $!            +              "    !  #.    '
M        !"            &                   %   ,    $
M  %.            ,              "       "     (           &
M          (              (       .-    /          !$
M    $                   !  +,               !&            -
M             "    %  (,    $          %+            -
M       *!   !  /     %           #            )
M$(       ),                "            +
M    !    $          $/                           *       %%
M   .          %                            "    !  +"    "
M        !*            *                   $  &(    *     !
M  %"            -              "    %  (-    -          !-
M          "            "      $  ".    )          %#
M    . (          , "       ,"    -          !%            *
M       !             )/    #           *            $
M       (    $  (-    ,           -            !
M      %  '.    (          !(            -
M$  '(    *    !     %"                                   ),
M   !           *            &                      .+    '
M         *            .              "    *  ,*    "
M  $             '              (    )  "(    &          !(
M          *              (    )  .'    &          !
M    *                   &  +     !          !*            (
M                  "  &#    (     "    !*            (
M            +  #'    (          $"            (
M      +  (*    %          "*
M,  $+    %           (            *              *    &  (+
M   *          $"            *                   *   %    &
M         "            (                   * %-"
M  $                                 % !-.#   .           *
M          (                %  &  &.    "          !(
M!##!"                   " $"+    %          -          .#-,(
M(,$#.#('!!'%.!".-'"  # #"!  ! #   "   %*
M "     "           $()!+.(/$     (                     *
M (             %!,,.              "!#"#!#"##"####      *
M             (      %(       $,,,,,$ ($(((  $  ,
M               "
M        $*    ###!"# " ! #"!   !""  ##  #          #########
M"  (     ($((($,,($,,,,( ,,,  ,, $       (( $((, ((,,,,(((
M                                                       /_\0
M%!$!                    L/_:  @! P$!/Q!H[__$ !01 0
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MCF7(5@JUDN.F=JP%/;G!^.UEKV+Z"FKE._\ "0$&!]G=4NI#SA[9Q'Q9,?\
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M&V"NDA1X Y2(M\6H"K %7P&UPPZ/@- 2$9)='56X2>(@:H#8^C.\98MMTL?
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MD-%TZCN?1[-S^)\0WBW.]*<EF;&C>3RF_,A^5J'(VFY4LQBUS.U)578S&18
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M0D(B"T'&(0AZDG,@B^%(/#^L;5&^+%*YA$@D^[^5#CR>/CVE?6CA    " $
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MX#;$]PRAJ[Q&)XY!-:X-^+"-B@#&,^, TLP!^B'J=*H\+4 )06C,%LU'Y8N
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M%T>\( PI%^V ^67)#%)K?OB9L#,C\A8J&[YSAW.VQ@A:-&T-9IYI M_*S?\
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MOE!SM)%S2M1S5G%T<*@XXC.,6 H84U)_R9K[8/1X)$F#+PK0""M;N> [!X]
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M,@RH ()L8T@1'PTCB T\'.FB$!4H(MQ[8_N( 4'.!Z =*\,9IW+/N=_QWQ@
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M"$?HG;S/!/S];Z>6S1%\L0VFNPFO)A!@G416=$02L&Y@89"=@ZCE0 &[B+!
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M3D*A7.6IHK.YYPMQ*)/-/]#G$.%8G\2J(!O^%?1V03BD=M 5M&P/(P/TUEH
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M<R#H8HK3J?SC^L3M%U$0T+2CE'P%X4+N.C&*P,Y9PX1F-$$9LOYW(1TK] 2
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MTCP;1DGE9[.%OMCM=:N9M4@H@S%-)@UW0 "KM6\)50OA#$8,8@S6%]*")+0
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MC:J@0UI1X5!:"'(QA1'PF1?M5?U>13*U+3I5EU_-_%Q3=H"@$MDHQ-.;7Z@
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M'C&[_P!?V]+3+L4(TJ/"N.,>$& @HW;;^[L7D[YN$8(CJY4X< *%,*=Z,>+
M))=C;>6Q7M@Y.I M00_*LE  !-!.XA[.HQW .R)K")B[VS!AH2@PO= ;N^-@
0D;5LTI)*&E;S;_\ Y%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746168224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,692,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746901488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember', window );">Collaboration Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 7,384<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember', window );">Deferred Collaborative Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,902<span></span>
</td>
<td class="nump">28,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">22,914<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">50,425<span></span>
</td>
<td class="nump">63,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">41,134<span></span>
</td>
<td class="nump">47,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,362<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,714<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,881<span></span>
</td>
<td class="nump">122,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,691<span></span>
</td>
<td class="nump">9,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">17,328<span></span>
</td>
<td class="nump">16,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">7,974<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">27,914<span></span>
</td>
<td class="nump">27,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">63,070<span></span>
</td>
<td class="nump">62,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">9,194<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease financing obligation</a></td>
<td class="nump">$ 2,506<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,693 in 2016 and 73,355 in 2015</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">560,762<span></span>
</td>
<td class="nump">558,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(533,749)<span></span>
</td>
<td class="num">(510,917)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,798<span></span>
</td>
<td class="nump">47,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 102,881<span></span>
</td>
<td class="nump">$ 122,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6739338880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,693,000<span></span>
</td>
<td class="nump">73,355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,693,000<span></span>
</td>
<td class="nump">73,355,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6733829360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">$ 4,820<span></span>
</td>
<td class="nump">6,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 20,579<span></span>
</td>
<td class="nump">17,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="nump">4,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,868<span></span>
</td>
<td class="nump">21,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,048)<span></span>
</td>
<td class="num">(14,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(1,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">(Loss) gain on foreign currency derivative</a></td>
<td class="num">(2,753)<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,832)<span></span>
</td>
<td class="num">$ (15,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">73,601<span></span>
</td>
<td class="nump">72,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available for sale investments</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (22,578)<span></span>
</td>
<td class="num">$ (15,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746412256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,832,000)<span></span>
</td>
<td class="num">$ (15,164,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,645,000<span></span>
</td>
<td class="nump">2,259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">2,753,000<span></span>
</td>
<td class="num">(464,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(1,141,000)<span></span>
</td>
<td class="nump">3,896,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(337,000)<span></span>
</td>
<td class="num">(527,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(313,000)<span></span>
</td>
<td class="nump">1,848,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(541,000)<span></span>
</td>
<td class="nump">3,404,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="nump">1,212,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(480,000)<span></span>
</td>
<td class="num">(359,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(18,842,000)<span></span>
</td>
<td class="num">(3,726,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(3,260,000)<span></span>
</td>
<td class="num">(565,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">$ (353,000)<span></span>
</td>
<td class="num">(2,487,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,378,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">$ 6,320,000<span></span>
</td>
<td class="nump">2,482,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">$ 2,707,000<span></span>
</td>
<td class="num">(3,948,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 326,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Increase in lease financing obligation</a></td>
<td class="nump">131,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">$ 1,501,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(15,997,000)<span></span>
</td>
<td class="num">(6,173,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">28,899,000<span></span>
</td>
<td class="nump">54,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 12,902,000<span></span>
</td>
<td class="nump">$ 48,367,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6737211728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 1 &#x2014; Significant Accounting Policies</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $78,915, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>    <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div>    <!-- Field: Page; Sequence: 6; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of March&nbsp;31, 2016 reflects $562 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March 31, 2016, the Company believes that the costs of its investments are recoverable in all material respects.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">21,666</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">53</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">15</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">(6</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">21,728</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">20,718</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">94</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">23</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(3</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">20,832</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,438</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">32</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">26</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(8</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,488</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">63,822</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(17</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" margin: 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">26,557</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">88</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">(99</td>      <td style="width: 1%; font-size: 10pt; text-align: left">)</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 8%; font-size: 10pt; text-align: right">26,546</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Corporate debt securities</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">21,820</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">184</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(41</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">21,963</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,884</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(72</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,838</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>    <!-- Field: Page; Sequence: 7; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at March&nbsp;31, 2016 and December&nbsp;31, 2015.</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 68%; font-size: 10pt; text-align: left">Maturing in one year or less</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">22,914</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">22,664</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">32,806</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">28,395</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after two years</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,328</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">19,288</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2016 and December&nbsp;31, 2015, the Company had the following receivables.</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">2,475</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">2,734</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">5,209</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,685</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,685</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">336</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">154</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">490</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,496</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,888</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,384</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td>     </tr>     <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">469</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">469</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">&nbsp;Seqirus UK Limited</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">210</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">238</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016 and December 31, 2015, the Company&#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div>    <!-- Field: Page; Sequence: 8; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following at March&nbsp;31, 2016 and December&nbsp;31, 2015:</div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Work in process</td>      <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,949</td>      <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,612</td>      <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Inventories</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">       <tr>     <td style="width: 5%">&nbsp;</td>     <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top; width: 1%">&nbsp;</td>     <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top">&nbsp;</td>    </tr>    <tr>     <td>&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td>     <td style="vertical-align: top">&nbsp;</td>     <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td>    </tr>     </table>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div>    <!-- Field: Page; Sequence: 9; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>    <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Income (Loss)</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>    <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. No reclassifications out of accumulated other comprehensive income (loss) were recorded during the three months ended March 31, 2016. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive income (loss).</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div>    <!-- Field: Page; Sequence: 10; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div>    <!-- Field: Page; Sequence: 11; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three months ended March&nbsp;31, 2016 and 2015:</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 68%; font-size: 10pt; text-align: left">Product sales, net</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 2%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 12%; font-size: 10pt; text-align: right">537</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left">Royalty revenue</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,890</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">1,518</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">U.S. Department of Health and Human Services</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,324</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,475</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi &amp; Co., Ltd.</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">296</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">296</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Seqirus UK Limited</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">310</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left">Total collaborative and other research and development revenues</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2,930</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">4,771</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,820</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,826</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>    <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div>    <!-- Field: Page; Sequence: 12; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended March&nbsp;31, 2016 and 2015 includes $1,338 and $1,315, respectively, related to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&nbsp;31, 2016 and 2015.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div>  <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended March&nbsp;31, 2016 includes $132 related to the lease financing obligation.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016, the lease financing obligation balance was $2,506 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.</div>  <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&nbsp;31, 2016 and December 31, 2015, no hedge collateral was posted under the agreement.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&nbsp;31, 2016 and 2015 does not include 1,330 and 3,529, respectively, of such potential common shares, as their impact would be anti-dilutive.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div>  <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div>    <!-- Field: Page; Sequence: 13; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&#x2019;s product candidates in development.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-09: <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU 2016-09&#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div>  <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No. 2016-02: <div style="display: inline; font-style: italic;">Leases (Topic 842)</div> (&#x201c;ASU 2016-02&#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div>  <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01: <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU 2016-01&#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div>    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11: <div style="display: inline; font-style: italic;">Inventory - Simplifying the Measurement of Inventory </div>(&#x201c;ASU 2015-11&#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div>      <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div>  <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In April 2015, the FASB issued Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs </div>(&#x201c;ASU 2015-03&#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</div>    <!-- Field: Page; Sequence: 14; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15 &#x2013; <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern </div>(&#x201c;ASU 2014-15&#x201d;)<div style="display: inline; font-style: italic;">,</div> which defines management&#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#x2019;s ability to continue as a going concern within one year after the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09 &#x2013; <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers </div>(&#x201c;ASU 2014-09&#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6629340896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 2 &#x2014; Stock-Based Compensation</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div>  <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">As of March&nbsp;31, 2016, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), both which were amended and restated in March 2014 and approved by the Company&#x2019;s stockholders in May 2014. Stock-based compensation expense of $2,645 ($2,556 of expense related to the Incentive Plan and $89 of expense related to the ESPP) was recognized during the first three months of 2016, while $2,259 ($2,165 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first three months of 2015.</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $16,164 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&nbsp;31, 2016. That cost is expected to be recognized as follows: $4,840 during the remainder of 2016, $5,856 in 2017, $3,796 in 2018 and $1,672 in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Since March&nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2016, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of March 31, 2016, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 15; Value: 3 -->  <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 700px;">         <tr style="vertical-align: top; text-align: left">      <td style="width: 33%">&nbsp;</td>      <td style="width: 34%; text-align: center">       <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15       <!-- Field: /Sequence --></td>      <td style="width: 33%; text-align: right">&nbsp;</td>     </tr>       </table>  </div>  <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0"></div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div>  <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">         <tr style="vertical-align: bottom">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards <br />Available</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options <br />Outstanding</td>      <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td>      <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted <br />Average <br />Exercise <br />Price</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 10%; font-size: 10pt; text-align: right">16</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 10%; font-size: 10pt; text-align: right">10,671</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="width: 1%; font-size: 10pt">&nbsp;</td>      <td style="width: 1%; font-size: 10pt; text-align: left">$</td>      <td style="width: 10%; font-size: 10pt; text-align: right">7.50</td>      <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(13</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards cancelled</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">15</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards granted</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards exercised</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&#x2014;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">(79</td>      <td style="font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">2.32</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Stock option awards cancelled</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">109</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(109</td>      <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td>      <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">9.58</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; text-align: right">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>     <tr style="vertical-align: bottom; background-color: White">      <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance March&nbsp;31, 2016</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">127</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,483</td>      <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td>      <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>      <td style="font-size: 10pt; text-align: left">$</td>      <td style="font-size: 10pt; text-align: right">7.51</td>      <td style="font-size: 10pt; text-align: left">&nbsp;</td>     </tr>       </table>  </div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div>  <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">No stock option awards were granted under the Incentive Plan during the first three months of 2016.&nbsp;</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)</div></div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 463 shares remain available for purchase at March&nbsp;31, 2016. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 34 shares during the first three months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6905750736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 3 &#x2014; Collaborative and Other Research and Development Contracts</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>    <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;).</div> On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $13,314 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $36,169. As of March 31, 2016, a total of $17,623 has been awarded under exercised options within this contract.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;).</div> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of December 31, 2015 could be up to $34,002, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. As of March 31, 2016, a total of $29,875 has been awarded under exercised options within this contract. BCX4430 is the lead compound in the Company&#x2019;s BSAV research program.</div>    <!-- Field: Page; Sequence: 16; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On June 16, 2015, the Company and Seqirus UK Limited (&quot;SUL&quot;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &quot;SUL Agreement&quot;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &quot;Territory&quot;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted an NDA for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div>    <!-- Field: Page; Sequence: 17; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by the Licensors.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&#x2019;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June&nbsp;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.</div>  <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6629340896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 4 &#x2014; Royalty Monetization</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Overview</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of March 31, 2016, the PhaRMA Notes remain in default.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of March 31, 2016, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div>    <!-- Field: Page; Sequence: 19; Value: 3 -->    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">   &nbsp;  </div>  <!-- Field: /Page -->    <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2016 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March 31, 2016 and December&nbsp;31, 2015, no collateral was posted under the Currency Hedge Agreement. The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of March 31, 2016, the maximum amount of hedge collateral the Company may be required to post is $9,750.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6737081712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 5 &#x2014; Stockholders&#x2019; Equity</div></div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February 26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</div>  <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6733995664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $78,915, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of March&nbsp;31, 2016 reflects $562 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,403 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March 31, 2016, the Company believes that the costs of its investments are recoverable in all material respects.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">21,666</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">53</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">(6</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">21,728</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">20,718</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">94</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(3</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">20,832</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,438</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">32</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">26</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(8</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,488</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">63,822</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(17</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" margin: 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at March&nbsp;31, 2016 and December&nbsp;31, 2015.</div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">22,914</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">32,806</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,328</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2016 and December&nbsp;31, 2015, the Company had the following receivables.</div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,475</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,734</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,209</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,685</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,685</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">336</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">154</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">490</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,496</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,888</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,384</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">&nbsp;Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016 and December 31, 2015, the Company&#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following at March&nbsp;31, 2016 and December&nbsp;31, 2015:</div><div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Work in process</td> <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,949</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,612</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr> </table><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Income (Loss)</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. No reclassifications out of accumulated other comprehensive income (loss) were recorded during the three months ended March 31, 2016. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive income (loss).</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three months ended March&nbsp;31, 2016 and 2015:</div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">537</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,890</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,518</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,324</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,475</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi &amp; Co., Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">310</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,930</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,771</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,820</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,826</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended March&nbsp;31, 2016 and 2015 includes $1,338 and $1,315, respectively, related to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&nbsp;31, 2016 and 2015.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Lease, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div><div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company will not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three months ended March&nbsp;31, 2016 includes $132 related to the lease financing obligation.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At March 31, 2016, the lease financing obligation balance was $2,506 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&nbsp;31, 2016 and 2015 resulted in a loss of $2,753 and a gain of $464, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&nbsp;31, 2016 and December 31, 2015, no hedge collateral was posted under the agreement.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&nbsp;31, 2016 and 2015 does not include 1,330 and 3,529, respectively, of such potential common shares, as their impact would be anti-dilutive.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&#x2019;s product candidates in development.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 22.5pt; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-09: <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU 2016-09&#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No. 2016-02: <div style="display: inline; font-style: italic;">Leases (Topic 842)</div> (&#x201c;ASU 2016-02&#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01: <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU 2016-01&#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11: <div style="display: inline; font-style: italic;">Inventory - Simplifying the Measurement of Inventory </div>(&#x201c;ASU 2015-11&#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In April 2015, the FASB issued Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Simplifying the Presentation of Debt Issuance Costs </div>(&#x201c;ASU 2015-03&#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">  &nbsp; </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15 &#x2013; <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern </div>(&#x201c;ASU 2014-15&#x201d;)<div style="display: inline; font-style: italic;">,</div> which defines management&#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#x2019;s ability to continue as a going concern within one year after the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</div><div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09 &#x2013; <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers </div>(&#x201c;ASU 2014-09&#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65670824&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6629781312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">21,666</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">53</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">(6</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">21,728</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">20,718</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">94</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(3</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">20,832</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,438</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">32</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">26</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(8</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,488</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">63,822</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">179</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(17</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Amortized <br />Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Accrued <br />Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Gross <br />Unrealized <br />Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Estimated <br />Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 8%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1.1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">22,914</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">32,806</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">8,328</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">64,048</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">March&nbsp;31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,475</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,734</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,209</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,685</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,685</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">336</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">154</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">490</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,496</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,888</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,384</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt">&nbsp;Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left; padding-bottom: 1.1pt">Work in process</td> <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,949</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">1,612</td> <td style="width: 1%; border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">537</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,890</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,518</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,324</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,475</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Shionogi &amp; Co., Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">310</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">&#x2014;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,930</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,771</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,820</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,826</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6737059008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Awards <br />Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Options <br />Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.1pt solid">Weighted <br />Average <br />Exercise <br />Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">16</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">10,671</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7.50</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(13</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">15</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(79</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2.32</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.1pt; padding-left: 20pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">109</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: right">(109</td> <td style="border-bottom: Black 1.1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1.1pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">9.58</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance March&nbsp;31, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">127</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,483</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">7.51</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6750135392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember', window );">Debt Issuance Costs Reclassifed from Other Current Assets [Member] | December 31, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior Period Reclassification Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Revenue from Sale of Inventory to be Recognized When the Inventory Transfer Is Complete [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">3,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">1,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember', window );">Agreement [Member] | CSL [Member] | RAPIVABMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">21,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVABMember | Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338,000<span></span>
</td>
<td class="nump">1,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital Leases, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityOfInvestments', window );">Maturity of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,820,000<span></span>
</td>
<td class="nump">6,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="nump">$ 1,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreationDateAxis=bcrx_December312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreationDateAxis=bcrx_December312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RevenueFromSaleOfInventoryToBeRecognizedWhenTheInventoryTransferIsCompleteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735924720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 21,666<span></span>
</td>
<td class="nump">$ 26,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">$ (99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,728<span></span>
</td>
<td class="nump">26,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">20,718<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">20,832<span></span>
</td>
<td class="nump">21,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">21,438<span></span>
</td>
<td class="nump">21,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,488<span></span>
</td>
<td class="nump">21,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">63,822<span></span>
</td>
<td class="nump">70,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 64,048<span></span>
</td>
<td class="nump">$ 70,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6733827072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 22,914<span></span>
</td>
<td class="nump">$ 22,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">32,806<span></span>
</td>
<td class="nump">28,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
<td class="nump">8,328<span></span>
</td>
<td class="nump">19,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 64,048<span></span>
</td>
<td class="nump">$ 70,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt maturities after two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746201344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 2,475<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">$ 5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,209<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 1,685<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 1,685<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">4,496<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">5,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 7,384<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6907172544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6739978752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 2,324<span></span>
</td>
<td class="nump">$ 4,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,820<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6747283696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Details Textual)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Stock Options and Restricted Stock [Member] | Vest 50% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMilestonesAchieved', window );">Number of Milestones Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 2,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockbasedCompensationPlans', window );">Number of Stock-based Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,645<span></span>
</td>
<td class="nump">$ 2,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockbasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfStockbasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6733749968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock Incentive Plan Activities (Details) - Incentive Plan [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock unit awards granted (in shares)</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock unit awards cancelled (in shares)</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">10,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised (in shares)</a></td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled (in shares)</a></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled (in shares)</a></td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">10,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6747792176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>May. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement', window );">Stock Issued During Period, Value, for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PaymentsForModificationOfLicenseAgreement', window );">Payments for Modification of License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementPeriodOfcontract', window );">Collaborative Agreement Period of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived', window );">Collaboration Agreement Additional Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyTerm', window );">Royalty Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaboration agreement additional payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborationAgreementAdditionalPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementPeriodOfcontract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement period of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementPeriodOfcontract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments for modifications of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PaymentsForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the date of the Agreement and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock issued during period value for modification of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6746651632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member] | Japan, Yen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="nump">22,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">4,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=bcrx_JapanYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=bcrx_JapanYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6737914112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Nov. 06, 2013</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RemainingAggregateOfferingPrice', window );">Remaining Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RemainingAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RemainingAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *1PJ4C[QI0%D@$  #$1   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%<H1+\@$DVC56_9+MI^_?8:4$0!=1"
M(^TECC.[.V.O/8=,7G<&W& KA7+3I/+>W!/B\@HD<ZDVH )2:BN9#U.[)(;E
M*[8$DHU&8Y)KY4'YH8\UDMGDN09K>0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2
MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M( ^R?-(TX.0^A,Q98X2H +T7J_$Z
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M^[E'$,*6]",WF/<G.AK^ X;2XY2>'\\%[2H[ZS_0T1M#<&B@V:#_2.]B7CW
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MEQ-65AG7'E,_HK-757X!4$L#!!0    ( *1PJ4B97)PC$ 8  )PG   3
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M7TQPKI%6F P3GZ:FHHG7<P;J,U"_ 90$D#?IP_Z9=#2R$!1H1WECH ,&.F@
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MJX4";05J8J YT,?5_K@)B AX%3#:BY@$[R?$]Y#\K@\T"Q9 0N6" O?+&9Y
MRB#D&_^=-+]:!N)E/*O_C--Z]R=NX0GEFZA=Y\UFE-30\$&Z%QQ_P33"-@A6
M*&W\DFJP#M5,H43QC[0*'=<Q_;G?3;3;A'PBY OA(8O&4Z-H\P=WO"P,CL3V
M/)S=:N_A)HAX9>*]63]VU#1Q\+(XEZM\7;!S$+K").)QPBP(YM5OMLCI+7H>
MZ?GW]/4U?9<<KB>'V?<"FVN!=1+83 *;6R,FS''&;/]KPB[V5(%IX]6QI,)!
MN[2E2W6YG8]Y/),O>%GTO(4_W+1"6W)"YT\V'D"#Z,"WS^ZVE'3^_2R)A,:%
M\-[')EVIE#CLYP>RO-+R$U!+ P04    " "D<*E(JQC7=Z4!  "Q P  &
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(53VVZC,!#]%<L?4!.2IE%$D)JN
MJN[#2E4?=I\=&,"J[6%M$[I_O[X 3:I(?<$SPSEGSOA2C&C>;0?@R(>2VAYH
MYUR_9\Q6'2AN[[ '[?\T:!1W/C4ML[T!7D>2DBS/LBU37&A:%K'V:LH"!R>%
MAE=#[* 4-_^.('$\T!6="V^B[5PHL+)@"Z\6"K05J(F!YD ?5_OC)B BX+>
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MT@V!8Z!I,6P/ XH^;,^*3=M")=&5Y+C[^^EBNTD1H"\229US2(I2.:%YM3V
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MV<QTSSE0*H@4%KY(NRKYD3$-&G(0ZA4I'TW;-0-!^_$K8OJ4*?X#4$L#!!0
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M;9J"@T]-AXXFW8T/F=G7[=>X;5U_:]8_U/8\7 *.-Y&K_P%02P,$%     @
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M!.Z,!DR*2+H[$3!TA4.+*)8-DD>#Q.286(/ULD'J-$BM0?E89*\UF<G2:)Y
ML@S)G)#,0-)X!F(T(%MFY$Y&;AE@AF$T(%]F%$Y&81EPAF$T(,X+CW_%VHE9
M6TSBPI0&8S3%RN-YE4Y(:2'I3"U&\U24RQ 0.REZ6V&RF5JL"*X2Z $";I#M
MUC2?J<>*0.Q3$'1SH \'VH[Q KD[&]C63HNY)V=$Y2KS. " ^P0 J4?G6!&
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M^:XX5?)1G-<<QA!KP8VHNO[7VYPZ*6I+\;VZ>#7[LNGW9_-/1H"&$Q@0V(7
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M'&!DP)Z!8O+L]Y<?,W5O7?7S[-V[<]I:\SO<XKW@(=0J$"? N@',M"Z)2/@
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M\D/NA]/"9UR<G[;>! [$4Y&>B!U)U4JD9S;FXG/#'5#TP"Y(U5U$#^QE$<A
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MC7@DCPK3$N66>7LH3&58N@Z>Q3LS,/X&'&!5FFB*KB7AR&$^IQRS)?7*H[U
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M/I@#^'\OL].]PQ.W)9'/93(]Q@TY.)GQADRPT%J*A,D&>Y3@GF2T[#W=#!R
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M\[N<.1SZ$E\<4]6KN["X.SM9XAOYYG-B)IQ_)HY(ITLRR(Y1$10P/ MZ3[S
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MYQ$7(H,AD9_ 8<U+;N<JTS+#R@S)Q]77Y5?T:0VM9L6^^R7%M;> J0=G%4!
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M8>G'XH'NM1L>Z%[P67I8E^6)5] X)3%<9!'SPJ2N2N0@ER(F-77"_5R_%ZX
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M0V]N=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @ I'"I2$AU!>[%    *P(
M  L              ( !PP$  %]R96QS+RYR96QS4$L! A0#%     @ I'"I
M2+:A'7%. 0  Q0\  !H              ( !L0(  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ I'"I2*6@G<Q_ @  -P@  !
M         ( !-P0  &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "D<*E(
M-$+'2C\!  !I P  $0              @ 'D!@  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "D<*E(F5R<(Q &  "<)P  $P              @ %2
M"   >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *1PJ4@QNVYE70(
M -(*   -              "  9,.  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ I'"I2.2*HNDI P  9PD   \              ( !&Q$  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( *1PJ4B'3$3/:P(  .((   8
M  "  7$4  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "D
M<*E(*#BJ;A $   _%   &               @ $2%P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ I'"I2,Y+G! 9 @  2@<  !@
M         ( !6!L  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( *1PJ4@S2C'-6P,  .8-   8              "  :<=  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "D<*E(3QHR>PX$   D$P
M&               @ $X(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ I'"I2##%#0NE 0  L0,  !@              ( !?"4  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *1PJ4@G[/$-I0$
M +$#   8              "  5<G  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "D<*E(JQC7=Z4!  "Q P  &               @ $R
M*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ I'"I2(&4
M)(JE 0  L0,  !@              ( !#2L  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( *1PJ4@>O,(EI@$  +$#   9
M  "  >@L  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MI'"I2/\[\H/* @  DPP  !D              ( !Q2X  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "D<*E(=Y5@0MP!  !%!0  &0
M            @ '&,0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( *1PJ4C5_L1CIP$  +$#   9              "  =DS  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ I'"I2$41\0G=!
MSQH  !D              ( !MS4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "D<*E(0Z=<$!<#  "F#@  &0              @ '+
M.@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *1PJ4@/
M^_R"W0$  !@%   9              "  1D^  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ I'"I2+^A9E?' @  1PP  !D
M     ( !+4   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *1PJ4CC?&ML60,  "\0   9              "
M 7A.  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ I'"I
M2$<T]KP? P  F@X  !D              ( !"%(  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "D<*E(PS7#MIX!  #5 P  &0
M        @ %>50  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( *1PJ4@=8X2RI7T  /G* 0 4              "  3-7  !X;"]S:&%R
C9613=')I;F=S+GAM;%!+!08     (0 A -D(   *U0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.4.0.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>220</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation</Role>
      <ShortName>Note 2 - Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization</Role>
      <ShortName>Note 4 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</ParentRole>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 1 - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 1 - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 1 - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 1 - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-inventory-details</Role>
      <ShortName>Note 1 - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 1 - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-1-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 2 - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-details-textual</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-2-stockbased-compensation-tables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-2-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 2 - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization-details-textual</Role>
      <ShortName>Note 4 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-4-royalty-monetization</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity-details-textual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160331/role/statement-note-5-stockholders-equity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcrx-20160331.xml</File>
    <File>bcrx-20160331.xsd</File>
    <File>bcrx-20160331_cal.xml</File>
    <File>bcrx-20160331_def.xml</File>
    <File>bcrx-20160331_lab.xml</File>
    <File>bcrx-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001171843-16-009811-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-16-009811-xbrl.zip
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M9 @A%H@68?+E[N\H;7Q";<) J+/H@HWB=/05"';*$>RT-/S6A?[@&)\'X3S
M6_2-T.PVS#(T!^TGB2;J>&/T=K/H>GS!Y@$8OBN1+%W+5O.QD2R'VBQ=&K,W
M>#2P.W6S>:A-US5+%ZK??XH8;[GIFN4KVW^\75>%YS:[KEFZF$WSL9$LA[I5
MNC;-P<$$/[+/1RN6(XSAU6N??9Z&03*9?GX(?L=+J ^@Z_V+5+W-94FK5--H
M-?N-[CIX;0;C4=!>O9C]TL7LMP:=)X&V>O<S/KQ-<$G=[!TJL"2]-=-OR?*W
M:&+.\CNSBCNR,N?-*(CC8/:BP,U3ZFA:X1Y:\H\L!Z48 LLZGQT>/#/7F0$0
M!7KXO[QHO=AD-CWBQ*:(#G7Q* %XYUG "P2&$8$1YA PR (_"J*=:@]G-?_
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MLJE-&R1QW>/E<GFR*X7R2,]#EH[D\%RF:2U36ETY$U.Y29=#HC@[9[2TRC>
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M7G5'@:/=B#OV="=7[+WVH!3;?B&ZI5"OB^9[WSDRCIW&CCARD$L0O+,\*UR
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M9E/S?9()ZGW@U>^BA&<3Z[@*L>0;ET2[!,M;K2'1E\!1KV=@J5&I)Q^E5/R
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M0N&J#!2$P$EX@H"Z'S5^1T>SNL@'<OPC ;7,-.K<5&\U^)7^]G#1'P_(%26
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M\NH#H""DI)40*T751CF;0I%Y0685<@?A63K5U(HTCL'UMA+?GA;0-*LY&SX
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M*]!U4@1X$CWYWPW+IJW+W7TU8QCAO2<205R#@L5"=TA \RE&-0N/Q4\F5;D
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M$GA]G01=:C*DDBN"6K(>WK<"3?Z$0U-XD02,FB-;**6$MG3'N:%3I]L,NM/
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M1G('8+B#,N7I(MQ*Z[BI<W?$%@$50--JRW"600ZGEZDB'+ ,[1Q^.#;EH[0
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M@.Q[,EX3Z U9UPH>-,07&0RA_QQD+N:>E'&0\<$MD/ EW \0TX+DK#<M^W
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M:FO1L)DUX'N@3:[EU6S6^8_/NP^\2900G[B<[NUWD0THZ6BSCE +64C#7NK
MV!CJM21N,W?H5NVNS>#^' <;-]UJ#J;UJOZ!NK??#\(Z=%HPW=-=@Q7CQ0Q?
M60 U8P.X*?*_W[-JH-[VG?R7BNHM=JFS+TQSUFO9N_6=;-UJ!'#]&U^9%([W
MJK.HW3ACL>0\;S>Z0#HGYQ?50UFPZ141]%'<R[74V"KHO'<ZQVL:W[P)C,N=
M28T"[*1SO"(F5X=QPP9"P#<.+H^MN#S4"9&!JH]G*WZ/FI[3'4ZVWD'#(6>?
M0NU3IN>KEJD%.0*.P*J7[7]ELB9F+Y>%+O;DKC-9@&?00O3JY$G=*EB7V9:Y
M&):Q%X-J9_KMD >!DS=+=*P8>*)\OO=P $\/92XJMLZE.LXC[WW01]T4BU+U
M\S[\"LQZ87]"I?SIL+@+9/7)@A<,,<E3KO^NS!+JUT,K#*/OA2YH6+ "MAA*
M-(AUO:)Y"5/)KY 698UH4W6]JB$M=TW!OK8R(1>S;!%W,;4>UF=-B=C2LQ.H
MGMBZF;0L Y+E:TO;4U-]1.Y0"U4JZ*X'LD ZM(B',V7U&R,L[,,_:A"HJC3^
MPI(-Z?31':>IA6^E^)! W*0W0&\G=0\!>>&X?3&F]G\]NCGR?K^\_.RZ%1D=
M.'DEQH;HMY&XRPG?T_J+3&7V\"@H(OA/RNV7A578I=KDFSNU2/ !OH.JGX*B
MJ>0S+[$XB=U^DV!&Y-)GOH'UW:#[(\O ,XH2[8[4W\K:4#AZU0P?:Q,DI>,O
MRP0S]56K<NZU;"7<PZ4KXT*GW%,C[EPXO(1I$Z"C'9><^S]-.16<LN&)FFZ%
M*E>@'3E)_<*JRM;M.?(2N4DD&X7('2TJC&4D^=;?M/1=AJGNB1>F=RHSW;GM
MY@[9M]<]8-TP9$K]0O!&$^_&:CN^C6[?A"J F=V?A"XJ%>5CZ96(X[6]J:OI
M-2MJ0U^)V[U'%KI*1&T595K)%OV=4J2-U^FT^],_/O?^L\*N#'R[VY 1=_K;
M3R3K]#^QJ[64<S6;[<%F3Y[*9K7LI8QXEKPU>P(M^//9/NQIAX:A,@I.3\_:
M@(YN^S^=\^Z;#7!B%1Y@Y]DE^03K5#&\BJCE"GJ:R]Q"41R+4);DJ7S5K=9&
M?+T!A18^X3OSAPCB8@S+_5&"W2(=XC5VMF,>GAXW^I>ZQY782"T"=XOCKTG_
M:6"Y.:O]K'>\/UA^)&PT.MQ.NNV+_<'&KN[US1C4NW04X<RO]'VQ+!9S>MSH
MU^^<GA_N\ *,6CB\5\;:+F_BVE32/&GA"5#)(]PZ\5>4E?G7?ZT6 3T];G2L
M]GJG^X[.1[ET:R*T.5&S<_*D9.3:&V\,=I"#?E\VOOK%7+#5QF23X^.+)WIK
M%NRV6;D^/S]_V-TN@*I1&3WKG3_413M9OSC\*9A5%E:;E-IM*!!;P]Y3,9A.
M&E7:DY,'DZ[WP/(C8:,QIV6_L/%4#*;FN/WQZ4/9GT_J"B^WEQK3"G;$[K9/
M)*>-ZN@3()+],Y=.FXN:.@^EY#ZM.[<N0IM[E#R4:ODP]W+=?3<KU;T]VO@V
MK*731DW]]&SO6="ZQM)ILU?XY/2!S9(%4#7G3'>I/=%]H=HT4ZY[R)3;6G&@
M.A/5.#...2C]M$H%UT_;F=OZP-FZFT5'+3PIZ2+WPE*H7":5V&--<<]$-.F7
M64XE;YF,#W.75^RMEDYEC3%F<.G<%\H7,J82YGJPL40/DKGD*7O)!XJCGG (
MG;L#I>714U*T>%__Y4GAXHX+NOGZOM+H%)^:<E$1)8Q1*T_X&25\Y<)Y'V)'
MM8ZF?8<R5TA@0V#&";;V%!XW/TWO9&=ZZEO:IVQ"6"G*QYSG0KV239MI:C[L
MS0V1)Q!5>:(A#E6GZ&9;C0.>'S%,\?4\A$]O8+T<LRU0*S7IQK_E:!$1QU/L
M:YJ,*/L;_YU/@X'ZMP2EC^27M8@TISG H_YZZ=U%83'^S3MKMZ??^3+S\IEZ
M]E;@I*4@5G>/N\=;OPS5+VMYE[N9(ES^7!UW\N0F3>_ZH\XJ;X!] CJ2__VI
MT_EIG=?9S :GCXKLI2>1J"!X%6,*),'A48M.@H8(;8ZD3JN@_5IDSQ;5O<?!
M-*N!/\16E1KX0VSV2PJ*Q2;W!=X#ZXXR$+,ALKPT^\W+1OT7W?:Q#^:-WSTY
M^:7N3DE.>-KYGSDUS-U.+(:,MW7D;?/9R??6O';E:]V\1 /D/R]?J[ULL0R/
MFU;K^L=G)UN$;K,M/QVLG?6.#UA;$VLG?K=]\2A8VY3G_'L,VO(*PKL!,*6%
M6P#B7_@_T$V/O/=%>+2R0+B_@G!O4EOQ/#O^Z?D"WO%@\.PO1HPY=;P+L/87
M,0],*H^A8RR%<9&:-F^*KX&,>VI_K@'9J+EM4T9M^"Y#+[W>G-VUFQT=#@,N
M[\D"7>=P&(][&,<7[5WNZ+$TJ^<G G<*U.XA.*!E[]"RIUI3]ZA[(H^&'$JV
MTWX#V6 M>V^&S6O0),-8;,&(WO@EEESPCR_6U9GNM9VM".IG?AA=__S\_' 8
M^W$89W[O?%T%=LN'87/:7RG\9_YYB$#N?5CLL2*0S7'M343W4\/V(0AY"$(>
M@I _4A!R-;?Y(:K6$%4[6>0L/6!MQU@[Q"(?PU]R?+H@LORC^H\.D<A')I0]
M]:C5:6J'B.1Z<9=N9Z=QE\-A.(>QKG/M<!8/=Q:]G1[&[M2K0^1B._[9T[,%
M$OG@*G_,HP"KZ'3'KO+#8>A[X7>/>[L]C&W$+?:T^.\#/#6.9UZ4W*;H7Z-Z
MMKSL3Z)"UK.M6Y9WSQI ;J:N2M8B "3.4T]@S7C,BTTDJ&I1H4#!-M\@8E0Q
MH>[$G04X=0]0/2T9HHA;98/8$UD\4\-\LV!0.&\W1N/%R]P#\3G YZD6$M]6
MY.X;Y7LDXO[$CP':H RCPNO/#/Y^Q_[:"0)]C[[NCTHY^U>-*T>\>3B#Z<<J
MQG7K4.]9B\L/ _'*J7B[*F1=Y>1J2^D7=EZOCKS$H4N7@T$YX6O/ X,!*9D8
MBR2/;L55,D@G0M;F\]C,5P*P*;X$W]>=(N6,^CYM;-'D=@C8'KB/BHG%P[^<
MH8>GS4.1JNT2'@X9+&\ND_"-D39R2/9FP\(ZS5U7VB=S33D6@+$1Q.O,8NLT
M]DOIG'6ZU=8[VX&8+^VZ/2TNVH>>%MN2HI;"91V/)\_G60O21GUN22L*%(.#
M,2S'0E#(RT<C9Z*$QD2'1]YUTR+R]Z@B#N(R%"@I/:DLTAP7I3G.O]F2URC&
M[1_( 2RU^T$!.X2;EN*OE+8P@'=%*')!K[X,;TE23X,93VA"O6&4IB$-S\F5
MVDZC8^XB +=/,VA"_!:8+.C*4M>0TVL:$0AZ='3+PSMYCM10(+;H=X-@2J3Y
M-V+OAD;N2,U%J32C!+_$R=L.SNVA2 PTKXW#HS(&TOZ)W@[^:BHRG+*]UH'Y
M"!CH*SP6/"K$)/=QH3Q-$A'S4?GRQZC7@&H59+3E!+6@1 PC_ &PC7((".%I
MZ_*I =Q7=,?Y .X(!5R:S;C;2)%^C] 3-YJ9'6CHT8IX??V)5J5I53&_+2^G
MTSC"1BCX+[0NQB((23>3$^[5C"R$ :CC%B<?E_!P"&I=A$/."AP)1A/ >'!'
M9-EOTBS[@";.(@)TMTJ'+?<I&ZD(_>^\ *15#X>-I"@+6]02C+9ZQ"/>B>S4
M0W/XX%%C@T%6JD6,\JMG&4ETRI%38 Y.04+2T'9I#2H3D'&JQA;)Q6EXN@A]
M5($S'%>4X3_8PBRG:=*,E31IC5+NM8+CK10&8R0]'J6F"'6 ,YWBF46M#\D7
M'W+MRS"DH52XG6H+FMR+>1RR%ZBYV3G/"*.S]_#LB9;E/"[O,NZ+#&15E, )
MP%EA0R8QHM%8'T08#= P@;__(_(Q& G>UP090H[3N)SN/I=O7W_Z4.GO<Y6$
M<*QXD31?\"D#P'WTZKJN,1#9\^9E ,)E'/2#28!&CYF(XR[U]?)592F>3R=I
MRAL*UW&2E_T:=,%EP"%YA4B(H>-#KMM$,S/K><WV@UP+,% %:4@6[&4F&;#E
ML^%.;2P0Q@$PB+[ \5Z2G2/SD] /:%"?'&5'[YWC^Q9GUU=2O4R^2?V&9JOQ
M-6W8E;WYNFT]V8OS1J',:;UE-I[A1,$<Q14<;*MZLB"?@BBLF/\N-PH&02@F
MT8"N60*DR]R+[/\IL7>2%"#K^<WD>E#B @RN"<YAANNB'I<BAV2D^Z0")2VS
MFK<B/Y^DH3;W6,62$FJ>XI6?0I.4QL@=>1UPJIVA4$W=R%;2LK"W1UQ%TTP%
M"JL!6;T+<!X!M'^D=A[Y*.$BH8(S#-'ID:II>',$S\^8J^&2>Q]T&W&K+B!P
MQYS&*H*R1.-),Q&P$S:8XILRG#,)T@.$U@!P96&(>2N-ZDOE-$H)P-I^F*5&
MWIQ5"-P51PV^#G)\#/\/CN:Z#6+"?V-S_F5/UG\J9^+%B.4LB-^EV6L@@ZB8
M;S;I^"B:)Q!UCMO5KHZ+X5IO_Y?%:SG \/]H8.%#H..:>^,9']HR9#0Z"$XJ
M0ZS7W-W#H*9YU/5QHV^F<W%:G7"SRYTL'=K=?"2=T\Y6SZ0 P2K"MT&& WAS
MR_\&@@DTK?M,1;]H[%K;.ND!N56=9,M V!SDI?B^:.0'K9-.^Z)SMB'(Q'NO
MC;*S:?/7BX.C;%N.,I;+UMG\(*XQHX3D1O&O-H&5+@+6]IJ]/V9 J&[-JOPB
M;A"+_#J@QL1L%F3R;PH2DPT.-XI]-GPL-)=[R:]Y472V24/;-#LU,[XSFN7^
MF_<B^L7@%WT[98"A!0\L=<#<@.S*(+%WQ$IJ_A(>M9^5;BBV;].!5#]MKYK1
M3I4KC=:P%V$O!1BW6<6QEZ'?0JJ0_7+&0]"'T7=^A0K/!93B@)AX$=U:R^(!
MBD%AC:@&Q.4I_GZ&.F%)!M/]B:MWU#[9JJ7D+$3_[72.3M9A2S57^_4<&5-(
MR6OTC5MS;IEVKQ4EWYL--&WL@2__4:_A?-2]HGNNC"YT)IB.RL:TY+GBYM]L
MU#?P ')CS#MTE=VC';I"RDQD# -T1$1D9$UCH&GM9+%]1TGJ#<M,F9M@")5X
MLZ7'C/P!:1_XK,K2R.864*OSTDT/4F8(_0+O5JX'GRN#],A[QXX:5*K)C8*_
M9Q22\]/X:LAXJ[A6I /=?OM2AXDU3CZ4WA$3F2>W)RP42"ZE4U^:MZ#1*WFR
M]LLQPXUR0H3Q R$RX:=#T*@LWRC\?SFZGGP'8[PRN?*H&GC5&A+N"F7 LNB-
MQ9L9S[;DNVDD^@=>_BM1PD!DJ!0N=)?/>SE<5ZDDKGSN+MINY\B<&S F:WU0
MQ@J3[C%(.4BBSMIU--BR7W=2ESH Q[LHD(04')'44 <K?;0J@).PWVJYL'D*
M)UR_]CO,>;$E UUO3)J+;X4,UTE5 - ^23/\$%"7)G =8GK&YXP8>12^#DP
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MBI!)HLI02)4!'E"J"O(KM"2!15'9CX%#.CU-G%061V9$N^SM,*85[5,Y<4'
M3H*!**E3&BKB6!LV>\+D)JUQ#JLP\\ZK/ \=3 /D'11*HP,*I!7&@?-1&?%W
M5"8TK[21*N8&(X%41O!H@G(JD+%N:H5C<@&>JF5OHY?2R>#"C0!9?VN-,1\
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M/#AB]LR5L@XK&*!N$L?/@ADLTJ0.M'] S--B"@^@%-S0]4^Y*^6STP4.]'Y
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M)P8D58*V%N"493R*$/@>[ UCQ&*1FPKVYBZ)LHYV>?G9%1I#TN/@**.)!2B
M!"Q:C0G'E:.$A3HKTRG+LTZ[]?^S<I""!5[HRX:6FKQC44)^?8X3PR^':5K
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M<T?@U@X.G#I ?,KWRH1-T03^TDOC5\C8E:G-U JFM15Z *,1.6G&41(6\8-
MWLZZM<:8+D4+-:6)</T<9OC%I.U'XF[^*J*^7 <&%G-P:B* 8]G <"'@*E*Q
M'Q?P(<;N  D"<PYEAA6&H8@%T=.#*!N4$\R?(GG-_G;!E[ZP37/#>I"?DJA
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M2O[WI\[%3^N\T_;R8$Q;9"^]9=/3"*05IN\H\-38C!_D!'J/<P"7:.*3?H0
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M:QQ.Z+GYJ^_GZ=V*\W-%WRHOY3X21ODT#F:_ 3?!4<YUGJ[5'Z,OX3/@3M&
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M)ZD:XM)$98'C_]SM^&=G9^H\JB C- Z_I2BT<P952\JR0:6-DF,+RA"5IJQ
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M= ]I!RQ11<FEJR@-S8:&X\1N$,B< 2"?_,?XX^EXED<#=)1PXS+XW3C-:68
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M;=$RF-QA)G_0  K1JK2"=>$F;%!G- /D%VRQCIJ1;U&6,6YEL($F1QCF: T
M)-6:5S93Q]#+S/)G?L@5'*S3U(K?"/_H HOR9D"[NDDEM^+3$T;D\F1KL^H,
M2C@ -)6^;<V@C4<AL5Y1!WX%$]SMC1N26*3)UPN'HV)K_8 )40[)EBV0\*2#
M'"Y=G&*KL1H!;"TMMYRYE,U."NQ(A2K\YHJ(I7_TNE4=HQDE^^6&6,W+73 2
M/+5W?]FQ]Z5"0B*\ZY^T3YVA<:K'=N#%&'TBC</TN$EUJ,)H.&K!W&@XL!*Z
M1XF .%:'<9Y).3'T:<;N+( 5%:2?C_WSWL5F1W-\--_];TOB;.>:P6OJ0#;
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M$M-DQ&#(F0Y*@:7DTPG"6!_<>1."0):H^ Q&&Z :@.?3=9Z#R'C]HNQ?*4R
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M!EP4\#P#BM67TY-9B298=J+C;V8<_F4PXAK4>0$=R3\9,!?LL6Q;7?X *D3
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MA_.1JXW-OW]^GT3UH>,\?S"R\+3A?<_'[W$R?>':^<(+>G]]_,?_U&H_J]\
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M+K52>3ZDL<NFX@[72!+L*=IHE8TD8MKK(TGYN"33'78=)-F>@W#GDGSL^;?
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M(!S=PZZ>.L!![[M8VE%Q5VCXL1 -88P#+=OGV+2>=^*F7[FM3\ .GD<F H<
MQ 8X8@6$<=+&AHETYOJ12U?4$\MXJH !X_C[1,#[M]T58OY:B)@3/16EA-/>
MX@Z%LT:1</K1Y48X=":A<*\<4S_84JR)YZ_MA>"P(/A?)\ZCI-:N</"W0AQ@
M>#(*F[5N4\V^<@N?AHY\+CR72F73WP/FK_<U<'&E7=GW8Z%]3^.9(6KUS]:5
M;O;UVG=72!?_V,/:M9OHR/;'1WG;[PH-W\6_WI87[4-\VR<3;R^@="9"5T Z
M_@:+#>O=@Q;RM4.M=''0$8YVUM\52#XT7H.\0:"#H>Y2GS!/V3Y]]@/B'=3M
MY&7I"EHGW\3_7(;26@^AM&\HG!(F[17Q HH6A46?]A>$KY4='D<*<Z.3M3YU
M&5M[?\2U;+<K=/U0BJYK$,SZ%05#U(!@VGV!8']6UG CF3[CC[T:0^H-2GC0
MR T\F'(6Q \DGA&8"EENV\ZPU+;AKL!4D9>-);-N(\DLD*P"56]H2HP:+!9$
MKO4\0QW*5CILZ! TU?5WA8WB+*W&1BB GILV KPA(+$0#EGN"[!19T;?KK(K
M.Q?G5M'.P[C--],6#S[HGN";C>Q<Y5V9NSB%NC6LP];?#+]S7=KQBJ9^0UT!
MHCCG6KT2?EN,%!D-S^S@$=,5M9<>X; >A=\,C^)VY2+J-]01.CYL966SZ,#S
M0*$DUCU( JO:6)(WU]'!!FK7WJ536;J"6'&^=K_-W3<756MCMFM\U6RE*^04
M)W'+MH/?,%%G+[=K2-1KI"M$%.=>RS:07Q4B/O?SE]RB)]G+</HJ7'3UWR(3
MI?WI6<^7 >UI$.']H?\.KB[N;@?<'8YN;NEB0F5/7^X[ZQ45,/3B>*\HK$0%
M4"OS VSR)RF"Y5E/OP_A$P/<]*SP_E#XRHI/KE@0QH=0@)KTK) P/';_H G=
M($R5I^_W[19_?#\Z'XPN!_&$D5.BM/A@JFQ$=QQHVKUZQG"<*KUWL$;XGGL
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MTQGC'#0HU*Z*^AMJU=QX>4&O(-"JJ5-":I)"8P"X7,/R)-J424F=6P$TYC)
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MP-P9*V6XC#H/N82&7$+21MT3*RXQDWG%XJ+@L[*MBO2>I$&"^UETG U)GQX
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M?8^!8)J9O>2(.O#*):[O,CCL-X1QXX7L-R_*R,5F]^.O(6'BZ8B?9$]$5>;
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M-YX?YA^6R@"TCXT,K;,[.1U'?[22P3:*^%)E7L3%Z)*1(%0L!FUC.REUQ<[
M)?C+FL;762$/_#?C]9K1)R]2D6?4]60)=144 MI;29_[F-XF2>;Q_33W0-[%
M<Y) O,L5Q:"*5\@BF$9.<MNQK,#Q\R'?O^5_^Z@B5=[. AG_N)^6M8EFV>/=
MW:6<$'5+"Z3<%:^JE&UVH5^3.3]=R>Z?XSB8T7GZC6M6<CI;#&,#A/ <WWG*
M3QZC<)&?_)\)IZ*4J%JJ#?K9()/&"[[GK?9':VFGV7SB.M(J6]72".UD@<#M
MR(6%0:$W*!M:)$1YJB=*_:#A$!:)7Y=?GBVY3O7P8@I5! .ZV2 RY.A3&I-[
M;U,(U;-, C5-+1!SO_2FG\9YT5'Y%B-M9(& Z?C^]K?QA?SCM0UL?)@LLBC?
M-V?9>LTGO#1Z":W(B[T@]$3TT_67(P4D$8HZWZK*@+@_23#UA$AO)EPO%F%$
M(O!^*_M<@FCTI-$H')-BA9D%P5R7$";QBIWT@5Z0/7F_+TG\L"3[OS(O3N:$
MW2;BU2 BJ>*@.]4W[,%G^Q#)4G7@T[9;PR_C*#FA"I -1[(!I?C<WKJOF!!U
MTZ;/_?QD^&%!G]X$)!0/$A_$#X+0#Y4'?EG1\9(\=4UR%"39,AM"29-4<*]0
M)ZOQWKT7_$KL:G^604\OPS E-AQ(%P= .#.#,,I$].S^(>3ZV8^RH+AXB1TI
M2TNR#V/V.*CL2&$YR=@.6,/XKKPH@KKXUO:9QM[^-_F.[?GY"V+M]M-RE.\$
MKGO/A$MO':9>E%_VDIN,:]FDO#J5"FURE<ELR$9]793MV#ZCC2-&O&!SS_<:
M$HP7"\;WT93LO/]D\$S[NZE,DG$2=P\)2N'4M'9!?L42(8)F+TCL+U=<AU8Z
M^D"[G0T@!-O$$86;'8T*SQAH-Q2 'C@19E@.>R" P;4'\0MO0=Y"<=1T00!$
M\-9LT1SWZ#D,#,L^$\E7UAY+-Y^]E7IYR)LZ()P?V(*A5_R<5A$M:>: X"Q)
MZ8JP(W%0G^BP7MW#N2HDM[SF>='.]281K%9B,NEZ=L#<+_EM;J7R!6L<!/D;
MEVP%Z9J[!U"Y?ZD/>'A';*"4!XQ)U[,#AF$]L?#)$V] PF]")-0! --WZ3T0
M3#/S"Z=G$N__K84CZ^ 2Q&V<I"P3XB\4 .4^I^_B$L@=31*CV9!UZ![$#64D
M7,37S_Y2[$5;J5>J!: ^#J!D+ [%D]XX#F["9_&3^NE3WZ%[$,(!+(P75T3X
MQ1;NSO)UH6Z,@7CE9JMKWEL [D^*@PRD$OHEK5R0NW,[*BL+2"F6->R>Z-R*
M %?6=<UQ %#*N[Y#KT&X7[8Y;4L:!;<KX8Q3W+659QB@AP,8I9.C<!'6K0I%
M4_>$JP5)V;B7Q+M? :4WHE+F:]LX(+6P'*M)K6O3/:D'V6_#V _7$4FN/19M
MQ@'-T[(K<9@/<-8@W:\3>3[C%^0J=MX&(SB 2>.@U*Y)H)X\><ONR0953),
M,>KK AKU"0GR-#YWH2_N#3>$)(7#YI'_J6$O)W""S$\G;$;8$R=,L6!439T1
M+JY!)3V)\L#7MN\Q!/?;L;3PEM9)PZ G(EB_,)H8(WK1"1$8K;)LT//,8"%>
M65\2,L^BNW N>]TRZ-D]K*EX?E!L"T=_=T2B4N>J:8&<3/?R?*C3"8V(Z^'9
M2D1KD:"(FCZN"5>&KQ9ZX0694R8JX\D G^(;+EBUSIB_%,]UVXCX0Y\MY?YF
MW/^,(6(0?'4!82E"6#=\@,;II<?8AM^N53[[#4?!!U="ON*(:SU@7YB@/ITL
M#/G=,P+#]E:D-Y:">_GG[@D4\<U)249YD[X+8[7F!.KC ,J0*AA3JN A6^Z0
M+5>:+9=_<3*OF-L5?%:V59'>D]RY<#=&=%D[00Z^ZM*X=8<&RE3!H&FJG5:H
MSW"W>68M2+ VE0,:@95FZ: &*=A0B:6*]Q2: Z3;DC 6]\S&5FHT$BE! G&A
MH+O\A392+:*2ZC;S*Q</8Y>-;NL&65P7ZCA0=,)O%"))P6D[48JT=&JH&3]:
M2:RE E 6)=;6<Q\ZV;;R@$=-\I^A%'L+\]M:6BPLG.Z*.UB5&V &;B 3/N+;
M/>KMX?@V@QJ3> 6&PG49YZ(^8OOAG/1KR6EF1^ZM#83R%W0+Q]B_#-V2,O&^
MJFK(D-QA*!>=R91!9AK7<Y3]&;>3LK[;)Y+3R3TTJAF(]]_1[6@ ,P&Z/:QI
M4M%=?>C>O:*K9XDV9DVK+>ROZ(19GX0,G2R;N]7M+BGU=8I0RJ]R8F@#;K02
MW)_0":X^&@:=X.I#8*B^/@1*855.QO&D02-HH(HA/E,[OC*U@&*?6B^E_6-/
M@WIF* 77=5E>/";VBF7 **<?.C$VRMY'.ZG#@E+T#28:+!Z]NN4W%!0$98V@
MK,3G3J%/MX)N/]&D6:&P>F(HMP#E;"AFS<8RQ^?2 $N0A4\^]4FQMC)J5B\8
MI\CJ)DDSH19$UY+DGNX%%IR3"^&1#'/SW;TUPS.!0K'B<UR!9-E$MRMI<VM6
MG>ATJ7-0[D2::5%.H(T#%)^/!+C>"SIIA51&J0(U*2*!4G@A4Z6:65M:(#Y_
M!;,"3/@E65;IJ_JV!8^R[(LPUT^9<IHA!<0Z5ICV\%_,7:.X#+Q [+W%XL?8
M7FG C]&6_SE^I%#O1/Q(6AOP\$/L+-('/RNL^Q;T ;)]'0$_ZE,Y0>%'?CH?
M5OS8;0:0XT>+)^X'/Z_L7?OQ8VUGW,*/[W3V>_S8[5B![#YME+_D.RAY3J^C
M_%L_OT[(0OQ@S <OBC2WY+NC)$9U_F<UZ7?067U@D$Z85!3(D>Y"+V <&:^$
M2\F?.3<F\_(N'2_R# V- '9GV80!U%7; L*R9-*S!FL?*SN.&/&"S3V?,1*,
M%_R2M>!_N/%"5I-L$XC6DEVH-=JJ7QTKG)YR-:((,.?S^2GD]^>4QJ1LM/>,
M:H3;DBG!VBPWJ*,!1&HI),K.#'_RTHR%Z:9PF2Q7:R-8EH)C+!XX+3+C C%;
MBJOH#',S3:)#'W:XP&Y]+7\-%\O_SKS<"RIWVA0:4T)\T2@\3)@*18Q%>2J"
M]Y[X6<.57PCP64O@6'2D%U.]+A'/EEQA>N!WO?U6U0PE%D6IB#PN+[![4%O<
M93Z!9ABQ:4W&Y32@0+$H3!6@\%I54)#8M*/Z?-10-%@T(-FK2A#D)#=$AT41
M*O;0K99^[VV*O>6Y^9Z"3=U1%J"&O@I@T6ZT&V5-_2LH1E3Z3/ZBMWONF#Q&
MX2*_5GTFZ61>OO<T@XE%>]F]%'CK,/6B''!RDXE<&N697J[&Y*KAQ>,=%A7F
MV AUQZ5T$N__W0P?-O5EC^<7/F![?-BTEG&<AD$890+1_A)Q_>Q'65!DB2T2
M(I6OE=<>B_GB3?AE9+;T&!FOA&-!,U9@TVV.S&8<I/@%OX.];880B[Y3=YV\
MH4R$-LYI%%+ $]#?WQS@Y!_Z6OPE_X,@=$KFK\3_OTQO=Z"^??OVPV-(?;9)
MTA]\NLI+ /SX_OW;-SFT9$OW**8I&;T;<9W%__K(]\U@Q%N+XSV?CE' [[EA
ME(R$E89??K=D%C4'!+[1=N"\CD#;<0OX22B"@[<<J&% V?K%-)X8<4$9_QV)
M^0)]K:S%<,R70A*R19:D_/?O:ZNX*-L4GX>5@I!\?IN?E__E@YP >2L+)%SS
M>:4;0DIGN'PKNQ!3<%F9@<\T7Q8D&'_S6)!4_R1L-=O@WY>1YGQ938E8KGP'
M$,:=Q/>B/XA7"]$=%:A9* B]H5G'+#O\*GH6/?!OD^YY].*S^)GTC3I@T?ZC
M-ADDSHG[TK%37!+E>R>PBP7B;G.5B>N.:H(4S2P0P2=JB_@J9'Q2**LO&0=L
M;8.D3 PXF>^>89*QOPS)<:5[8&N+),UV^D95HL7$'!98,NUF@<B]RCV9\^^L
M:)Q_-U^@R059A+&X?M31:=;SU*1>QT$3.E]VLTSDS(L\D1AGNR%4OG[P.BBC
M%SZ"!=+K-^6*1]C%1C3)1;)\5LDWZI*2G=SFC.4HMHO^Y96U"K6;+W;'FJ))
ME=*;D"7I;WR/$<$0N75M/$\)^X5W3$4$3PNN-/^8+88<;4[ZF2M.]B_E.;\7
M=2D?3O -&_#%"ISDL2S"XVKO#5 L3>E1:-+/ IE"%MY]+#EP[?E+H2Q]X7I!
M=)-%T>:WG$%R:AMTMT3TQQ];$6W8W1+1(L??+/-]DB3S+"KSG.6/>+,B_-*_
MXAI&1(LDYSO-0PW%RJ F .V4DQQ'^=>X8-=N9@=VI(/ZDF:='8 3&\QAU.8A
MAKHV#DE5%JV5M.H)N>XKZ^8$'?K6UQ%=G^:C2U*;7,0?:.I%A[?QSS3]@Z3'
MOJ@'L$_^/8<LW!_FRN+<VO;=0Z@M;W- MJ($3J>DUM5Z.2157@^F2U*YTC&G
M;"6J/Q97$B71FM8.R(^\^##*^9#FFB;N"%4>$O6->D&L^P/M*&'# ;V2*E^=
MDZA<8-+$$FC)=#_QVI0QA^7K82EF>@D!P6PT?0G*__/B)>BM#/T)/M$C1NU"
MR,9)DJV*AYFMG>DJ? H#$HO\T[*;:F??[1%+=8^SMED)_5Z/6/@2RSA+EY0I
M[E@G^TY_6?;DA9$(T[FAQ?/WB3DG^UR/&%B^2N?D)[=QL:6_\(2VQ3O]EQ"R
M+5&>@_F[3AR =/U3?FI@G.&GD.AX>BL7J3=SE0K8-%PLTT1J3NOD6SUBW62K
M<'$082(V[M^)0$6"TF>W\.7+<T04B9XR+Q+QD$HMV@TE#M@N=7T^Y(K<1]H=
MT75)4V5TRXN2.2']18X:&<TUB6RZ)9;Z7V_YI8;?8S*VNQN6WC8R-SGY3+0:
MK7OX#V%:5,4*Q"6.KU6%F"G;(B#]]S!=3DF4;V7),EP_T.N:/,DZ4+!1OA.X
M[M6-\A!7B&5-"V=D*GE?VZ8'I)H(P2FSQMLL,BNU"[7-%F<&"5(KJ/[B1*&.
MTQT# M:5K>-_S?P@RMG?>J:,?.Z[!6=Q92G<1M MK9.^;%1X G2H0+E2Z^>3
MNGCE@ ;5HEL34@T%W8JH5U%H6_]:E))=-RO'D]:K$^C4&UI#GW!T?-*+>2./
M[&XW* 3RL--\(*YAZ+BCEP*+SNQ ]/BJYRH<P]$=7S*_\%V&"V7. I2G5#W[
MZ^:G5R>5;J9TR1V @/ 5?04\HJ);5DW?2+>3"0VH1KD U1.FFMDF3ZM %N"K
M$2OQL$4GRW5.MA48"L]\E-()K537DV-!-SOR$ \@%'QU:0'&6Y22U[ZJ)PJ9
M'"J8&NXD^)&8JLP]0=3U(RQ^MIQ*-<./W.3M$C\:,VN@W;/Q<:CN==*<J1U'
MG*![9 3D735.H-7M6Z*]3,(-TF1T^\YC#6I'602Z?2VP(^VN<YIV>U'$SK/:
M;)1 %J%*7MUY3E,@DU#5_.@Z.2Z01]BJAW00=@+5YK#5(#E=^#64(V>CX$+#
M"J&,0:G3ZA+60L%AT64[2/0(90D6G;?+'*!0WF#1>-'$VT$9AT7M;;V[PE(%
M0-F"1=6US19U'@ H=U#IN&W244,!8U%8&^<UASZ385$_FR5&AZ(\&Y72++4,
ME#VH%,LN4[!#&81%.;4:A;P'WTUEK_<CGT;\,*(L+YXW\N)@1-,E82-.-.'4
M+/-?!7N'VY%?JCQ)R^)?I_ATP<0.ZH.=COAV)<2N+R>?QG%P.[U3U!"3-;*0
MX7P\NY]>C*=7XZUBK"!#W=0&,67A8"^J.(R7NKV"+G O*R0^"?_]SS0-?5)L
M&%PK%%>),"YK.XX7C)"J7?0EL>;];9 =QUQP]^6T%85*-$U/0<S+.NU*8NI*
MNK<BYB)7>'6R+V]E@83+V=U=N J5]0]D;6Q\?K\Q\@-[*WS[5;6MM7M8@?T%
M>0W'L$O^$]E]NEA:D_EV$]<0#>AI@=2M4:#@0GZCY'I+\=Z5F^6*DXAO]96=
M;"MVM56E[(QH =HOG'OQI7B6O:1L70J"7)P!S2T0I2G>7B4(5.?=+C'R74_3
MU 8Q&;\(KKFFN_+DDR1M9(& SUZQ,=S&21JF6<HOJ^,H(FRQ$8I./.=2'=(L
MN0J3O/BWH@Q=FX$L -GN;'RU?:*!"'8KC_'RT%)J \:=;1!<[F]JPF2-;!#
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MDAC-AJQ#]R!VFM#%9O?CKR'7G)B_Y!KB$XD4\V+6V2&XVWB=I4E.T3ME?B5
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M)D)-<*2^%J-\\WY1V$1ITIP2><)=K,1I4==Y&[\LJ'X)OS!,4?!P:6 0&CU
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MNZ,S("H(G=,?I.JWSJ? 352%A.OUTA)'+77T-LV8'L! A%7+M>: F##6LQ=
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M(LE7O9?R-[LKO(JRB[Q*J]WU\HQ]A0LZ4]5N(JNH"Q*&MA,;4)SG_6, D$#
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M8,WHK[[][KOZ5]^%+FTQFM]"/B.&MK">R]X37JP*S(\"$1)]O:0CJ(HH'BR
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MW\/!]\D^DC]\^9?7K_[\8UU()8B@:<\&,66Q7V&]P06/::*,X";'85<JQ=9
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MB"D:J,VJ*SR/0J7B<+_ID0!2<7@ ]9E[17^BOVQ^1?^/D:2_^7]02P,$%
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M.X<B>LO?L)76&X'-,%%:B$1LAT_R8KFSQ6<O_H8RPS" 2-VYK55"@M"J,]$
MH1>(^C'>Y,CPGK%>M 60J3'- )'7W&^$:%*(658E,-]R]_ZJK+<M@/"&CS+
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M*=VS>\[Q1O'&BY.MHCN(;&CWA'\BCRB.RKOE08H$#,BFV!2Y\LEPN/:*;E[
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MN!*;TM:N5=L.Z JP?0YKZ6UE I!]$N(/+O["_\/+<K#?_']02P$"% ,4
M" "D<*E(:!Y*9-CZ  "N( @ $0              @ $     8F-R>"TR,#$V
M,#,S,2YX;6Q02P$"% ,4    " "D<*E( 2B^<A(1  "'KP  $0
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MKP$ 8F-R>"TR,#$V,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  (OP 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
